Vol. 2, 2043, December 1996 Clinical Cancer Research 2043
A �CR l�u1letin Board
Institution of Page Charges
Effective January 1, 1997. a page chargeof $35 per printed page will be leveled onall manuscripts published in C!inica! Can-
cer Research. It is understood at the time
of submission that the author(s) agree topay this charge in the event of publication.
Under exceptional circumstances, whenno other source of grant or other supportexists. the author(s) may apply to Dr.Margaret Foti, Director of Publications,AACR Publications Department (see pageii for address) at the time of submissionfor a waiver of the page charges. All suchapplications must be countersigned by an
appropriate institutional official statingthat no funds are available for the pay-ment of page charges.
Annual MeetingThe AACR’s Annual Meeting is one ofthe largest and most important annualgatherings of scientists engaged in cancer
research worldwide. The next AnnualMeeting will take place in San Diego. CA,April 12-16, 1997. The Chairperson ofthe Annual Meeting is Frederick P. Li ofthe Dana-Farber Cancer Institute. ClaraDerber Bloomfield of the Roswell ParkMemorial Institute and Stephen H. Friendof the Fred Hutehinson Cancer ResearchCenter will serve as Co-Chairpersons. TheProgram Committee has invited outstand-ing scientists in the field to organizeplenary sessions. symposia. controversysessions. and meet-the-expert sunrise ses-sions. They are also now reviewing the
proffered papers submitted by membersof the cancer research community. Thedeadline for abstract submissions was No-vember 12. 1996. Up-to-date program in-
formation can be obtained via the Internetat the AACR’s website (http://www.aacr.org/meetings.html).
Gertrude Elion Cancer ResearchAwardApplications for the AACR’s 1997 Ger-trude Elion Cancer Research Award. sup-ported by an educational grant from GlaxoWelleome Oncology. are due Fchruars’
14, 1997. The one-year. $30,000 grant to anontenured Assistant Professor supportsmeritorious basic, clinical, or translational
research in cancer causation, prevention,or treatment. Tenured faculty in academia,government employees. and employees ofprivate industry are not eligible for thisaward. Information and application formswere mailed to AACR members and tothose who requested applications. Non-members should request information andapplications from the AACR office.
AACR Research FellowshipsThis year the AACR will offer at leastsix one-year, $30,000 research fellow-
AACRThe American Association for CancerResearch (AACR) was founded in 1907to bring together active investigators ofthe cancer problem for the presentationand discussion of new findings and tofoster advances in cancer research. To-day the Association has more than1 1 ,000 members working in all of thesubdisciplines of cancer research in the
United States, Canada. and more than50 other countries. Information onAACR programs and activities can beobtained from
American Association forCancer Research
Public Ledger Building150 South Independence Mall West
Suite 816Philadelphia, PA 19106-3483
Phone: (215) 440-9300Fax: (215) 440-9313
The AACR welcomes applications formembership from the readership. Scien-tists engaged in all areas of cancer re-search are eligible for membership.There are three categories of member-ship: active membership, open to cancerresearchers working in the Americas:corresponding membership. to thoseworking outside the Americas: and as-
sociate membership. to graduate andmedical students, postdoctoral fellows,and physicians-in-training. Further in-formation on the qualifications for eachcategory as well as the benefits of mem-bership can be found on the application
forms at the back of this issue.
ships for clinical or postdoctoral fellows
working in the U.S. or Canada. Infor-mation and a universal application formwill be mailed to all AACR Members inthese countries and to others upon re-quest for any of the following: the Re-search Fellowship in Clinical Research,sponsored by Bristol-Myers Squibb: theResearch Fellowship in ClinicaliTrans-lational Research, sponsored by Amgen:the Research Fellowship in Prevention,sponsored by the Cancer ResearchFoundation of America; and three Re-search Fellowships in Basic Research,sponsored by The Sidney KimmelFoundation for Cancer Research,Hoechst Marion Roussel, and theAACR. Additional fellowships andsponsors may be announced. To be eli-gible for these fellowships. candidatesmust have completed the M.D., Ph.D.,or other doctoral degree. Candidatesmust currently be a postdoctoral or elm-icab research fellow and must have beena fellow for at least two years but not
more than five years prior to the year ofthe award. The deadline for applicationsfor the research fellowships is Friday,February 14, 1997.
AACR Special Conferences inCancer Research
A number of meetings are now beingorganized in the AACR’s series ofsmaller scientific meetings. Followingare the topics. dates, locations. and pro-gram committees for some of thesemeetings. When full details of eachmeeting are available, AACR memberswill be the first to receive complete bro-ehures and application forms for partic-ipation in these important conferences.Nonmembens may receive this informa-
tion by sending their names and addressesto Meetings Mailing List, American As-sociation for Cancer Research, Public
Ledger Building, 150 South Independence
Mall West, Suite 8 16. Philadelphia. PA19106-3483. Telephone: (215) 440-9300.FAX: (215) 440-9313. E-Mail: [email protected]. Up-to-date program informationis available via the Internet from the
AACR’s website (http:llwww.aaer.org/eonfrnc.html).
January 10-14, 1997Basic and Clinical Aspects ofLymphoma
Joint ?vleeting wit/i tile America,z Society
of C!inica! Onco!ogv
Chairpersons:
JOSEPH R. BERTINO. New York,NYJAMES 0. ARMITAGE. Omaha, NEStouffer Renaissance EsmeraldaResort, Indian Wells (Palm Springs),CA
March 7-12, 1997Basic and Clinical Aspects of Breast
Cancer
Chairpersons:
J. CARL BARRETF. Research TrianglePark, NC
KAREN S. H. ANTMAN, New York,NYMARY-CLAIRE KING, Seattle, WAKeystone Resort, Keystone. CO
June 7-11, 1997
Cancer of the Central Nervous System
Conference with Neurosurgery Joint
Section on Tumors
Chairpersons.’
PETER MeL. BLACK, Boston, MAWEBSTER K. CAVENEE, La Jolla,CALoews Coronado Bay Resort, SanDiego, CA
Vol. 2. 2045-2047, December /996 Clinical Cancer Research 2045
‘*October I. 1995 - September 30, 1996.
Acknowledgment to Reviewers
The Editor-in-Chief, the Associate Editors, and the Editorial Advisory Board acknowledge with appreciation the assistance of the following
individuals who have generously contributed their time and effort during the past year� to review manuscripts for Clinical (�ancer Research. The
quality of the journal can be attributed in large measure to the quality of their effirt, for which we are sincerely grateful.
A
Stuart A. Aaronson
Reed Adams
G. Adema
Carol Aghajanian
David Agus
Mark AlbertiniFrancis Ali-Osman
Suresh Ambudkar
Kenneth Anderson
Marshall W. Anderson
Paul AndersonKian Ang
Jack I. ArbiserSusan G. Arbuck
Ralph B. Arlinghaus
Carlos Arteaga
Vasilios Assikis
Michael B. Atkins
B
Debabrata Banerjee
Menashe Bar-EliRichard BarakatLini Bartlett-Pandite
Jose Baselga
Susan Bates
Atul BediDorthea BekkerWilliam Bellamy
William Bennett
Christopher Benz
Andrew BerchuckMichael Berens
Nathan Berger
Ira BergmanNancy Berliner
Ralph BernackiDonald BerryJoseph Bertino
Kapil N. Bhalla
Jaclyn Biegel
Darrel D. Bigner
Archie Bleyer
Carl BlomqvistArthur W. Boddie, Jr.
Michael Bookman
Anne-Lise Borresen
Piet BorstJeffrey BoydGleen BranoffMichael G. Brattain
Eric Bremer
Dean E. Brenner
Vli Brinkeman
Jim BrooksBarry Brown
Carol BrownPowel Brown
Hal E. BroxmeyerH. Broxterman
Corazon BucanaDonald Buchsbaum
Paul BunnAntonio Buzaid
C
Paul Cairns
Mitchell Cairo
Michael Caligiuri
Lisa Cannon-Aibright
Giovanni Capranico
David Carbone
Michael CarducciAshele Carlo
Jorge Carrasquilbow. E. Carson
Ronald Cartenhaus
Terrence CascinoDoug CaseDiana Casper
Raju Chaganti
Richard Champlin
Paul ChapmanMartin Cheever
Luci Chen
Yung-Chi Cheng
Bruce D. ChesonJia Lin Chou
Randolph Christen
Kathy Christman
Gary M. ClarkPinchas Cohen
Daniel Coit
Thomas H. Corbett
C. Cordon-CardoJoseph M. Corey
Marion Couch
Patrick J. Creaven
S. P. CreekmoreR. CrystalKevin Cullen
David Cunningham
Brendan Curti
John P. Curtin
D
William Dahut
William S. Dalton
Robert DamatoPeter Danenberg
Mary K. Danks
Ian DavidAndre Davidoff
Nancy Davidson
Lisa M. Deangelis
A. De La ChapelleGeorge D. DemetriSamuel Dermeale
Beth DeutchRussell Devore
G. E. Dc VriesTheodore Deweese
Daniel Dexter
Kapil DhingraAlan M. Diamond
Chaitanya R. Divgi
Ethan DmitrovskyLawrence A. Donehower
M. Dowsett
Glenn DranotI
Anatoly Dritschilo
E
Janet EarylGail Eckhardt
Stephen Egde
Janine Einspahr
Elizabeth A. EisenhauerWafik S. El-Deiry
Richard Elledge
Matthew Ellis
Mike Emmertbuck
Adel K. El-Naggar
Elihu Estey
Sharon Evans
F
Thomas J. Fahey
Dominic Fan
David C. Farrogia
Alexander FeferCarolyn Felix
Robert A. Fenton
Rena FernmanNapoleon Ferrara
Soldano FerroneRobert Figlin
James Finke
Jonathan L. Finlay
Richard Fisher
Kathy FlandersGini F. Fleming
Jonathan A. Fletcher
Carlos Flombaum
Antonio T. Fojo
Kwun FongKeeneth A. Foon
David A. Foster
Paula M. FracassoArnold Freedman
Eileen Friedman
Herbert FritscheJohn Fruehauf
Yasuhiro Fujiwara
Minoru Fukuda
Bernard Futscher
G
Janice Gabrilove
John GalivanGary GallickSteven GallingerVarsha Gandhi
Giampietro Gasparini
Adi F. Gazdar
Akihiko Gemma
Robert Gemmill
Eugene W. GernerStanton L. GersonAlan Gerwitz
Maria-Ana Ghetie
Cecilia M. Giaehilli
Tern GilewskiStephen Gillies
Claude GimmiBeppin Giovanella
Ruth A. GjersetEli Glatstein
Bonnie Glisson
David Goldenberg
Jared Gollob
Michael Gordon
Michael Gottemsan
Michael Gould
Kenneth Grabstein
Stephen GrazianoAnthony GrecoMark GreenJean Grem
Liam Grogan
Michael Grossbard
H. Bartgon Grossman
Stephen GruberF. Peter Guengerich
Jose G. GuillemElora GuptaHiral L. GurtooGordon Gutterman
2046 Acknowledgment to Reviewers
H
Peter HafkmeyerWilliam N. Hait
Ruth Halaban
Dennis HallahanHoward HalpernThomas C. Hamilton
James W. Hardin
Steadman Harrison
John HausdorffHarald Zur Hausen
M. J. HawkinsRuth Heimann
Martin HemlerMeenhard Herlyn
James E. Herndon, II
Warren Heston
Steven HillSamuel Ho
Robert Hoffman
Jeff HoltChung I. Hong
Gabriel N. HortobagyiDavid P. Houchens
Alan HoughtonWilliam J. M. Hrushesky
Peng Huang
Robert Huben
Clifford HudisMien Chi HungPaul Hutson
Patrick Hwu
Nancy Hynes
I
John T. IsaacsMark Israel
J
Ann L. Jackman
Gerrit JansenRobert Jenkins
Suresh C. JhanwarBruce Johnson
David JohnsonMichael Johnson
V. Craig Jordan
Joseph JurcicMalik Juweid
K
Jacob KaganBurton A. Kamen
Crystal KanerHagop KantarjianJames P. KarrSeymour KaurmanFrederic J. KayeAbbruzzesel KhuriFadbo Khuri
Gretchen KimmiekHedy Lee KindlerKenneth Kinzler
E. S. KleinermanHynda K. Kleinman
David KnowlesMaggie KnowlesSusan J. Knox
Wayne Koch
Elise C. Kohn
Kristin KomschliesSteven Kornblau
Robert KreitmanMark G. K.ris
Davud Krizman
Susan Krown
Athanassios P. Kryitsis
John G. Kuhn
Rakesh Kumar
Jonathan KunieJohn F. Kutteseh, Jr.
L
Steven Larson
Julia LawrenceJ. Jack Lee
Jin Soo Lee
Mong Hong Lee
Sam W. Lee
Catherine LeitchHeinz-Josef Lenz
Ellis LevineFrank LiebermanEugene W. LingerIlona LinnoilaMartin Lipkin
Scott LippmanAlan List
Virginia A. Livolsi
Charles Loprinzi
Gemt LosReuben LotanScott Lowe
M
Greg MacewenBruce Mackay
Timothy MaddenDavid Mahvi
Louis MalspeisDaniel C. Maneval
Sridhar ManiA. Mantovani
Li MaoSanford MarkowitzMary Beth MartinM. Jules MattesHelena MauceriJohn D. McConnelTimothy J. McDonnell
Cornelius McGinnRobert J. Melder
Stephen J. MeltzerNeal J. Meropol
Edward M. Messing
Joseph Michaeli
James Mier
Tom MikkelsenGerard MilanoLangdon MillerWilson Miller
Gordon MillsSin MineishiJames B. Mitchell
Margalit MokyrT. Monig
Terry W. Moody
M. J. Moore
Malcolm A. S. MooreRichard MoranJoanne Mortimer
Robert Motzer
Elaine A. Muchmore
Franco Muggia
Carolyn MullerSharon Murphy
James Lee MurrayRuth MusehellJeffrey Myers
N
David Nanus
Alfred Neugut
Stephen Nimer
Perry NisenJohn L. NitissJames C. Norton
Gabriel Nunez
0
Augusto C. Ochoa
P. M. O’ConnorPeter J. O’Dwyer
Paul Okunieff
Susan Ostrand-Rosenberg
P
Paola A. Paciucci
R. PackerDavid L. Page
Lance C. PagliaroRamon Parsons
Jens Pedersen-Bjergaard
Anthone E. Pegg
Roman Perez-SoberJames J. PerryGodefridus J. Peters
Elizabeth M. PettyDavid PfisterJames Phan
Steven Piantadosi
Gary PiazzaKenneth J. Pienta
Stefano Pileri
Silvana Pilotti
Renate Pitz
David Piwnica-Worms
William K. Plunkett
Ian PollackMichael N. Pollack
Bruce PolskyYves Pommier
Carl Porter
Carol Portlock
William Powell
E. A. Poynor
Michael Prados
Harvey Priesler
R
Robert RadinskyA. RameswamyTimothy Rebbeck
Eddie Reed
Ralph A. Reisfeld
Elizabeth Repasky
Leonard ReynoDaniel Rifldn
Jinee Rizzo
Anita Roberts
Michael Robertson
James RoccoWilliam Rose
Neal Rosen
Maury Rosenstein
Miriam Rosin
Marsha Rosner
Eric Rowinsky
Eric H. Rubin
Stephen Rubin
Jeffrey RubnitzValerie W. Rusch
Youcef Rustum
S
Michael Sadelain
Nagahiro Saijo
David Salomon
Leonard B. Saltz
Michael K. Samoszuk
Leona D. Samson
D. S. R. Sarma
Stimson Schantz
David Scheinberg
Russell J. SchilderChristine Schold
S. Clifford Schold, Jr.
Jan H. Schornagel
Gary Schwartz
Sidney A. Scudder
Andrew SeidmanYoshitaka Sekido
D. SewellJatin P. Shah
Kevin Shannon
Walter J. Urba
U
V
Clinical Cancer Research 2047
Fred Shapiro
William Shapiro
Robert Sharkey
Thomas C. SheaDarryl Shibata
Moshe Shike
Dong M. Shin
Tzipora Shoshani
Clay B. Siegall
Branimir I. SikicLewis M. Slater
Kendall Smith
Martin Smith
Mitchell R. Smith
Thomas J. Smith
Harriet 0. Smitt
Mark Sobel
A. Sobrero
Mel SorensenLee Paijeff Sosman
Thierry Soussi
Lisa Speicher
Richard Spencer
Margaret Spitz
Michael B. Sporn
Georg F. SpringerWilliam Stetler-Stevenson
R. G. Stoller
Walter Storkus
Yan Su
Saraswati Sukamar
T
Raymond Taetle
Michael A. Tainsky
Chris H. Takimoto
Hiroshi Takita
Moshe Talpaz
Rajeshwar Rao TekmelNitin Telang
Franz Thiebaut
John Thompson
Joyce Thompson
Timothy Thompson
Snori Thorgeirsson
Philip E. Thorpe
Linda Titus-Ernstoff
Debra A. Tonetti
Giampaobo Tortora
Anthony Treston
Dean TroyerDonald Trump
Robert Tucker
Eva Turley
Juan Carbos Vera
Jacob Verweij
Ellen S. Vitetta
Cathy D. Vocke
E. E. Voest
Nicholas Vogelzang
Everett Vokes
Israel Voldavsky
w
Alan Wakeling
C. C. WangRaymond P. Warrell
William R. Waud
George Weber
Jeffrey WeberMichael Weinder
Louis Weiner
Howard J. Weinstein
I. Bernard Weinstein
Bernard Weissman
Steven D. Weitman
Anton Wellstein
Sidney Welt
Harold Werbin
Max Wicha
George Wilding
S. WilliamsMark C. Willingham
C. Roland Wolf
Renella WollEugene A. Wolterine
Y
Joachim Yahalom
Alan M. Yahanda
David YandellSamuel Yeh
Charles Young
Garret Yount
W. K. Alfred Yung
z
Daniel Zelterman
Wei Zhang
Karen Zier
Vol. 2. 2049-2054, December 1996 Clinical Cancer Research 2049
AUTHOR INDEX
Volume 2
A
Abad, A., 1083
Abbruzzese, J. L., 1489, 2015
Abraham. A.. 707
Ahlert, T., 21
Ahn, H-J., 1255
Aizawa, S., 1583
Akamatsu, K-i., 253
Akazawa, K., 763
Akiyoshi. T., 1619
Aksentijevich, I., 973
Alberti, D., 1299
Albertini, M. R., 319
Alberts, D. S., 947
Albino, A. P., 1077Alcaraz, A., 137
Aldaz, C. M., 1993
Allay, J. A., 1353
Allegra, C. J., 477
AIbred, D. C., 585, 1 199
Almadori, G., 175, 1895
Altenschmidt, U., 1001Alvarez, R. D., 1089
Alvord, W. G., 501
Anderson, D., 659
Anderson, J. M., 97
Anderson, L. W., 1481
Anderson, P. M., 721
Andersson, B., 1825
Andersson, M., 223
Ando, N., 909, 1155
Andreeff, M., 799
Andrews, P. A.. 991, 1859
Angeletti, C. A., 1067
Anker, L., 843
Antoine, E. C., 1405
Apostobi. P., 1829Apuzzo, M. L. J., 619
Araki, K., 1781
Araya, J. C., 1851
Arch, R., 447Arias, I. A., 695Ariza, A., 1083
Arteaga, C. L.. 207
Arzoomanian, R. Z.. 1299
ABmann, V., 1607
Assikis, V. J., 223
Atkins, M. B., 1341
Au, J. L-S., 1275
Aulitzky. W. E., I I 15
Avet-Loiseau, H., 1673
Avramis, V. I., 1533
Ayelbo, J., 873
Ayyagari, S. R.. 379
B
Baba, K., 1619
Badalament. R. A.. 1275
Bader, M., 287Badger, B., 1901
Bagshawe. K. D., 897
Bajorin, D. F., 295
Baker, J., 659
Baker, S. D., 1921
Balch, C. M., 419
Baldi, A., 1239
Baldi, F., I 239
Baluna, R., 1705
Bammer, T., 1031
Bank, A., 873
Banks, M., 1263
Banks, P., 1713
Barbareschi, M., 1591
Bar-Eli, M., 1969
Barbogie, B., 947
Barnes, M. N., 1089
Basolo, F., 1777
Bast, R. C., Jr., 81
Basu,J., 181
Bataille. R.. 1673
Batsakis, J. G., 903Battaglia, C., I 19
Bauman, L., 1685
Bauman, P. A., 97
Baylin, S. B., 805
Beck, N., 21
Becker, M., 457, 1289
Begemann, M., 1017, 1638
Begent, R. H. J., 897
Beger, H. G., 1469
Beijnen, J. H., 43, 1717
Bell, M. C.. 161
Bellacosa, A., 175, 1895
Belotti, D., 1725, 1843
Bench, K., 1717
Benedetti, F. M., 471
Benedict, W. F., 1 169
Benhammouda, A., 1405
Benhar, I., 1523
Benini, E., 2007
Bennett, W. P., 1767
Benson, P. D., 1543
Bentel, J. M., 277
Berchuck. A., 1571
Berd, D., 1383
Berger. M. S.. 735
Berger, N. A., 1649Bergman, A. M., 521
Bergstralh, E. J., 137
Berlingieri, M. T., 1 19
Bernhard, H., 1427Bertazzoli, C., 593Bertino, J. R.. 1819
Berzin. T. M.. 1445Berzofsky, J. A., 877
Bevilacqua, 0., 1067, 1777
Bevilacqua. P., 1 191
Bhardwaj. B.. 773
Bianchi, S., 261, 1577
Bianco, A. R., 207, 601
Bianco, C., 601
Bianco, R., 207
Bi#{232}che,I.. 1 163
Bigini, D., 1067
Bigler, S. A., 1039
Bigner, D. D., 963
Bigner, S. H., 963
Bird, R., 75
Bischoff, E. D., 511
Bischoff, E. K., 1859
Bitran, J. D., 1509
Bladou, F., 1039
Blagosklonny. M. V., 1221
Blamey, R. W., 923
Blank, A.. 735
Blaser, K., 593
Blumenson, L. E., 669
Bobola, M. S., 735
Boddi, V., 261, 1801
Bogenrieder. T., 1077
Boguniewicz. A., 1251
Bone, E. A., 1207Bonetti, A., 1829
Bonoldi,E., 1191
Bonzanini, M., 1591
Boon, P., 1009Boracehi, P., 1 191, 2007
Borchert, A., 319
Borden, E., 29Borel, C., 1405
Borell, T. J., 137, 883
Borowitz, M. J., 331Borsotti, P., 1843
Bourgeon. A.. 507
Bouyge, I.. 1673
Bower, M., 897Bowling, M. K., 1921
Brachman, D., 755
Bracy, D.. 947
Brandt, R. M. P., 1825Brennan, J. M., 549
Brenner, A. J., 1993Brinkmann, U., 1523
Brodeur, G. M., 1097
Brossart, P., 767
Brown, J. A., 137Brown, M. T., 963
Brown, R. W., 585Brown, T. J., 359
Brown, T. R., 339
Bruce, J. N., 1017, 1638
Brunette, E., 59
Bnjnner, N., 155
Bruntsch, U.. 1717Bucana, C. D., 1679, 1969
Buchanan, G., 277
Bucheik, R., 21
Budd, G. T., 347
Budning, A., 1499
Buhler, K. R., 1039Bukowski, R. M., 347
Bunch, R. T., 791Burns, D., 319
Burns, D. J., 201
Burns, P. A., 1795Bussolati, G.. 1757
Buttitta, F.. 1591
Butzer, U., 1469
C
Cadoni, G., 175, 1895
Caffo, 0., 1591
Cagle, P. T., 1169Caldarelli, D. D., 1453
Caliguri, M. A.. 669
Calvez, V., 47
Calzolari, A., 261, 1577
Camitta, B.. 331Campbell. P. A., 379Cantilena, L. R., Jr., 477Cao, S., 369, 707, 1961Capizzi, R. L., 1 107
Caputi, M., 1239
Caraglia. M.. 207
Carbone, D. P.. 877Cardarelli. C. 0.. 973Cardueei, M. A.. 379
Caron, D.. 1713Caron, G., 1767
Carter, C. A., I 143
Casazza. A. M.. 1725Case, L. D., I 107Casero, R. A., Jr., 441
Castelli, C.. 641
Castellsague, X., 1887
Castronovo, V., 1777Cavalli, F.. I 123, 1717
Cavallo, S., 175, 1895
Cawley. H. L., 1767
Cerutti, J., I 19
Cetto, 0. L., 1829Chambers, C. A., 1417
Chambers, J. T., 1693, 1699Chambers, S. K., 1693, 1699
Chamness. G. C., 1199Chan, H. S. L., 1499
Chan, K. K., 1461Chan-Tack, K. M.. 379
Chapman, P. B., 295, 679Chartier, S.. 493Chazal, M., 507
Chelstrom, L. M., 1533Chen, L. B., 1335Chen, T-L., 1481, 1921Chen, Y., 889
Cheo, D. L., 331
Cheshire, P. J., 107
Cheung. N-K. V., 1361
Chiarelli, I., 1577Chine, S., 1067Chinn, P., 457
Chitambar, C. R.. 1009
Chiu, J. J., 215Choi, J-J., 2029Choi. Y-j. A.. 1017, 1638Christiansen, K. M.. 1017, 1638
Chu, E., 477Ciardiello, F., 207, 601
Cidlowski, J. A.. 889
Ciernik, I. F., 877
Ciocca. D. R.. 1199
Cirisano, F. D.. 1571
Clark, G. M.. 585. 1 199Clary, B., 59
Clayman, G. L., 1659
Cleary. K. R.. 1679. 1999, 2015
Clemm, C.. 1565Clendeninn, N. J., 1685
Cliby, W., 1907
Cody, B. V., 295
F
G
2050 Author Index
Cohen, P., 837Cohn, S. L., 1097Colb#{232}re-Garapin, F., 47
Colby, T. V., I 767Coleman, C. N., 269
Coleman, M., 1751Coleman, R. E., 963
Collins, H., 493Collins, J. M., 953, 1481
Cobombatti, M., 1829Colvin, 0. M., 1481Connolly, J. M., 1751Conrad, N. K.. 1103Consoli, U., 1731Coon, J. S., IV, 1453
Coons, S. W., 187Cooper, M. R., 483Corneo, G. M., 593Comish, A. L., 923Cossette, N., 773Couldwell, W. 1., 619, 843Courjal, F., 1601Courtois, S., 1439Cowan, K. H., 215Creaven, P. J., 669
Cress, A. E., 97
Cristiano, R. J., 1665Crowley-Nowick, P. A., 161Cuartero-Plaza, A., 13
Cullen, K. J., 1859Curiel, D. T., 1089
Curley, S. A., 1397Curtis, D., 1039
D
Daidone, M. G., 2007Dakhil, S. R., 1285Dalla Palma, P., 1591
Dalton, W. S., 7, 97Damiano, V., 207, 601
Danforth, D. N., Jr., 827
Dante,S., 1191Das Gupta, T. K., 1391Daskal, I., 561Dave, A., 1077Davidson, N. E., 441, 805, 847Davies, P. J. A., 511
Davis, B. M., 1353
Davis, C. A., 1693, 1699Davis, P. L., 1571Davis, 1., 457
Day,R., 1129de Angebis, E., 601
de Anta, J. M., 1083Deb, N., 457, 1289
Dc Benedetti, V. M. G., 1767Debinski, W., 1743
DeBoer, G., 1499Debruyne, F. M. J., 1055Deeley, R., 773Degen, D., 1713
DeGiorgio, C. M., 619
de Giuli, R., 403Dehdashti, F., 933Deisseroth, A. B., 799deiong,J., 1123, 1717
Dekan, G., 1231
DeKoning. T. F., 1 143DeLap, R. J., 1475Dc Luca, A., 1239
deMagalhaes-Silverman, M., 434
DeMaria, D., 1685
DeMichele, M. A. A., 411de Murcia, G., I 163
Densmore, C. L., 1819
Depiseh, D., 1231Dermime, S., 593Deshane, J. S.. 1089deTakats, P. G., 659DeVictoria, C., 1981Devilder, M-C., 1673Dezso, B., 1543Diasio, R. B., 477
Dickson, R. B., 1207
di Isernia, G., 207
Dinareblo, C. A., 1341D’lncalci, M., 1123Dmitrovsky, E., 1077
Doglioni, C., 1591Domagala, W., 147Donehower, R. C., 541, 1921Donnelly, S., I 129Dorr, R. T., 947Dos Santos, B., 253Downey, G., 1285Dreyling, M. H., 1993
Drudis, T., 1843
Drum, P., 287
Dubois, J. S., 1341Duffy, M. J., 613Duigou, G., 1017, 1638
Dukowicz, A., 147
E
East Japan Paclitaxel StudyGroup, 941
Eastman, A., 791Ebert,A., 1879
Edwards, C. L., 837, 1285Eguchi, K., 553Ehring, B., 1427Eieher, S. A., 1659
Einhorn, L. H., 1063Ek, 0., 1533Elbendary, A. A., 1571
El-Deiry, W. S., 623, 1221Elder, E., 87Eller, S., 541Elliott, B., 773Ellis, A. L., 1489
Ellis, L. M., 1679
Ellis, W. J., 1039El-Naggar, A. K., 419, 903, 1553
Els#{228}sser, H-P., 1607Elson, P., 347Emadian, S. M., 1559
Emerson, D. L., 7Endo,Y., 1411
Engebstein. D., 1077Epstein, J. I., 389Epstein, M., 1341Ermak,G., 1251
Escobedo, A., 1887Eshleman, J. R., 1649Esposito, V., 1239
Estey, E., 799Etienne, M. C.. 507Evans, A. C.. Jr., 1571Evans, D. B., 2015
Evans, W., 1533
Fabbro, D., 1017, 1638
Fabra, A., 1887
Fagin, J. A., 1 19
Falette, N., 1439Faranda, A., 2007
Farr#{233},M., 13
Fearon, E. R., 1097Feierabend, C., 1299
Felsberg, G. J., 963Fenaux, P., 1031Fenoglio, C. J., 2015Ferguson, A. T., 805Fernandes, D. J., 1 107Ferrandina, G., 175Ferry, D. R., 659Fidler, I. J., 1627Fields, A. L., 1981
Figg, W. D., 483
Figge, J., 1251
Filipits, M., 1231
Filippa, D. A., 295
Fina, P., 1591
Finke, J., 347Finnegan, M. B., 837
Fisch, M. J., 1063
Fischer, P. H., 75Fisher, D. E., 435
Fisher, R. A., 897Fbechtenmacher, J., 21Fbeisher, M., 1819Fleming, R. A., 1107
Fojo, T., 1725
Fong, K. M., 1369
Fontanini, G., 1067, 1777
Forman, A., 837Fowber, S., 457, 1289Fox,S.B., 1191
Fracasso, P., 933Franeeschi, T., 1829
Franchi, A., 1801
Francis, D., 155
Frankel, A., 1307Fredericks, R. K., 963Freedman, R. S., 837, 1285
French, F. S., 889
Freytag, S. 0., 53Friedman, A. H., 963Friedman, H. S., 963
Fritsche, H. A., 419
Fuchs, I., 1879Fueger, R., 1285Fujie,T., 1619Fujinami, K., 929
Fujiuchi, S., 915
Fukuda, M., 553
Fults, D., 1559Fuqua, S. A. W., 1 199
Furihata, M., 1781
Furuya, Y., 389
Fusco, A., I 19
Fyfe, D. W., 659
Gacrama, P., 1285Galivan, J. H., 707Galli, J., 175, 1895
Gallick, G. E., 1397Gallie, B. L., 1499
Galbo, J. M., 549, 1685Gallo, 0., 261, 1577. 1801Gambacorti-Passenini, C., 593
Gan,J., 1951Gan, Y., 1275Gandhi, V., 653
Ganesan, 1. S., 303
Gansauge, F., 1469
Garand, R., 1673Garcia, E., 1439
Garner. R. C., 1795
Garnick, M. B., 295
Gasparini.G.. 1191
Gates, S. B., 1135Gazdar, A. F., I 185
Geissler, D., 1031
Genuardi, M., 1895
Gerald, W., 1361Gerken, S. C., 1559Gerl, A., 1565Gerson, S. L., 577, 1 129, 1353
Gerstmayer, B., 1001Ghosh, S., 1017, 1638
Ghoumari, A., 47Giantonio, B., 1685
Giavazzi, R., 1725, 1843
Giedlin, M. A., 669
Giesbreeht, E., 1499
Gill, G. M., 471
Gillies, S. D., 1951
Gimotty, P., 1901Giordano, A., 1239
Glaves, D., 1315
Gleason, M. J., 1931
Glennon, M. C., 981Goepfert, H., 903
Goh, H-S., 1049
Goldberg, G. L., 181, 1981Goldstein, R., 531
Goldwasser, F., 687Gollin, S. M., 641
Gonzalez de Leon, C., 837Gopabaknishna, R., 843
Gore, S. D., 1921Goris, M. L., 457, 1289
Gossett, L. S., I 135
Gottesman. M. M., 973Graham, M. L., 331Granchi, S., 1757
Grant, S., 1, 1915Grant, S. C., 1819Grassi, M., 601
Graubert, T. A.. 785Graves, D., 755
Greenberg, H., 1285
Greene, G., 1627Gregory,M.L.,SblGrem, J. L., 477Griem, K., 1453
Griffin, T., 287
Grillo-L#{243}pez, A., 457Grindey, G. B., I135
Grizzle, W. E., 1811Grochow, L. B., 1481Gr#{248}ndahl-Hansen, J., 155Groner, B.. 1001Groot, Y., 1717
Groshen, S., 1461Grossman, S. A., 541
Guarrasi, R., 207
Gubish, C. 1., 75
Clinical Cancer Research 2051
Guillot, C., 1439
Gundimeda, U., 843
Gunn, H., 347
Gunther, R., 1533
H
Haas, G. P., 1543
Habeck, L. L., 1 135
Haddad, G., 1499
Hafstrdm, L., 3 1 1
Hagmuller. E.. 21
Haider, K., I 231
Hall, S. H., 889
Hallman, J. D., II, 107Hamatake. M., 763
Hamide, J.. 1851
Hamil, K., 889
Hamilton, T. C., 549
Hamzavi, F., 1543
Han, N. M., 1397
Handschumacher, R. E., 1699
Hank, J. A., 319, 1951
Hara, I., 1837
Haraf, D. J., 755
Harezga, B., 147
Harousseau, J-L., 1673
Harrington, A. M., 1767
Harris, A. L., 303, 1191, 1591
Harris, C. C., 1767
Harrison, M. P., 331
Hartenstein, R., 1565
Hartman, N. R., 541, 953
Hartmann, L. C., 883, 1907
Harvey. H., 1215
Hasz, D. E., 721
Hattori, Y., 1373
Hatty, S., 1123
Hausheer, F. H.. 707
Hayashi, K., 1937
Hayashi, S., 1583
Hayashi, Y., 141 1
Hayes, J. S., 5 1 1
Heath, D., 311
Hedrick, L., 1097
Heelan, R. T., 1819
Heffelfinger, S. C., 1873
Heimer, M., 81
Heindl, L. M., 97
Heitjan, D. F., 1017, 1638
Helbe, S. I., 1515
Henderson, B. E., 743
Herath, J. F., 137
Herbst, H., 1879
Herndon, J. E., II, 963
Herold, M., 1031Herrmann, K., 447Hesdorffer, C., 873
Hess, K. R., 1489
Hessels, D.. 1055
Heston, W. D. W., 1445Heyman, R. A.. 51 1
Hickey. T. E., 277
Hieken, T. J., 1391
Hillman, G. G., 1543
Hilsenbeck, S. G., 585, 1199
Hinton, D. R., 619, 843
Hirabayashi, H., 127
Hirata, S., 915
Hirohashi, S., 1373
Hittelman, W. N., 1787
Hoffman, A. D., 1077
Hoflehner, E., 1031
Hohaus, S., 1895
HohI, R. J., 483
Hdhne, A., 1427
Homesley, H., I 107
Hong, W. K., 287, 855, 1787
Hord, M., 837
Horsfall, D. J., I 177
Horwitz, S. B., 1981
Hosaka, M., 929
Hosokawa, K., 1373
Houghton, A. N., 295, 679, 1837
Houghton, J. A., 107
Houghton, P. J., 107
Howard,C.M., 1239
Howard, K. L., 1063
Howard, S. P., 269
Howell, S., 3 1 1
Hozumi, N., 1417
Hsu, P. H., 883
Hu,S-X., 1169Hu,X.F.,7I3
Huang. P., 653
Huang. S., 1969
Huber, C., 11 15, 1427
Huff, V., 903
Hughes-Davies, L., 269
Hui, R., 923, 1177
Huland, E., I I 15
Hulme, M. J., 201
Hum, M., 69
Hungerford, J. L., 1499
Hunt, J. D., 75, 1851
Hurr, K., 903Hurr, K. G., 419
Husain, S. R., 1743
Huseby-Moore, K., 319
Hutchinson, J., 1453
Huynh, H., 2037
Hwang, E-S., 2029
Iglehart, J. D., 1571
Ikeda, T., 821
mo, y., 1373Inoue, A., 1781
Inoue, M., 2023
Irvin, J. D., 1533
Isaacs, J. T., 389
Ishida, T., 763
lshii, H., 1373
Ishikawa, H., 2023
Ishikawa, T., 1781
Issa, J-P. J., 805Itoh, H., 1373
Iwama, H., 1583
Iwasaki, Y., 929
Izquierdo, M. A., 1713
J
Jaeger, P., 1951
Jagannath, S., 947
Jam, R. K., 359
Jakubowski, A. A., 295
Jarvis, W. D.. 1, 1915
Jeffers, S., 1461
Jenkins, R. B., 137, 883, 1907
Jennings, T., I 251
Jett. J. R.. 1767
Johnson, B. E., 1103
Johnson, C., 947
Johnson, J. T., 127
Johnson, M. D., 1207
Johnson, P. C., 187
Johnson, S. W., 549
Johnston, A. L., 1685
Jones, J., 1981
Jones, P. A.. 743
Jordan, V. C., 223
K
Kahl, R., 1001
Kamen, B. A., 69, 331
Kanaya, T., 2023
Kanthanidis, P., 713
Kappler, K., 1341
Karbach, J., 641
Karp, D., 29
Kashimawo, S. A., 1017, 1638
Kasprzyk, P. G., 75
Kast, W. M., 1825
Kato, M., 1255
Katsaros, D., 201
Katsumata, N., 553
Katzenellenbogen, J. A., 933
Kaufmann, S. H., 847, 1921
Kavanagh, J. J., 837, 1285
Kawakubo, K., 1583
Keilholz, U., 767
Kelley, M. J., 1 103
Kemp, B. L., 419
Kennedy, M. J., 1481
Keohavong, P., 411
Kerbel, R. S., 1417
Kern, H. F., 1607
Kerr, B. M., 7Kerr, D. J., 659Kessler, M., 1 I 15
Khanna, C., 721
Khayat. D., 47, 1405
Khazaeli, M. B., 1811
Khil, M. S., 53
Khorsand, M., 319
Kida, Y.. 1369
Kidouchi, K.. 1937
Kiessling, R., 1825
Kikuchi, K., 915
Kilinski, L., 59
Killion, J. J., 1627
Kilpatrick, D., 549
Kim, E. E., 837
Kim, I. Y., 1255
Kim, J. H.. 53
Kim, S., 1017, 1543, 1638
Kim, S. H., 53
King, C. R., 75
Kingston, J. E., 1499
Kinsella, T. J., 981, 1299
Kirkwood, J. M., 29, 1 129, 1263
Kitadai, Y., 1679
Kitagawa, Y., 909
Kitajima, M., 909, 1155
Kitamura, M.. 821
Klassen, J., 773
Klausner, J. S., 721
Klein, L., 1509
Klempner, M. S., 1341
Klintmalm, G., 531
Knox, S. J.. 457. 1289Knuth, A., 641, 1427Kobayashi. T., 799
Kobayashi, Y., 749
Ko#{231},0. N., 1353Kohn, K. W., 687Kohorn, E. I., 1693
Koishihara, Y., 253
Kolesnick, R. N., I
Kondo, S., 821
Kono, K., 1825
Kopp, W. C., 501
Koren, G., 1499
Kornmann, M., 1469
Kotelnikov, V. M., 1453
Kozlowski, J. M., 1255
Krajewski, S., 389
Kramer, K.. 1361
Kris, M. G., 471, 1819
Knistjansen, P. E. G., 359
Krol,G., 1819
KrUger, A., 811
Kubo, Y., 915
Kubota, Y., 929
Kubushiro, K., 749
Kudelka, A. P., 837, 1285
Kuiper, C. M., 521
Kumada, K., 1937
Kumar,R., 1215Kunugi, K. A.. 981, 1299
Kuo, D. Y-S., 1981Kurie, J. M., 287, 1787
Kursar, J. D., I 135
Kyo, S., 2023
Kyritsis. A. P., 1931
Kyrtopoulos, S. A., 303
L
LaFollette, S.. 1453
Lah. T. T., 561Lai, P., 161
Lamerz, R., 1565Lampen, N. M., 1017, 1638
Lamph,W.W.,511
Land, V. J., 331
Landreneau, R. J., 41 1
Lang, S., 1255
Langdon, S. P., 201
Lange. P. H., 1039
Langton-Webster, B. C., 207
Lapidus. R. G., 805
Larson, L. V., 477
Larson, M., 29
Lattime, E. C., 1383
Laub, P. B., 1685
Lauriola, L., 1895
Law, R. E.. 619, 843
Lazo, S., 493
Leach, S. D., 2015
Lebkowski, J., 59
Lechago,J., 1151
Lechago, L. V., 1151
Ledakis, P., 561
Leder. G. H.. 1469
Lee, C., 1255Lee,C.S.L., 1177Lee, J-H., 2029Lee, J. J., 1787, 2015
Lee, J. S., 287, 1 103, 1787Leek, R., 1591
2052 Author Index
Lehnert, M., 403
Leichman, C. G., 1461
Leiehman, L., 1461
Lengyel, E., 1879Leone, R., 1829LeRiche, J., I 103
LeSauteur, L., 1361
Lesser, G. J., 541
Leveille-Webster, C. R., 695
Leventhab, B. G., 331
Levin, B., 37
Levin, V. A., 1931
Levy, R., 457
Ley, T. J., 785
Li, C-W., 339
Li,J., 1169, 1619
Li,L.H., 1143
Li, Y., 107
Liang, B., 483
Liang, J. C., 1553
Liang, M. D., 477Lidereau, R., 1 163
Lieber, M. M., 137
Liles, T-M., 457
Lim, P. C., 1907
Lin, F., 1867
Lin, S., 1445Lin, W-e., 127
Lin, Y., 929
Lindemann, M. J., 669
Lindn#{233}r,P., 31 1
Lindstrom, M. J., 981, 1299
Ling, V., 1499
Link, K. H., 1469
Lippman, S. M., 287, 1787
Lipton, A., 1215Lissner, R., I I 15
Litwin, S., 1895Liu, L., 577, 865, 1129
Liu,T., 1811
Liu, T-J., 1659
Livingston, P. 0., 679Lloveras, B., 1887
Lloyd, T. L., 7
LoBuglio, A. F., 1811Loewen, G. M., 669
Loewen, G. R., 471Logan, T. F., 1263Loggie, B. W., I 107
Lokiec, F., 1943
Longo, D. L., 501
L#{248}nning, P. E., 1515Lopez, M. P., 1083Lorber, M. I., 1699
Lorenz, J., I 1 15Lotan, D., 855Lotan, R., 855, 1659
Lotze, M. T., 87, 127, 641
Loughlin, S., 1489
Low, J. A., 1207Lower, E., 1873Loyer, E., 1285
Lu,C., 1417Lu, Z-H., 477Luechi, M., 1067
Ludi, C. W., 97
Luna, M. A., 903
Lundgren, S., 1515
Luo, X., 107Lutz, L., 107Lyerly, H. K., 59
M
Madden, T., 1489
Maeurer, M. J., 87, 641
Maggi, M., 1757
Magliubo, G., 601
Mai, M., 1679
Malkhandi, J., 659
Malliek, S., 1981
Mandal, M., 1215Mann, K., 1565
Manni, A., 1901
Mantovani, G., 161
Manzano, R. G., 1321Marehesi, E., 593
Marchetti, A., 1591
Markiewski, M., 147
Markowitz, S. D., 1639, 1649Marks, J. R., 1571
Marquez, C., 457, 1289Marras, S. A. E., 1055Marshall, J. L., 1475
Martelli,M.L., 119
Martin, D., 87, 641
Martinec, J., 1509
MartInez-Miralles, E., 13
Marubini, E., 1 191
Marverti, G., 991Masri, L., 619
Massimini, G., 287
Mastrangebo, M. J., I 383Masuoka, K., 1383
Matsui, H., 915
Matsumoto, T., 821
Mauger, D., 1901
Maughan, R. L., 1543
Maurel, J., 1083
Maurizi, M., 1895May, F., 1445Mazzarella, G., 1239MeCaffery, M., 679
MeCaul, K., 1177MeClelland, R. A., 923MeCloskey, D. E., 441, 847
MeCue, P., 1383McDonald, J. D., 1559
McDonnell, 1. J., 1999McGinn, C. J., 1299MeGovren, J. P., 1 143MeLain, D., 347
MeLendon, R. E., 963
Mebacrinos, A. C., 41 1
Melief, C. J. M., 1825
M#{233}nard,S., 1777Mendelsohn, J., 601
Mendebsohn, L. G., 1135
Mera, R., 1851
Meredith, R. F., 1811
Meropol, N. J., 669Messinger, Y., 1533
Meyers, R., 947
Meyn, R. E., 1665
Mick, R., 755
Mier, J. W., 1341
Mikhail, M. S., 181
Milano, G., 507
Miller, A., 865
Miller, C. B., 1921
Miller, M. A., 1873
Miller, R. D., 1767
Miller, V. A., 471, 1819
Miller, W. R., 201
Mills, G. B., 1307
Milpied, N., 1673
Minami, H., 43
Minderman, H., 369, 1961
Mitchell, K., 303
Mitsudomi,T., 763, 1185
Miyamoto, H., 929
Miyazono, K., 1255
Miyokawa, N., 915
Mizokami, M., 1937
Mohler, J. L., 889
M#{246}hler,T., 767
Moisan, J-P., 1673
Monegier du Sorbier, B., 1943
Montag, A., 755
Montecillo, E. J., 1543
Montgomery, E. A., 1859
Monz#{243},M., 1083Morelbi, D., 207
Morelli, L., 1591
Moreno, A., 1887
Moreno, I., 1083
Mon. M., 1619
Mori,T., 821
Morice, R. C., 1787
Moritz, D., 1001Morris, R., 1107
Mortimer, J. E., 933
Motzer, R. J., 1077Mouawad, R., 47, 1405Mouridsen, H. T., 223
Mueller, M., 1017, 1638
Mues, G., 531
Muggia. F. M., 1461
Mukherjee, B., 1445Mullen, C. A., 53
Mundle, S., 1453
Murphy-Boesch, J., 339Murray, C., 493
Murray, M. K., 1315
Murray, N., 1103
Murugesh, D., 59
Musgrove, E. A., 923
Muss, H. B., I 107
Mussi, A., 1067
Myers, C. E., 483
Myers, D. E., 1533
Myers, J. N., 127
N
Naftzger, C., 1837
Nagel, M., 21
Nair, M. G., 707
Nakagawa, K., 1103
Nakagawara, A., 1097
Nanus, D. M., 1077
Naor,D.,81l
Naredi,P., 311
Negendank, W. G., 339
Negrin, R., 457
Nelson, J. B., 379
Nelson, W. G., 379
Nemeth, J. A., 1255
Neri, G., 175, 1895
Newkirk, K., I 859
Newlands, E. S., 897
Newman, R. A., 1489
Nguyen, D., 1665
Nicholson, R. I., 923
Nicholson, S. K., 897Nickerson, T., 2037
Nicobetti, M. I., 1725
Ning, S., 1289
Ning, S-C., 457
Nishida, K., I 185
Nishimura, T., 1859
Nishiwaki, Y., 941
Nodzenski, E., 755
Noordhuis, P., 1327Norman, S. A., 187
Normanno, N., 601
Noviello, C., 1601
Nozawa, S., 749
Nussler, V., 1031
0
Obasaju, C. K., 549
Obini, N. I.. 1743
O’Brien, J. M., 1499
Ochiai, A., 1373
Ockert, D.. 21
Oda,M., 1411
O’Dwyer, P. J., 339, 549, 1685
Oefelein, M. G., 1255
Oelkuct, M., 75
Oesterreich, S., 1 199
Ogami. A., 1185
Ogoshi, S., 1781Ohe, Y., 553Ohsaki, Y., 915
Ohsugi, Y., 253
Ohta,Y., 1411
Ohtsuki, Y., 1781
Ohyashiki, J. H., 1583
Ohyashiki, K., 1583
Okamoto, A., 821
Olencki, T., 347
Olopade, 0. 1.. 1993
Oppenheim, J. J., 501
O’Reilly, S., 541, 953
Oridate, N., 855
Onto, E., 1937
Orlando, C.. 1757
Ortiz, V., 1713
Osaki,T., 1185
Osborn, M., 147
Osborne, C. K., 585, 1 199
Oshita, F., 553
#{216}sterlind, K., 155
Ottaviano, Y. L., 805
Oyama. T., I 185
Ozawa, S., 909, 1155Ozols, R. F., 549
Ozturk, M., 1439
P
Pacini, F., 1777
Padavic-Shaller, K. A., 339
Pagani, A., 1757
Pagani, 0., 1 123
Pairolero, P., 1767
Paladugu, A., 1993
Palan, P. R., 181
Paleologos, N., 963
Palmer, J. L., 1553
Panje, W., 1453
Pantel, K., 1879Papandreou, C. N., 1077
Clinical Cancer Research 2053
Pappot. H., 155
Paradinas, F. J., 897
Park, S. J., 269Park. W., 2029Parkin, J. D., 713
Parl, F. F., 805Parmiani, G.. 593
Pastan, I., 245, 973, 1523
Pathak, S., 1627
Pati, R., 707
Patronas, N.. 483
Pavanel, F., 1829
Pawlita, M., 767
Pazdur, R., 37, 227
Pazzagli. M.. 1757
Pegram, C. N.. 963
Peinado, M. A.. 1887
Pepe, S., 207Perez, R. P., 669Pen, A., 1757
Persons. D. L.. 883
Peschel,C.. 1115
Peters, G. J., 521, 1327
Peters, W. P., 81
Petersson, M., I 825
Pettaway, C. A., 1627
Pfister, D. G.. 1819
Philip, M., 59
Philip. P. A., 303
Philip. R.. 59
Piatyszek, M. A., 799
Pierceall. W. E., 1097
Pifarr#{233},A., 1083
Piblasch, J.. 1469
Pinedo. H. M., 1327
Pinkel. D. P.. 331
Pinto, J. T., 1445Pioli. P., 873
Pirker, R., 1231
Pisters, K. M. W., 1819
Pitelli, M. R., 1843
Plott,W.E., 1811Plowman, J., 1 143Plunkett. W.. 653, 1731Podratz, K. C., 1907Pogliani, E., 593
Pollak, M., 2037Pollina, L., 1777
Pommier, Y., 687
Pontes, J. E., 1543Porfirio, B., 1577
Porter, M., 669Potkul, R. K., 1825Prabhu, N. S.. 1221
Prasanna, P., 865
Preisler, H. D., 1453
Press, M. F., 743
Prestigiacomo, L. J., 847
Price, B. D., 269
Pritze, W., I 879
Pu, Q., 843
Pugh, M.. 29Puisieux. A., 1439Pullen, D. J., 331Pun, R. K., 1743
Qian. M., 1685
Qian, Z., 1851
Qiao.C.H., 1445
R
Raber, M. N., 1489
Rabinowich, H., 161, 1263
Rager. H. C.. 501
Raghavan. D.. 1315
Rak, J. W., 1417Ramage. A. D.. 201Ramirez. E.. 1627
Rapp. M-J.. 1673Rasmussen, A. A.. 1859
Ratain, M. J., 43
Ravagnani, F., 593
Rayman. P.. 347
Raymond. E.. 1713
Real, F. X., 13Reale, M. A., 1097Redovan, C., 347Reed, E.. 483Reed, J. C.. 389Reichert, T. E., 1263
Reid, I. N., 1795
Reilly. D., 1685
Reiman, R.. 963
Reisfeld, R. A., 1951
Reiss, R., 873
Reiter, Y., 245
Ren#{233}e,N., 507Ressing. M. E., 1825
Resta, D., 347
Reyes-Mugica, M., 1097
Richards, F., I 107
Richardson. C.. 873
Richelme. H.. 507
Richmond, E., 1475
Rieppi. M., 1725
Rigas. J. R.. 471, 1819
Rim, P., 1867
Ritz, J., 493Rixe, 0., 47, 1405Ro, J. Y., I103, 1787
Robertson, J. F. R.. 923
Robinson, R. A., 883
Roeha,M., 811Roche, P. C., 1907
Roddey, G.. 1999
Roe, D. J., 947Rogatko, A., 549Rogers, E., 635
Rollinger-Holzinger. I.. 1031
Romero-Fisehmann, D.. 561
Romney. S. L., 181
Ronayne. L.. 1341
Rose, D. P., 1751
R#{246}sel,M., 447
Rosell, R.. 13. 1083Rosenberg. N., 561
Ross, R. K., 743
Roth. J. A., 1659, 1665Rowinsky. E. K.. 541. 953, 1921
Rubinstein, M. C.. 1097
Ruggiero, A., 207
Ruiz van Haperen. V. W. T., 521
Runowiez, C. D., 181, 1981
Rusinkiewiez, J., 1285
Russell, C. D., 181 1
Russell, G. B., 1107
Rustin, 0. J. S., 897
Rustum, Y. M., 369, 707. 1327,
1961
S
Saal, J.. 1289Saeger, H-D.. 21
Saijo. N., 553, 941
Sakamoto, H., 1373
Sakayori. M.. 749
Salisbury. A.. 303
Salomon, D. S., 601
Salter, R., 641
Salvadori, B.. 2007
Salwen, S.. 1383Samid, D., 483, 865
Samoszuk, M., 1867
Samuels, B.. 1509
Sanchez, J. J., 1083
Sanderink, G-J., 1943
Sandoval, A., 1731
Sandstrom, K., 347
Santoro, M., 119
Santucci, M., 1801
Sar, M., 889
Saragovi, H. U., 1361
Sartorius, S. E., 1921
Sasaki,T., 1411
Sato. T.. 1383Sausville, E. A., 1705
Scambia, G., 175
Seardino. P. T., 399, 635Schadendorf, D., 447
Schalken, J. A., 1055
Schaller, G., 1879
Scheck, A. C., 187
Scheibenbogen, C., 767
Scheper. R. J., 369Scherf, U.. 1523
Schieren, I.. 1017, 1638Schiff, P. B., 1017, 1638
Schiller, J. H.. 29, 319Schirrmaeher, V., 21, 811
Schlom,J., 1811Schmier, J. W., 767
Schneider, M., 447
Schnierle, B. S., l0()l
Schold, S. C., Jr., 963
Schroeder, L., 1509
Schwartz, P. E.. 1693, 1699
Schwulera, U.. I 115
Scoppa. C. A.. 75
Seelig. S. A.. 883
Seiter, S., 447Sekine. I., 941
Seliger, B., 1427
Selvam, M. P., 601Sengupta. S., 773
Serio, M., 1757
Seshadri, R., I 177
Sessa, C.. 1 123. 1717
Sessions, R. B.. 1859
Sestini, R., 1757
Seymour, J. F.. 653
Sgagias. M. K.. 215. 827
Shack, S., 865Shackelford, K. A., 1 135Shalinsky. D. R., S I I
Shapiro, C., 493
Shapiro, J. R., 187Shapiro, L., 1341
Shaw,E.G., 1103
Shaw, J. W., 1255Shay. J. W., 799
Sheehan, C., 1417
Shen, H-J., 1981Shen, Y., 1999
Sherman, M. L., 295Shibata, A., 743
Shih, C., I 135
Shih, I-M., 569
Shillitoe. E. J., 1659
Shimamoto, T., 1583
Shimamura, A.. 435
Shimizu, J., 141 1
Shimizu, N.. 909
Shin, H. J. C.. 1787Shinkai, T., 553
Shinozaki, H., 1 155
Shipley, L. A.. 359Shuster, J. J., 331Siegal, G. P.. 1089Siegel. B. A., 933
Siegfried. J. M., 75, 411Sierra, A., 1887
Silber, J. R., 735
Silvestrini, R., 2007Simonetti, L., 261, 1577
Simons, J. W., 379
Simpson, B. J. B., 201
Singletary. S. E., 419Sinierope, F. A.. 37, 1999. 2015
Sirotnak, F. M., 1819Skenderis, B. S., II, 1961Skibber, J. M.. 1665
Skrepnik. N., 1851
Slater, A., 713
Sledge. G. W.. 1063Slovak, M. L., 369, 1961Smid, K., 1327Smith, A., 69, 659
Smith, D. C., I 129
Smith, D. R., 1049Smith, H. S., 805
Smith, J. W., II, 501
Smith, P. J., 1369
Smith, S., I 107
Sneige. N.. 419Soiffer, R. J., 493
Sondel, P. M., 319, 1951Song. K.. 1335
Sonobe, H.. 1781
Sorce, D.. 1341Sorich, M., 59Soubrane, C., 47, 1405Souliotis, V. L.. 303
Sperotto. L.. 1829Spicer. D.. 1461
Spitz, F. R., 1665
Staib, L., 1469
Stambrook, P. J.. 1639
Stapleton. A. M. F.. 399, 635Steek, K., 419Steekelman, E., 1077
Stephens. L. C., 1999
Sterns, E.. 773Stetler-Stevenson, M. A., 1705Steuber, P., 331Stoelben, E., 21
Stone, M. J., 531, 1705Storer, B., 319Storkus, W. J., 87, 641
Storm, H. H., 223Storthz, K. A., 1659
Stower, M. J., 1795
2054 Author Index
Strathearn, G., 1867
Strong, J. M., 541, 953, 1481
Struck, R. F., 541Struff,W.G., 1115Su, D., 531Suchomel, R. W., 1231Suffoletto, B. P., 1445Sugarman, S. M., 1489Sugimachi, K., 763, 1 185
Sugimura, T., 1373
Sugio, K., 1185
Sullivan, 1. L., 75Sumi, S., 1937Suminami, Y., 127Sun, X., 1335Surfus, J. E., 1951
Surnock, A. A., 619Sutherland, R. L., 923, 1 177Suzuki, H., 821Swaney, W., 641
Sweatt, W. H., 379
T
TactIc, R., 253Tagliafem. P., 207Takahashi, S., 137
Takahashi, Y., 1679Takechi, Y., 1837Taketani, Y., 427Takimoto, C. H., 477
Tamp#{233},R., 1427Tamura, 1., 553Tanaka, M., 1411
Taniguchi, 1., 821
Tao, Y., 295Tarabobetti, G., 1725, 1843
Tates, A. D., 303Taylor, S., IV, 1453Tazelaar, H., 1767
Templeton, M. A., 295Terada, M., 1155, 1373Tester, D., 1907Tester, W. T., 561Thaler, H., 295Theiblet, C., 1601Thibault, A., 483, 865Thibodeau, S. N., 1907Thiessen, J. J., 1499Thomas, M. P., 287
Thomazy, V., 511
Thompson, C. B., 1215Thompson, T. C., 399, 635lien, R. D., 963
lilgen, W., 447
Tillery, G. W., 531lilley, W. D., 277limme, I. L., 399, 635loi, M., 821lomasic, G., 2007lomida, A., 427lominaga, I., 821Tompkins, A. C., 483Tong, A. W., 531Tong, W. P., 471, 1445, 1819
lorres, R., 687l#{243}rtola,S., 1887
lortora, G., 207, 601
16th, K., 369, 1961
louroutogbou, N., 227loyama, K., 1583loyoshima, E., 915
Trapasso, F., 1 19
Irehu, E. G., 1341
Irepel, J., 483Iresukosol, D., 837Inicarico, C., 1757
Iricot, G., 947
Trisber, K., 457, 1289
Irivers, G. E., 1767
Irock, B. J., 1859Troncoso, P., 1553Trovati, M., 261True, L. D., 1039
Iruglia, J. A., 471Irujillo, Y., 1509
Trump, D. L., I 129Truong, L. D., 399, 635
Tsai, Y. C., 743
Tseng, S. H., 735
Isukazaki, K., 749
Tsuruo, I., 427
Isuruta, H., 1155Isuruta, K., 821
lu,Z.N.,419Tuason, L., 347Tubbs, R., 347luck, A., 773Tucker, M. A., 1103lutsch, K. D., 1299Twentyman. P. R., 403, 1321lyer, C. L., 81Tyson, L. B., 1819
U
Uchino, S., 1373Uckun, F. M., 1533Ueda,M., 909, 1155
Ueda, R., 1937
Uemura, H., 929
Ueno, H., 2023Ueo, H., 1619
Uhr, J. W., 1705
Ullrich, S. E., 1969Ulm,E.H.,47lUmansky, V., 81 1
Urba, W. J., 501Urzi, G., 873
V
Vadell-Nadal, C., I 3
Vaickus, L., 669
Vabdimarsson, G., 1231Valenti, M., 687van Debft, J. H. M., 303van der Pod, H. G., 1055
van der Wilt, C. L., 1327
Vanhoefer, U., 369, 1961
van Laar, J. A. M., 1327
van Tellingen, 0.. 1717
Varma, D., 837Vams, C., 457
Veerman,G.,521
Venzon, D. J., 483Verderio, P.. 1 191
Vergani, V., 1843
Verjee, Z., 1499
Verola, 0., 47
Veronese, S., 1591
Veronesi, U., 2007
Verret, A. L., 471Verschraegen, C. F., 837
Verweij, J., 43
Vesole, D. H., 947
Vessella, R. L., 1039
Vet, J. A. M., 1055Viale, G., 1843
Vick, N. A., 963
Vignati, S.. 1067
Visconti, R., 1 19
Vitetta, E. S., 1705Voeltzel, I., 1439
Vokes, E. E., 755
von Hoegen. P.. 811Von Hoff, D. D., 1713Vredenburgh. J. J., 81
w
Wada, Y., 1937Waldman, I., 1221Wall, D. M., 713Wanders, J., 1717Wang, H., 1993Wang, P., 47Wang,R-Y., 1553Wang. T-L., 569Ward, M., 873Warrell, R. P., Jr., 471
Watanabe, K., 941Watanabe, Y., 141 1Waud, W. R., 1 143Webber, K. 0., 1523Weber, C., 287Weichselbaum, R. R., 755Weil, M., 1405Weiner, L. P., 619Weinstein, I. B., 1017, 1638
Weiss, M. H., 619, 843
Weitzel, H., 1879
Weitzman, S. A., 805Welch, M. J., 933Wels, W., 1001Wereley, J. P., 1009
Wesly, 0., 319Westra, W. H., 569Weyant. R. J., 41 1Wheeler, R. H., 1811
Wheeler, I. M., 399, 635
Whitehead, V. M., 331
Whiteside, I. L., 127, 161, 1263
Wientjes, M. G., 1275Wikstrand, C. J., 963
Wilding. 0.. 319, 1299
Wilhelm, K., 1115Wilkes, K. A.. 669
Willhauck, M., 767Williams, L., 295, 679
Williams, R. H., 635
Wilmanns, W., 1565
Wilson, E. M., 889
Wilson, M. R., 1627
Winick, N. J., 69
Winn, R., 128S
Wissel, P. 5., 7
Witherspoon, S. M.. 7
Witjes, J. A., 1055
Wolff, I.. 1717
Wong. J. R., 1335Wood, N., 1453
Worzalla, J. F., I 135
Woster, P. M.. 441
Wright, K. A., 1321
Wright. W. E., 799
Wu, E. Y., 1685Wu, 0. 5., 623, 1221Wu, X., 1461
x
Xie, K., 1969Xu, H., 1851
Xu,H-J., 1169Xu, X., 1795Xu, X-C., 855Xu, Y., 1837
V
Yamada, M., 427Yamaguchi. N., 1373
Yamamoto, N., 553Yamamoto, Y., 821Yanagihara, K., 1373
Yang, B., 1639, 1649Yang, G., 399, 635
Yang. J.. 441
Yang, X., 2037Yang. Y., 1619Yanishevski, Y., 1533
Yao, T-J., 679Yassin, R., 1873
Yasumoto, K.. 1 185Yasumura, S., 127
Yau, J., 59Yoneda, S., 941
Yoshida, M., 821
Yoshikawa, C.. 1781
Yoshikawa, H., 427
Younes, M., 1151
Yu, R., 1787Yung, W. K. A.. 1931
z
Zaidi, N. H., 577
Zalcberg. J. R.. 713
Zabutsky, M. R., 963
Zaninelli, M., 1829
Zelner, D. J., 1255Zeng, Y-X., 1221Zhang, L., I 19
Zhang, R., 477Zhang, W., 799, 843
Zhao, X. G., 963Ziesmer, S. C., 1907
Zimmerman, P. V., 1369
Zdller, M., 447Zwelling, L. A., 1489
Zwierzina, H., 1031
Vol. 2. 2055-2072, December /996 Clinical Cancer Research 2055
SUBJECT INDEX
Volume 2
A
Acroleinmultidrug resistance protein
modification, 1321
Adenocarcinoma, colonirinotecan combined with 5-tluorouracil
or etoposide, xenograft models, I 07
Adenocarcinoma, pancreaticresectable
bcl-2 and p53 expression, 2015
Adenovirusp21
truncated, growth suppression, I 221
wild-type p53. radiation sensitization,
I665
Adhesion moleculesCD8� I cells
GM-CSF release, melanoma T-cell
epitope detection and, 87
CD2O�#{176}Y-labeled anti-CD2O mAb,
recurrent B-cell lymphoma therapy.
457
CD44
expression, pancreatic carcinoma,
I 607
mRNA isoforms. thyroid and breast
carcinoma, I 251
variant isoforms. malignant
melanoma, 447expression, lymphoma liver metastasis,
811
5’-AdThd: see 5’-Amino-S’-deoxythymidine
Aerosol deliveryinterleukin 2 liposomes. canine studies,
721
natural IL-2, pulmonary malignancy,
I I 15
AG331continuous infusion, phase I trial, 1685
06-Alkylguanine-DNA alkyltransferasemodulation by carmustine and
streptozocin, refractory melanoma,
I 129
Alkyltransferasequantitative immunohistochemistry.
malignant colon. 577
retroviral gene transfer, human
hematopoietie progenitors. 13S3
ALRT1OS7combined with cisplatin
antitumor effects, human oral
squamous carcinoma xenografts, S I I
9-Aminocamptothecincisplatin cytotoxicity potentiation, 687
5’-Amino-S’-deoxythymidineIdUrd metabolism modulation, colon
cancer xenografts. 981
Aminopterinleukemia treatment, 69
Androgenreceptors
gene mutations, prostate cancer. 277
prostatic hyperplasia and carcinoma,
889
Aneuploidybreast carcinoma, 883
Aneusomychromosome-specific
breast carcinoma, 883
prognostic significance. prostate
carcinoma, 137
Angiogenesisdetermination
and estrogen receptor status. node-
positive breast cancer. 1 191
inhibition by IL-b, melanoma, 1969
inhibition by paclitaxeb. 1843
intestinal-type gastric carcinoma, I 679
Anthracyclinebifunctional chemotherapy with
nitrosourea, bladder cancer, I 315
MDRI expressionupregulation prevention by
cyclosporine A and PSC 833, 713
Antibody: see also Monoclonal antibodyanti-GD2-1L2 fusion protein
effector cell activation, 1951
anti-p53
serum, predating cancer, I 767
antireceptor
combined with retinoids, myeboma,
253
dual therapy with interferon, metastatic
colorectal cancer, I 8 1 1
engineering
recombinant Fv immunotoxins, 245
Antigen-expressing cells
TNF-B I (Fv) fusion protein cytotoxicantitumor activity. 1523
HLA-Abmelanoma T-cell epitopes. detection,
87
HLA-A2melanoma loss, 641
proliferating cell nuclear
and occult neck metastases, laryngeal
carcinoma. 1801
truncated p21 adenovirus, growth
suppression, 1221
prostate-specific
-producing prostatic carcinoma
xenograft LuCaP 23. 1039
prostate-specific membrane
folate hydrolase, prostatie carcinoma
cells. 1445
transporters associated with processing
MHC class I and, renal cellcarcinoma, 1427
tumor
gene expression. gastric carcinoma,
1619Antisense oligonucleotides
anti-EGF-related growth factorgrowth inhibition, colon carcinoma,
601c-mvc blockade, thyroid carcinogenesis,
1 19
Apoptosisand chemosensitivity, tumor cells, 623
coloreetal tumorigenesis. I 999
induction
ATRA and 4HPR. head and necksquamous cell carcinoma cell lines,
855
ceramide and, Iphenylbutyrate. prostate cancer. 379
loss, ductal breast carcinoma, 1887
modulation by HER2 overexpression.
MCF-7 cells, 1215modulation by PKC signal transduction
pathway, 1915
AR209
effects on orthotopic human lung
cancer, 1851
Arabinosylcyosine: see CytarabineArea under the concentration-time
curve
total topotecan, limited sampling model,
43
Aromatic fatty acidsmultidrug resistance vulnerability, 865
ATRA: see all-trans-Retinoic acidAUC curve: see Area under the
concentration-time curveAutologous tumor cell vaccine
Newcastle disease virus-infected
active specific immunotherapy.
colorectal carcinoma, 21
Autotransplantshigh-dose melphalan. renal failure, 947
Axillary lymph nodes-negative breast cancer
hsp27, 1199
Ki-67 vs S-phase fraction. 585
BAGE
B
expression, gastric carcinoma, 1619
Batimastatgrowth inhibition, solid breast tumors,
I 207BB-94: see
B cellschronic lymphocytie leukemia
chromosome l3qb4 deletions, 1673
lymphoma
recurrent. �#{176}Y-labeled anti-CD2OmAb therapy, 457
precursor, leukemia
B43-PAP plus cytosine arabinosidetreatment, SCID mice, 1533
bcl-2 proteinexpression
non-small cell lung cancer, 915
prostatie cancer, 389
reseetable pancreatic adenocarcinoma,
2015
T� breast cancer. 1887
-induced apoptosis
modulation by HER2 overexpression.
MCF-7 cells, 1215prognostic significance
2056 Subject Index
early stage head and neck cancer afterradiotherapy, 261non-small cell lung carcinoma, 1067
bcl-XL protein-induced apoptosis
modulation by HER2 overexpression,MCF-7 cells, 1215
BCNU: see CarmustineBEC2
anti-idiotypic vaccine
immunization, melanoma, 679Bile
irinotecan metabolites, 1943Bioassay
P-glycoprotein inhibition, serum, 403Biological agents
metastatic melanoma, phase I study, 295Biomarkers
p53 mutations, multifocal transitional
cell carcinoma of bladder, 1795
Bisantrenehematotoxicity
bisantrene resistance, retroviral MDRIgene transfer, 973
Bizelesinantitumor activity. mice. I 143
Bladder carcinomachemotherapy
bifunctional anthracycline and
nitrosourea, I 315
p53 mutations, 1055telomerase activity, 929transitional cell
multifocal, molecular screening withp53 mutations, 1795
Bladder tumorsdoxorubicin pharmacodynamics. 1275
Bladder washingsp53 mutations analysis, 1055
Bleomycinresistance
cytokeratin expression and, 97Blood: see Peripheral blood; Whole
blood
Blood vessels
tumorcounts, intestinal-type gastric cancer,1679eosinophil peroxidase, 1867
Bone marrowbisantrene resistance, retroviral MDR1
gene transfer, 973B43-PAP
combined with cytosine arabinoside,B-cell precursor leukemia, 1533
Brain tumors
methylator resistanceMGMT and, 735
resection cavities with subarachnoid
communication
intrathecab ‘311-labeled 8lC6 mAbtherapy, phase I trial, 963
Breastepithelial cells
lymphokine-activated killingsensitivity, 207
proliferative disease
vascularity. 1873Breast carcinoma
aneupboidy, 883
apoptosis modulation by HER2
overexpression, I 215bilateral, cbonal analysis, 743
CD44 mRNA isoforms, 1251cell death
paclitaxel-induced. 847
chromosome 6q loss of heterozygosity,1601
cyclin Dl and estrogen receptor mRNA
levels, 923DNA/RNA content, flow cytometric
analysis, 419
ductalapoptosis loss, I 887
estrogen receptor status
FES-PET and, 933
mRNA levels, 923immunomagnetic purging from
peripheral blood progenitor cells, 81
immunotherapy
active, gene modification of tumor
cells, 59
interleukin 6 paracrine growth factor,215
keratin 18 protein expression. 1879
MRP and MDRI expression, 1231
node-negative
hsp27, 1199
Ki-67 vs S-phase fraction, 585p53 expression, prognostic value,2007
node-positive
adjuvant tamoxifen, predictors ofoutcome, 1191treatment failure, Her2/neu
overexpression, 1509omega-3 fatty acid suppressive effects,
17�1pl6m�4” expression, 1993
�J9ARF expression, 1993PARP expression and genomie
instability, 1163
PDGF-�3 receptor, 773
positron emission tomography, 933postmenopausal
plasma estrogen and megestrolacetate, 1515
prognostic markers
cathepsin D. 613cyclin Dl gene amplification, 1 177
Ki-67 vs S-phase fraction, 585
MIB-1 tumor cell proliferation rate,
147
ornithine decarboxylase, 1901
p21 expression, 1591p53 expression, 1591
p53 expression, validation, 2007
urokinase plasminogen activator, 613RNA content, biological significance,
419systemic therapy response. PET and,
933
lymph node metastases, 1887lGF-�3, secretion
stimulation by INF-a, 827
treatment failure
Her2/neu overexpression, I 509
Breast carcinoma in situpreinvasive vascularity, I 873
Breast tumors
ER and PR gene methylation, 805
growth inhibition by batimastat. mice,
1207
Bronchial epitheliummetaplastie
EGFr expression. I 787D,L-Buthionine-(S,R)-sulfoximine
and multidrug resistance protein
function. 1961
C
E-Cadherinand occult neck metastases, laryngeal
carcinoma, 1801
Cancer: see CarcinomaCanthaxanthin
plasma levels, cervical intraepithelial
neoplasia and cancer, I 81
Carboplatincombined with cyclosporine A
refractory gynecologie cancer, phase I
trial, 1699refractory ovarian and fallopian tube
cancer, phase II trial, 1693
combined with paclitaxel.
pharmacokineties, 549
platinum-DNA adducts, ICP-MS
quantitation in peripheral blood
leukocytes. 1829
Carcinomaadvanced
combined leucovorin-fluorouracil and
iododeoxyuridine. 1475
high-dose edatrexate with oral
leucovorin, phase I trial, 1819PALA combined with fluorouraciland dipyridamole, phase I study, 1 107
9-cis retinoic acid, phase I trial, 471
choriocarcinoma
tebomerase activity. 2023
cisplatin resistance
thioredoxin, 427
interleukin 1 receptor antagonist
induction after IL-I therapy. 501
lovastatin, phase I study. 483
metastatie
interleukin-2 effects on natural killer
cells, 493
serum anti-p53 antibodies predating,
I 767
Te activity, mitoehondria, I 335TNF-B1(Fv) fusion protein antitumor
activity. 1523
Carcinoma, bladderchemotherapy
bifunctional anthracycline and
nitrosourea, I 315
p53 mutations. 1055
telomerase activity, 929Carcinoma, breast
aneuploidy, 883
apoptosis modulation by HER2
overexpression, 1215
bilateral, clonal analysis. 743
CD44 mRNA isoforms, 1251cell death
paclitaxel-induced, 847
chromosome 6q loss of heterozygosity,
1601
Clinical Cancer Research 2057
cyclin DI and estrogen receptor mRNA
levels, 923
DNA/RNA content, flow cytometrieanalysis. 419
estrogen receptor status
FES-PET and, 933
mRNA levels, 923
immunomagnetic purging from
peripheral blood progenitor cells, 81
immunotherapy
active, gene modification of tumor
cells, 59
interleukin 6 paracrine growth factor,
215
keratin 18 protein expression, 1879
MRP and MDRJ expression, 1231
node-negative
hsp27, 1199
Ki-67 vs S-phase fraction, 585
p53 expression, prognostic value.
2007
node-positive
adjuvant tamoxifen, predictors of
outcome, 1191
treatment failure, Her2/neuoverexpression, I 509
omega-3 fatty acid suppressive effects,
I 751
pj61N1(4�� expression, 1993
p/9ARF expression, 1993
PARP expression and genomic
instability, 1163
PDGF43 receptor, 773postmenopausal
plasma estrogen and megestrol
acetate, 1515
prognostic markers
cathepsin D, 613
cyclin Dl gene amplification, 1 177
Ki-67 vs S-phase fraction. 585
MIB-l tumor cell proliferation rate,147
ornithine decarboxylase. 1901p21 expression, 1591
p53 expression, 1591
p53 expression, validation, 2007
urokinase plasminogen activator, 613
RNA content, biological significance.
419
systemic therapy response, PET and,
933
lymph node metastases, 1887
TGF-�3, secretion
stimulation by TNF-a, 827
treatment failure
Her2/neu overexpression, I 509
Carcinoma, cervicalCD3 � expression. peripheral blood
lymphocytes, I 825
mieronutnent plasma levels, I 81paclitaxel activity. 1285
telomerase activity, 2023
Carcinoma, colonadjuvant therapy
sulindac plus 5-FU and levamisole.
phase I trial, 37
cisplatin resistance
thioredoxin, 427fluoropyrimidine efficacy and
thymidylate synthase inhibition,
murine 26-B tumors, 1327
growth inhibition by anti-EGF-related
growth factor antisenseoligonucleotides. 601
therapy
cytotoxicity. potentiation by wild-type
p53. 1649
wild-type p53 dominance, 1639
xenografts
5’-AdThd modulation of IdUrd
metabolism, 981
Carcinoma, colorectalc-mvc overexpression. 1049
immunotherapy
active specific, Newcastle disease
virus-infected autologous tumor cell
vaccine, 2 I
metastases
dual antibody therapy with interferon,
1811
liver, c-src and c-yes activation, 1397
p53 point mutations, 1049
radiosensitization by adenovirus wild-
type p53. 1665
radiosensitization by 5-fluorocytosine,
53
Carcinoma, ductal breastapoptosis loss. I 887
Carcinoma, endometrialabnormal glycolipid expression,
quantitative assay. 749
and tamoxifen, 223
telomerase activity. 2023
tumor blood vessel markers
eosinophil peroxidase. 1867
Carcinoma, epithelialovarian
docetaxel, phase II study. 837
Carcinoma, fallopian tuberefractory
carboplatin combined with
cyclosporine A, phase II trial, 1693
Carcinoma, gastricBAGE, GAGE, and MAGE gene
expression, 1619
cisplatin resistance
thioredoxin. 427intestinal-type
angiogenesis. 1679
K-sam protein, immunohistoehemicaldetection. I 373
Carcinoma, germ celladvanced
platinum-DNA adduets. 1063
Carcinoma, gynecologicrefractory
intravenous earboplatin and
cyclosporine A, phase I trial. 1699
Carcinoma, head and neckglutathione S-transferase staining, 1859
Carcinoma, hepatocellularchemosensitization
cyclosporine A, post-liver transplant
patient plasma, 531
multidrug resistance. murine model. 695
Carcinoma, laryngealoccult neck metastases, 1801
Carcinoma, lunganti-erhB-2 oncotoxin activity. 75
endogenous mutant p53-specific CTLs,
877prognostic markers
K-ras mutations, 41 1
thrombomodulin, 763
retinoblastoma gene family expression.1239
second, genetic analysis, I 103
serum cytokine levels, 553
vascular endothelial growth factor
mRNA expression. 141 1Carcinoma, non-small cell lung
advancedpaclitaxel, phase II study. 941
bel-2 protein expression, 915
chromosome 3p loss of heterozygosity,
I 185
K-ras mutations, 1083
orthotopie humananti-erbB-2 effects, 1851
p53 protein expression
prognostic significance. I 55
retinoblastoma and, I 169
and survival time, 915
prognosis
biological parameters. model. I()67
retinobbastoma protein expression. I I 69
TIMPI expression and adverse
prognosis, 1369Carcinoma, ovarian
cell motility inhibition by paclitaxel(Taxol), 1725
cyclic AMP-binding proteins, 201
immunotherapyactive, gene modification of tumor
cells, 59
p21 expression and p.53 mutation. 1571
refractory
earboplatin combined with
eyelosporine A, phase II trial. 1693
refractory advanced
docetaxel, phase II study. 837
signal transduction defects, tumor-
associated lymphocytes. 161
tebomerase activity, 2023tumor blood vessel markers
eosinophil peroxidase, 1867
variant and wild-type estrogen receptors,
2029
Carcinoma, pancreatichyaluronan receptors expression, 1607
Carcinoma, prostaticandrogen and glucocorticoid receptors.
889apoptosis
phenylbutyrate induction. 379
AR gene mutations, 277bel-2 protein expression. 389
chromosomal aneusomies, prognosticvalue, 137
clustered p53 immunostaining, 399hormone-refractory
‘�#{176}Y-CYl-356 treatment, 1289metastatie variants, orthotopie
implantation in nude mice, 1627
progression
trisomy 7 marker. 1553
prostate-specific membrane antigen
folate hydrolase, 1445
TGF-�3 I receptor expression. 1255
TGF�3R-Il levels, 635
2058 Subject Index
xenografts
LuCaP 23, characterization, 1039Carcinoma, renal
local tumor irradiation combined withIL-2 therapy, murine, 1543
Carcinoma, renal celllL-l3 antitumor effects, 1743MHC class I, LMP, and TAP genes,
1427
13-cis-retinoic acid antiproliferativeeffects, 1077
retinoic acid receptor �3 expression,1077
Carcinoma, small cell lunggemeitabine pharmacokinetics and
metabolism, 359second lung cancer, genetic analysis,
1 103
Carcinoma, squamous cellcervical
paclitaxel activity, 1285
esophageal
cyclin A overexpression, 1781
cyclin Dl gene amplification, TNM-
Gene, 1155EGFR gene amplification, 909
head and neckantitumor effects of cisplatincombined with ALRT1O57, humanxenografts, 5 1 1apoptosis by ATRA and 4HPR, 855
cytotoxie therapy, tumor cellproliferation, 1453growth stimulation by interleukin 4,127
human papilloma virus and p53, 755
microsatellite alterations at llp boci,
903radiotherapy, bcl-2 protein andprognostic significance after, 261
recurring, p53 mutations, 1577
topical gene therapy, organotypic
model, 1659laryngeal
cyclin DI gene amplification, 175lung
‘31l-labeled EGF radiolocalization, 13
thrombomodulin, prognostic value,
763
oralantitumor effects of cisplatin
combined with ALRI1OS7, human
xenografts, S 1 1Carcinoma, thyroid
CD44 mRNA isoforms, 1251c-myc overexpression, 119Mr 67,000 expression, 1777
Carcinoma, transitional cellbladder
multifocal, molecular screening with
p53 mutations, 1795p53 mutations and, 1055
recurrencedetection, clonality and, 1795
Carcinoma in situ, breastpreinvasive vascularity, 1873
Carmustinecombined with streptozocin, refractory
melanoma, I 129�1-Carotene
plasma levels, cervical intraepithelial
neoplasia and cancer, 181
Carzelesinphase I clinical and pharmacokinetie
study. 1717Cathepsin B
malignant lung tissue, 561
prognostic significance, breast cancer,
613Cathepsin D
malignant lung tissue, 561
prognostic significance, breast cancer,613
Cathepsin Lmalignant lung tissue, 561
prognostic significance, breast cancer,
613CD3
peripheral blood lymphocyte expression,cervical cancer. I 825
CD8I cells
GM-CSF release, melanoma I-cellepitope detection and, 87
CD2Oanti-CD2O mAb
‘�#{176}Y-labe1ed,recurrent B-celllymphoma therapy, 457
CD44
expression, pancreatic carcinoma. 1607mRNA isoforms, thyroid and breast
carcinoma, I 251variant isoforms, malignant melanoma,
447
Cell cycleG2 checkpoint
inhibitor UCN-0b, cisplatin
cytotoxicity and, 791
Cell death: see also Apoptosis
ceramide and, I
cisplatin-induced
modulation by growth factors, ovariancancer, 1307
HSV-IK DNA and gancielovir, 47p53 protein. 435
programmedpaclitaxel-induced, MDA-MG-468
cells, 847
polyamine analogue-induced, lungtumor cells, 441
all-trans retinoic acid and antireceptor
antibodies and, myeloma, 253
Cell growthall-trans retinoic acid and antireceptor
antibodies and, myeloma, 253
Cell proliferationcytotoxic therapy, head and neck
tumors, 1453prognostic significance. breast
carcinoma, 147Cells
-mediated immunity
lymphocytes, 785
p53 protein, 435
Ceramideand apoptosis induction, I
c-erb-B2
anti-erbB-2 oncotoxin, orthotopic human
lung cancer, 1851overexpression
apoptosis modulation. MCF-7 cells,
1215
Cervical carcinoma
mieronutrient plasma levels, 181
paclitaxel activity. 1285
peripheral blood lymphocyte CD3 �
expression. 1825
telomerase activity, 2023
Cervical intraepithelial neoplasiamieronutrient plasma bevels, 181
CGP 41251growth inhibition, glioblastoma, 1017,
I638
Chemosensitivity
apoptotie tumor cell death and, 623
-directed regional chemotherapy.
prospective decision-aiding trial. 1469
enhancement by gene therapy. 1089
Chemosensitization
cyclosporine A, post-liver transplant
patient plasma, 531
Chemosensitizers
P-glyeoprotein inhibition. serum
bioassay, 403
Chemotherapy: see also specific agents
bifunctional anthracycline and
nitrosourea, bladder cancer, 1315
combined with cyclosporine, intraocular
retinoblastoma, 1499
differentiation-inducing
telomerase inhibition, 799
high-dose
breast cancer treatment failure, Her2/
izeu overexpression, 1509
-induced cell death
modulation by growth factors, ovarian
cancer, 1307
regionalchemosensitivity-directed, prospective
decision-aiding trial, 1469
resistance
cytokeratin expression and, 97
standard-dose adjuvant
breast cancer treatment failure, Her2/
imeu overexpression, I 509
chl8-IL2effeetor cell activation. 1951
Childrenacute lymphocytic leukemia
red blood cell methotrexatepharmacology. 331
Chloroacetaldehydemultidrug resistance protein
modification, 1321
Choriocarcinomatelomerase activity, 2023
Chromosome 3ploss of heterozygosity, non-small cell
lung cancer, 1 185
Chromosome 4aneusomy, breast carcinoma, 883
Chromosome 6aneusomy. breast carcinoma. 883
long arm
loss of heterozygosity. breast cancer.
1601
short arm
rearrangement. melanoma, 641
Chromosome 7aneusomy, breast carcinoma, 883
Chromosome 8
Clinical Cancer Research 2059
aneusomy
breast carcinoma. 883
prostate carcinoma, I 37
Chromosomes 9-12
aneusomy. breast carcinoma, 883
Chromosome 1 ip
microsatellite alterations. head and neck
squamous carcinoma, 903
Chromosome l3ql4
deletions. B-cell chronic lymphocytic
leukemia, 1673
Chromosome 17
aneusomy, breast carcinoma, 883
Chromosome 17p
loss of heterozygosity, medulboblastoma,
I 559
Chromosome 18
aneusomy. breast carcinoma, 883
Chromosomes-specific aneusomy
breast carcinoma. 883
prostate carcinoma. I 37
Chromosome X
aneusomy. breast carcinoma. 883
Chromosome Y
aneusomies, prostate carcinoma. 137
Chronic obstructive pulmonary diseaseserum anti-p53 antibodies, predating
cancer, 1767
Cisplatinaccumulation and passive permeability.
modulation by genistein. 991
cell death
modulation by growth factors. ovarian
cancer, 1307
combined with ALRT 1057
antitumor effects, human oral
squamous carcinoma xenografts, 5 I I
cytotoxicity
9-aminocamptothecin potentiation,
687
UCN-0l enhancement, 791
gemeitabine interactions, 521
platinum-DNA adducts, ICP-MS
quantitation. 1829
resistance
thioredoxin. 427
Clonality
bilateral breast cancer, 743
and transitional cell carcinoma
recurrence detection, I 795
c-myc
overexpression
coloreetal carcinoma, 1049
thyroid carcinogenesis, 1 19
c-neuoverexpression
apoptosis modulation, MCF-7 cells,
1215
Colonmalignant
alkyltransferase. quantitative
immunohistochemistry. 577
Colon adenocarcinomairinotecan combined with 5-fluorouracil
or etoposide. xenograft models, 107
Colon carcinomaadjuvant therapy
sulindac plus 5-FU and levamisole.
37
5’-Adlhd modulation of IdUrd
metabolism, xenografts. 981
cisplatin resistance
thioredoxin, 427
fluoropyrimidine efficacy and
thymidylate synthase inhibition,
murine 26-B tumors, 1327
growth inhibition by anti-EGF-related
growth factor antisense
oligonucleotides. 601
therapy
cytotoxicity. potentiation by wild-type
p53. 1649
wild-type p53 dominance. 1639
Colon rhabdomyosarcoma
irinotecan combined with 5-fluorouracil
or etoposide, xenograft models. 107
Colon tumorsfluoropyrimidine efficacy and
thymidylate synthase inhibition,
murine 26-B tumors. 1327
Colorectal carcinomac-mvc overexpression. I 049
GlutI overexpression. I 151immunotherapy
active specific. Newcastle disease
virus-infected autologous tumor cell
vaccine, 21
metastases
dual antibody therapy with interferon,
1811
liver. c-src and c-yes activation, 1397
p53 point mutations, 1049radiosensitization by adenovirus wild-
typep53. 1665
radiosensitization by 5-fluorocytosine,
53Colorectal tumors
apoptosis. 1999
Complementary DNAalkyltransferase
retroviral transfer, human
hematopoietic progenitors, I 353
Costimulatory molecules
expression, lymphoma liver metastasis,
811
CPT-ll: see Irinotecanc-src
activation, colorectal carcinoma liver
metastases. I 397
CTL: see Cytotoxic T lymphocytesCyanine
tellurium-containing
anticarcinoma activity. mitoehondria.
I 335
Cyclic adenosine 3’,S’-monophosphate-
binding proteinsovarian cancer, 201
Cyclin Aoverexpression. esophageal squamous
cell carcinoma, 1781
Cyclin Dlgene amplification
laryngeal squamous cell carcinoma,
175
prognostic significance, breast cancer,
I 177
TNM-Gene, squamous cell carcinoma
of esophagus. 1155
mRNA levels, breast cancer, 923
Cyclophosphamide
high-dose
cyclophosphamide and
4-hydroxycyclophosphamide/adophosphamide
kinetics, 1481
kinetics, high-dose cyclophosphamide
chemotherapy, 1481
Cyclosporincombined with chemotherapy.
intraocular retinoblastoma, 1499
Cyclosporin Achemosensitization, post-liver transplant
patient plasma. 531
combined with carboplatin
refractory gynecologic cancer, phase I
trial, 1699
refractory ovarian and fallopian tube
cancer, phase II trial, 1693
prevention of MDR I upregulation. 713
c-yesactivation, colorectal carcinoma liver
metastases, I 397
Cytarabinecombined with methotrexate
red blood cell pharmacology. acute
lymphocytie leukemia in children,
311
continuous infusion
fludarabine interactions, 653
Cytokeratin
expression
and drug resistance, 97
Cytokinesserum levels, lung cancer, 553
Cytolysistumor cell, I-cell-mediated, l()0l
Cytosine arabinosidecombined with B43-PAP. B-cell
precursor leukemia. 1533
Cytosine deaminasegene
5-fluorocytosine radiosensitization
and, colorectal carcinoma, 53
Cytotoxicitycisplatin
9-aminocamptothecin potentiation,
687
UCN-0l enhancement, 791cisplatin combined with ALRTIO57.
human oral squamous carcinoma
xenografts. 51 1
potentiation by wild-type p53. colon
cancer. 1649
TNF-Bl(Fv) fusion protein activity. Le�’antigen-expressing cells, 1523
Cytotoxic therapytumor cell proliferation, head and neck
tumors. 1453
Cytotoxic T lymphocytesmutant p53-specific, lung cancer cells,
877
D
DacarbazineDNA damage
peripheral white blood cells,
malignant melanoma. 303
DCC
loss of expression, disseminated
neurobbastoma, I 097
DDATHF: see Lometrexol
2060 Subject Index
cis-Diamminedichloroplatinum(II): see
Cisplatin5,10-Dideazatetrahydrofolic acid: see
LometrexolDietary folate
and folate receptor expression.neoplastic murine tissue, I I 35
Dihydrofolate reductaseinhibitors
MDAM, antitumor effects, 707Dihydropyrimidine dehydrogenase
deficiency
5-fluorouracil neurotoxicity, 477
peripheral blood mononuclear cells and
liver, 507
Dihydropyrimidinuriaasymptomatic adult, 1937
Dipyridamolecombined with PALA and fluorouracil,
advanced cancer, 1 107
Dissemination
DCC boss of expression. neuroblastoma,
1097Disulfide-stabilized Fv immunotoxins,
245
DNA
breast carcinoma content, flow
cytometric analysis, 419
HSV-IKcombined with ganciclovir.
melanoma, 47DNA adducts
methyl
peripheral white blood cells,
malignant melanoma treated with
dacarbazine and hydroxyurea, 303
platinum
advanced germ cell cancer, 1063
ICP-MS quantitation, peripheral bloodleukocytes. 1829
DNA damagedacarbazine-induced
peripheral white blood cells,
malignant melanoma, 303
p53 response
tamoxifen and, 1439
DNA repair
mismatch
genes. sporadic endometrial tumors,
1907nueleotide excision
fludarabine-mediated inhibition, and
apoptosis, 1731
peripheral white blood cells, malignant
melanoma treated with dacarbazineand hydroxyurea, 303
Docetaxel
refractory advanced ovarian carcinoma,phase II study, 837
DoxorubicinMRP-mediated drug resistance
glutathione depletion and. 1961
pharmacodynamics, bladder tumors,
I 275resistance
cytokeratin expression and. 97PAK-104P reversal, 369
Drug interactions
cisplatin and gemeitabine. 521
fludarabine and continuous infusion
cytarabine. 653
Drug resistance: see also Multidrugresistance; specific drugs
cytokeratin expression and, 97
Drugs: see also specific drugs
drug-induced apoptosis
modulation by PKC signal
transduction pathway. 1915
exposure after intraperitoneal
administration
vasopressin and, 3 1 1
intraperitoneal
pharmacokinetics, vasopressin and,
311
Dysplasia: see also Myelodysplasticsyndrome
cervical
micronutrient plasma levels, 181
E
Eastern Cooperative Group TrialIFN--y, metastatie melanoma, 29
Edatrexatehigh-dose
combined with oral leucovorin, phase
I trial, 1819
EfTector cells
activation by anti-GD2-1L2 fusion
protein, 1951
e23(Fv)PE38KDELlung cancer activity, 75
orthotopic human lung cancer, 1851
EGF: see Epidermal growth factorEndometrial carcinoma
abnormal glycolipid expression,
quantitative assay, 749
and tamoxifen, 223telomerase activity, 2023
tumor blood vessel markers
eosinophil peroxidase. 1867
Endometrial tumorssporadic
DNA mismatch repair genes, 1907
EndometriumMDRI expression. 1981
Endothelial growth factorvascular
intestinal-type gastric cancer, I 679
mRNA expression, lung cancer, 141 1
serum levels, 821
Enzyme-linked immunosorbent assayp53 protein
prognostic significance. non-small cell
lung cancer, 155
Eosinophil peroxidase
tumor blood vessels, ovarian and
endometrial cancers, I 867
Epidermal growth factoranti-EGF-related growth factor antisense
oligonucleotides
growth inhibition, colon carcinoma.
601
‘31l-labeled
squamous lung carcinoma
radiolocalization, I 3
receptor
expression, metaplastic bronchial
epithelium, 1787
gene amplification. esophagealsquamous cell carcinoma. 909
Epithelial cells
mammary
lymphokine-activated killing
sensitivity. 207
ovarian
malignant. p2l expression and p53
mutation, 1571
Epithelial ovarian carcinomarefractory to platinum
docetaxel. phase II study. 837
Epithelium
androgen and glucocorticoid receptors.
prostatic hyperplasia and carcinoma,
889
metaplastic bronchial
EGFr expression, 1787Epitopes
I-cell
melanoma, detection. 87
erbB-2anti-erbB-2 oncotoxin
lung cancer. 75
orthotopic human lung cancer, I 851
erbB-3
receptors
tumor cells expressing, T cell-
mediated cytolysis. l(X)l
erbB-4receptors
tumor cells expressing. I cell-
mediated cytolysis, l0()l
Erythrocytesglucose transporter
overexpression, colorectal
carcinogenesis. I 151
methotrexate pharmacology. acute
lymphocytic leukeniia in children,
331
Erythropoiesisstimulation by stem cell factor,
myelodysplastic syndrome, I 031
Esophageal squamous cell carcinoma
cyclin A overexpression. 1781
cyclin Dl gene amplification, TNM-
Gene, 1155EGFR gene amplification. 909
Estrogen
plasma
suppression by megestrol acetate,
postmenopausal breast cancer. I 5 15
receptors
FES-PET and, breast cancer, 933gene methylation. breast tumors, 805
mRNA levels, breast cancer, 923
status. angiogenesis determination
and, 1191
variant and wild-type, ovarian
carcinoma, 2029
3-Ethyl-3’-methyl-
thiatelluracarbocyanine iodide
anticarcinoma activity. mitochondria,
I335
7-Ethyl-l0-(4-i-piperidinoj-l-piperidino)-carbonyloxy-camptothecin: see
IrinotecanEtoposide
combined with irinotecan, colon
adenocarcinoma or
rhabdomyosarcoma xenograft models.
107
Clinical Cancer Research 2061
F
Fallopian tube cancerrefractory
carboplatin combined with
cyclosporin A. phase II trial. 1693
Fatty acids
aromatic
multidrug resistance vulnerability. 865
omega-3
suppressive effects. breast cancer.
1751
Ferecombinant human TNF receptor
chimera
combined with IL-2. phase I trial,
I 341
FDG: see 2-I’8F]Fluoro-2-deoxy-u-
glucoseFES: see l6a-[m8F]Fluoro-l7�3-estradiol
Fibronectinserum levels. immunotoxin therapy,
1705
Flavonoids
quercetin. phase I clinical trial, 659
Flow cytometryDNA/RNA content. breast carcinoma.
419
GG918 inhibition by Pgp. 7Flow resistance
gemcitabine. small cell lung cancer. 359
Fludarabinecytarabine interactions. 653
nucleotide excision repair inhibition
and apoptosis. quiescent lymphocytes.
1731
Fluorescence in situ hybridization
chromosomal aneusomies, prostate
carcinoma, 137
chromosome 13ql4 deletions. B-cell
chronic lymphocytic leukemia, 1673
dual-color
trisomy 7. prostate cancer. 1553
5-Fluorocytosine
radiosensitization. colorectal carcinoma.
532-I ‘8FlFluoro-2-deoxy-D-glucose
positron emission tomography. breast
cancer, 933
l6Q�lmKFlF1uoro�l7��estradio1
positron emission tomography. breast
cancer. 933
Fluoropyrimidine
therapeutic efficacy
and thymidylate synthase inhibition.
colon 26-B tumors. 1327
Fluorouracilcombined with iododeoxyuridine and
leucovorin. phase I trial. 1475
combined with PALA and dipyridamole.
advanced cancer, I 107
5-Fluorouracil
catabolism
hepatic, ‘�F MRS quantitation. 339
combined with irinotecan, colon
adenocarcinoma or
rhabdomyosarcoma xenograft models.
107
combined with levamisole and sulindac,
colon carcinoma, 37
cytotoxicity
potentiation by wild-type p53, colon
cancer. I 649
neurotoxicity, dihydropyrimidine
dehydrogenase deficiency. 477
prodrug tegafur
combined with uracil. phase I and
pharmacokinetic study, 1461
Folate
analogue thymidylate synthase
inhibitors, 227
dietary
and folate receptor expression.
neoplastic murine tissue. I 135
receptors
dietary folate and. neoplastic murine
tissue, I 135
Folate hydrolaseprostate-specific membrane antigen,
prostatic carcinoma cells. 1445
Folinic acid rescue
combined with lometrexol, phase I
study. 1123
5-FU: see 5-Fluorouracil
Fusion proteinanti-GD2-1L2
effector cell activation, 1951
GM-CSF/IL-3effects on human tumor colony-
forming units. 1713
TNF-Bl(Fv). 1523
Fv immunotoxinsdisulfide-stabibized, 245
e23(Fv)PE38KDEL
lung cancer activity. 75
orthotopic human lung cancer, 185 I
recombinant
antibody engineering, 245
TNF-B I (Fv)
cytotoxic antitumor activity. Le�
antigen-expressing cells. 1523
GAGE
G
expression. gastric carcinoma. 1619
Gallium nitrateresistance
transferrmn and Ga-PIH and, lymphoid
leukemic cells, 1009
Gallium-pyridoxal isonicotinoylhydrazone
and resistance to gallium nitrate.
lymphoid leukemic cells, 1009
Ganciclovir
combined with HSV-TK gene transfer.
melanoma. 47
Ganglioside
GD2
anti-GD2-IL2 fusion protein. effector
cell activation. 1951
GD3BEC2 anti-idiotypic antibody mimic,melanoma. 679
Gastric carcinomaBAGE, GAGE. and MAGE gene
expression, 1619
cisplatin resistance
thioredoxin, 427
intestinal-type
angiogenesis, 1679
K-sam protein, immunohistochemical
detection. 1373
Gemcitabineinfusion pharmacokinetics and
metabolism, small cell lung cancer.
359
interactions with cisplatin. 521
Genes: see also Oncogenes; Proto-
oncogenes
androgen receptor (AR)
mutations. prostate cancer, 277
BAGE
expression, gastric carcinoma, 1619
cyclin Dl (CCNDI)
amplification, breast cancer, I 177
amplification, laryngeal squamous cell
carcinoma. I 75
amplification. TNM-Gene. I 155
expression. breast cancer. 923
cytosine deaminase
5-fluorocytosine radiosensitization
and, colorectal carcinoma, 53
DCC
loss of expression. disseminated
neuroblastoma, 1097
DNA mismatch repair. sporadic
endometrial tumors. I 907
epidermal growth factor receptor
( EGFR)
amplification. esophageal squamous
cell carcinoma, 909
estrogen receptor (ER)
expression, breast cancer, 923
methylation, breast tumors, 805
GAGEexpression. gastric carcinoma, I 6 I 9
K-ras
mutations. lung carcinoma. 41 1
mutations. non-small cell lung
carcinoma. 1083
MAGE
expression. gastric carcinoma. 1619
MDR
transfer into peripheral blood
progenitor cells. 873
MDRJ
bisantrene resistance. 973
expression, breast carcinoma, I 231
expression. endometrium, I 981
upregulation prevention by
cyclosporin A and PSC 833. 713
MRP
expression. breast carcinoma, 123 1�/6iNK4a
expression. breast cancer. 1993
p1 #{231}�ARF
expression. breast cancer. I 993
p53endogenous mutant CTL target. lung
cancer cells. 877
human papilloma virus and. head and
neck cancer. 755
mutations, bladder cancer, 1055
mutations. p21 expression and. 1571
mutations, recurring head and neck
cancer, 1577
point mutations, colorectal carcinoma,
I ()49
p’07expression. lung cancer, I 239
poly(ADP-ribose) polymerase ( PARP)
2062 Subject Index
expression and genomic instability,
breast cancer, 1 163
pRb/p105
expression, lung cancer, 1239
pRb/p130
expression, lung cancer, 1239
progesterone receptor (PR)
methylation, breast tumors, 805
retinoblastoma family
expression, lung cancer, 1239
retinoblastoma (RB)
expression, lung cancer, I 239
somatostatin receptor type 2
expression, neuroblastoma, 1757
TAP
MHC class I and, renal cellcarcinoma, 1427
TIMPI
expression and adverse prognosis,
non-small cell lung cancer. 1369
INM-Genecyclin Dl gene amplification,
squamous cell carcinoma of
esophagus, 1155
tumor antigen
expression, gastric carcinoma, 1619
wild-type p53
adenovirus, radiation sensitization,
1665Gene therapy
chemosensitivity enhancement, 1089
topical
head and neck squamous cell
carcinoma, organotypic model. I 659
Gene transferliposome-mediated
active immunotherapy, breast and
ovarian cancer, 59retroviral MDR1
bisantrene resistance, 973
retroviral MDR, peripheral blood
progenitor cells, 873
retroviral MGMT, human hematopoietic
progenitors, 1353
virus-free HSV-TK
combined with ganeiclovir,
melanoma, 47
Genisteinmodulation of cisplatin accumulation
and passive permeability, 991
Genomic instabilityleukemia, 1583PARP expression and, breast cancer,
1 163
Germ cell canceradvanced
platinum-DNA adducts, 1063
Germ cell tumorsmetastatie nonseminomatous
serum tumor marker half-life, 1565
GG918Pgp inhibition, flow cytometric assay, 7
Glioblastomagrowth inhibition by CGP 41251, 1017,
1638
Glioblastoma multiformerecurrence
low-grade, biological and molecular
analysis, I 87
Gliomamalignant
hypericin-enhanced radiosensitivity,
843
recurrent, high-dose I 3-cis-retinoic
acid treatment, 1931
recurrent, high-dose tamoxifen
treatment, 619
Glucocorticoid
receptors
prostatic hyperplasia and carcinoma,
889
Glucose
erythrocyte transporter
overexpression, coborectal
careinogenesis, I I S I
Glutathionedepletion
and multidrug resistance protein
function, 1961
Gbutathione S-transferaseimmunohistochemical staining, head and
neck cancer, 1859Gluti protein
overexpression. coloreetal
earcinogenesis, 1 151
Glycolipid
abnormal endometnab expression,
quantitative assay, 749
Glycoprotein 75cell surface target, melanoma, 1837
GM-CSF: see Granulocyte-macrophage
colony-stimulating factor
Granulocyte colony-stimulating factorcombined with topotecan, phase I trials,
1489
serum levels, lung cancer, 553
Granulocyte-macrophage colony-
stimulating factor
CD8� I-cell releasemelanoma I-cell epitope detection
and, 87
combined with IL-2, phase lB study,
319
GM-CSFIIL-3 fusion proteineffects on human tumor colony-
forming units, 1713
serum levels, lung cancer, 553
Growth factorEGF-related
anti-EGF-related growth factor
antisense oligonucleotides, colon
carcinoma, 601
epidermal
‘31I-labeled, squamous lung
carcinoma radiobocalization, I 3
receptor expression, metaplastic
bronchial epithelium, 1787
receptor gene amplification,
esophageal squamous cell carcinoma,
909insulin-like, I
regulation by ICI 182780, 2037
lipid
cisplatin-induced cell death
modulation, ovarian cancer, 1307
modulation
gene therapy strategy and
chemosensitivity enhancement, 1089
paracrine
interbeukin 6, breast carcinoma, 215
peptide
cisplatin-induced cell death
modulation, ovarian cancer, 1307
platelet-derived
l� receptors. breast carcinoma, 773transforming. 1�2
stimulation by INF-a. MCF-7 cells,
827
vascular endothelial
intestinal-type gastric cancer. 1679
mRNA expression, lung cancer, 141 1
serum levels, 821
Gynecologic cancer
refractory
intravenous carboplatin and
cyclosporin A, phase I trial, 1699
telomerase activity. 2023
H
Head and neck cancerglutathione S-transferase staining, 1859
Head and neck squamous cellcarcinoma
antitumor effects of cisplatin combined
with ALRTIO57, human xenografts.
511
apoptosis by ATRA and 4HPR, 855
cytotoxic therapy
tumor cell proliferation, 1453
early stage
radiotherapy, bcl-2 protein and
prognostic significance after. 261
growth stimulation by interleukin 4, 127
human papibboma virus and p53, 755
microsatellite alterations at llp loci, 903
recurring
p53 mutations, 1577
topical gene therapy, organotypic model,
1659
Head and neck tumorscytotoxic therapy
tumor cell proliferation, 1453
Heat shock protein 27prognostic significance, node-negative
breast cancer, 1 199
Hematological neoplasiareplication errors, 1583
Hematopoietic progenitor cells
autologous
breast cancer treatment failure, Her2/
nets overexpression, 1509
human
retroviral MGMT gene transfer, 1353
Hematotoxicitybisantrene-specific
resistance, retroviral MDR1 gene
transfer, 973
Hepatocellular carcinoma
chemosensitization
cycbosporin A, post-liver transplant
patient plasma. 531
multidrug resistance, murine model. 695
Hepatomamultidrug resistance, murine model, 695
HER2
overexpression
apoptosis modulation, MCF-7 cells,
1215
HER2/neuoncotoxin. orthotopic human lung
cancer, 1851
Clinical Cancer Research 2063
Fv
overexpression. breast cancer treatment
failure, 1509
Herpes simplex virus thymidine kinasegene transfer
combined with ganciclovir,
melanoma, 47
Heterozygosity, loss ofchromosome 3p. non-small cell lung
cancer, 1185
chromosome 6q, breast cancer, 1601
chromosome I7p. medulboblastoma,
1559
HLA: See Human leukocyte antigen
Hormonesrefractory prostate cancer
9�Y-CYT-356 treatment, 1289
4HPR: see N-(4-
Hydroxyphenyl)retinamideHSP: see Heat shock protein
HSV: see Herpes simplex virusHT-29 cells
thioredoxin, 427
Human leukocyte antigen
Al
melanoma T-cell epitopes. detection,
87
A2
melanoma loss, 641
Human papilloma virus
and p53, head and neck cancer, 755
Human tumor colony-forming assay
chemosensitivity
-directed regional chemotherapy,
prospective decision-aiding trial, 1469
Hyaluronanreceptor expression, pancreatic cancer
cells. 1607
Hybrid protein
pml/RAR-a
immune recognition. acute
promyelocytic leukemia, 593
4-Hydroxycyclophosphamide/adophosphamidekinetics, high-dose cyclophosphamide
chemotherapy, 1481
N-(4-Hydroxyphenyl)retinamideapoptosis induction, head and neck
squamous cell carcinoma cell lines,
855
7-Hydroxystaurosporinecisplatin-induced cytotoxicity and, 791
Hydroxyureacombined with dacarbazine
DNA damage, malignant melanoma,
303
Hypericin-enhanced radiosensitivity, malignant
glioma cells. 843
Hyperplasia
prostatic
androgen and glucocorticoid
receptors. 889
Hypoxanthine-guanine phosphoribosyl
transferasemutations
peripheral white blood cells,
malignant melanoma, 303
I
ICI 182780IGF-IR regulation. 2037
ICP-MS: see Inductively coupled plasmamass spectroscopy
IdUrd: see Iododeoxyuridine
IFN: see Interferon
IGF: see Insulin-like growth factor
IL: see Interleukin
Immune recognitionpml/RAR-a, acute promyelocytic
leukemia. 593
tumor escape. melanoma, 641
Immunity
cell-mediated, lymphocytes, 785
Immunization
BEC2 anti-idiotypic vaccine, melanoma,
679
Immunodeficiencysevere combined
B-cell precursor leukemia, B43-PAP
plus cytosine arabinoside treatment,
1533
multidrug resistance, murine
hepatoma model, 695
Immunoglobubin G
recombinant human TNF receptor
chimera
combined with lL-2, phase I trial,
1341
Immunohistochemistryglutathione S-transferase staining, head
and neck cancer, 1859
K-sam protein detection, stomach
cancer, 1373
MDRJ expression, endometrium, 1981
Mr 67,000 expression. thyroid cancer,
1777
p21 and p53 expression. breast
carcinoma, 1591
predictors of occult neck metastases,
laryngeal carcinoma. 1801
quantitative
alkyltransferase. malignant colon, 577
steroid receptors, prostatic hyperplasia
and carcinoma. 889
TGF�3R-II bevels, prostate cancer, 635
Immunomagnetic purging
peripheral blood progenitor cells, breast
cancer, 81
ImmunoreactivityMel-CAM, mesenchymal neoplasms.
569
Immunostaining
clustered p53. prostate carcinoma, 399
Immunotherapy
active
gene modification of tumor cells,
breast and ovarian cancer. 59active specific
Newcastle disease virus-infected
autologous tumor cell vaccine,
colorectal carcinoma, 21
melanoma
TCR-V�3 repertoire after, 767
metastatic melanoma
signaling activity in I cells before
and after, 1263
serum fibronectin levels, 1705
Immunotoxinse23(Fv)PE38KDEL
lung cancer activity. 75
orthotopic human lung cancer, 1851
disulfide-stabilized, 245
recombinant, antibody engineering,
245
ricin A chain-containing
treatment, serum tibronectin levels,
1705
TNF-B l(Fv)
cytotoxic antitumor activity, Le’�’
antigen-expressing cells, 1523
Inductively coupled plasma mass
spectroscopyquantitation of platinum-DNA adducts,
peripheral blood leukocytes, I 829
Insulin-like growth factor I
receptor regulation by ICI I 82780. 2037
Interferondual antibody therapy with, metastatic
coborectal cancer, 18 1 1
Interferon �
metastatic melanoma trial, 29
Interleukin 1
receptor antagonist induction after IL- 1
therapy. 501
Interleukin 2
anti-GD2-IL2 fusion protein
effector cell activation, 1951
combined with GM-CSF, phase lB
study, 319
combined with rhuTNFR:Fc, phase I
trial,1341
immunotherapy
combined with local radiation, murine
renal carcinoma, I 543
I-cell signaling activity. metastatic
melanoma, I 263
TCR-V�3 repertoire after, melanoma,767
inhaled natural, pulmonary malignancy,
I I 15
liposomes
aerosol delivery, canine studies, 721
low-dose
daily subcutaneous injections, toxicity
and immunological effects, 669
and natural killer cells, metastatic
cancer, 493
non-MHC-restricted lymphokine-
activated killing
sensitivity, MCF-IOA cells, 207
Interleukin 3
GM-CSF/IL-3 fusion proteineffects on human tumor colony-
forming units. 1713
subcutaneous recombinant human
refractory malignancy, phase I trial,
347
Interleukin 4growth stimulation. head and neck
squamous cell carcinoma. I 27
Interleukin 6
anti-IL-6 receptor antibodies
combined with retinoids, myeloma
and, 253
growth-stimulatory factor, melanoma.
1417
levels, lung cancer, 553
levels, metastatic malignant melanoma,
1405
paracrine growth factor. breast
carcinoma, 215
Interleukin 10
2064 Subject Index
K-ras growth factors
antiangiogenic effects, melanoma, 1969
production, melanoma, 1383
Interleukin 13antitumor effects. renal cell carcinoma,
1743
Intestinal-type gastric carcinomaangiogenesis, 1679
Intraepithelial neoplasia, cervicalmicronutrient plasma levels, 181
Intrahepatic xenograftshepatocellular carcinoma
multidrug resistance, murine model,
695Intraocular retinoblastoma
chemotherapy combined with
cycbosporin, 1499
Intraperitoneal drugspharmacokinetics
vasopressin and, 3 1 1
Intratumor pharmacokineticsgemeitabine, small cell lung cancer, 359
Iododeoxyuridine
combined with leucovorin and
fluorouracil, phase I trial, 1475
metabolism modulation by 5’-AdThd,
colon cancer xenografts. 981
5-Iododeoxyuridineradiosensitization
leucovorin modulation, phase I study,
1299
Irinotecancombined with 5-fluorouracil or
etoposide, colon adenocarcinoma or
rhabdomyosarcoma xenograft models,
107
metabolites, bile and urine, 1943
K
KDR
intestinal-type gastric cancer, 1679
Keratin 18protein expression, breast cancer, 1879
Ki-67
prognostic value, axillary node-negative
breast cancer, 585
Kidney carcinomalocal tumor irradiation combined with
IL-2 therapy, murine, 1543
Kidney failurehigh-dose melphalan autotransplants,
947
Kinase
herpes simplex virus thymidine
gene transfer, combined with
ganciclovir, 47
protein, A
subunits, lymphokine-activated killing
sensitivity and, 207
protein, C
inhibitor COP 41251, growth
inhibition, 1017, 1638
signal transduction pathway, drug-
induced apoptosis modulation, 1915
protein tyrosine
pp6O’src, activation, 1397pp62�ves, activation, I 397
tyrosine
inhibition by quereetin, phase I
clinical trial, 659
mutations
lung carcinoma, 41 1
non-small cell lung carcinoma, 1083
K-sam protein
immunohistoehemicab detection,
stomach cancer, 1373
L
LamininMr 67,000 receptor
expression, thyroid cancer, I 777
Laryngeal carcinomaoccult neck metastases, 1801
squamous cell
cvclin Dl gene amplification, 175
telomerase activity, 1895
Leptomeningeal neoplasmsintrathecal ‘311-labeled 8 1C6 mAb
therapy, phase I trial, 963
Leucovorincombined with fluorouracil and
iododeoxyuridine, phase I trial, 1475
IdUrd radiosensitizaiton modulation,phase I study, 1299
oral
combined with high-dose edatrexate,
phase I trial, 1819
Leukemiagenomic instability, 1583
lymphoid
gallium nitrate resistance, transferrin
and Ga-PIH and, 1009
Leukemia, acute
refractory
topotecan, phase I study. 1921
Leukemia, acute lymphoblastictreatment
aminopterin, 69
Leukemia, acute lymphocytic
children
red blood cell methotrexate
pharmacology, 331
Leukemia, acute myelogenoustebomerase activity, 799
Leukemia, acute promyelocyticimmune recognition of pm1IRAR-ct, 593
Leukemia, B-cell precursorB43-PAP plus cytosine arabinoside
treatment, SCID mice, 1533Leukemia, chronic lymphocytic
B-cell
chromosome l3ql4 deletions, 1673
Leukemia, 1-celladult
-derived factor, cisplatin resistance,
427
Leukocytes
peripheral blood
platinum-DNA adducts, ICP-MS
quantitation, 1829
Levamisolecombined with 5-FU and sulindac, colon
carcinoma, 37
Le’ cellsantigen-expressing
INF-B1(Fv) fusion protein cytotoxic
antitumor activity, 1523
Lipids
cisplatin-induced cell death
modulation, ovarian cancer, I 307
Liposomes
interleukin 2
aerosol delivery, canine studies, 721
Liverdihydropyrimidine dehydrogenase
activity, 507
5-fluorouracil catabolism, ‘9F MRS
quantitation, 339
metastasis
adhesion and costimulatory molecule
expression, lymphoma, 81 1
c-src and c-yes, colorectal carcinoma,
1397
Liver carcinoma
cycbosporin A chemoenhancement, post-
liver transplant patient plasma, 531
Liver transplantcycbosporin A chemosensitization, post-
liver transplant patient plasma, 531
Liver tumorsregional chemotherapy
chemosensitivity-directed, prospective
decision-aiding trial, 1469
Lometrexolcombined with folinic acid rescue, phase
I study, 1123Loss of heterozygosity
chromosome 3p, non-small cell lung
cancer, 1185
chromosome 6q, breast cancer, 1601
chromosome l7p, medulloblastoma,
1559
Lovastatin
phase I study, 483
Low molecular weight proteinMHC class I and, renal cell carcinoma,
1427
LuCaP 23characterization, 1039
Lungchronic obstructive pulmonary disease
serum anti-p53 antibodies, predating
cancer, 1767
malignancy
cathepsins, 561
inhaled nIL-2, phase I trial, 1 1 15
metastasis
local tumor irradiation combined with
IL-2 therapy and, murine renal
carcinoma, 1543
Lung carcinomaanti-erbB-2 oncotoxin activity. 75
endogenous mutant p53-specific CILs,
877
non-small cell
advanced, paclitaxel. 941
bcl-2 protein expression. 915
chromosome 3p loss of
heterozygosity, I I 85
K-ras mutations, I 083
orthotopic human, anti-erbB-2 effects.
I851
p53 protein expression, 155, 915,
I 169
prognosis, biological parameters.
1067
retinoblastoma protein expression,
1 169
Clinical Cancer Research 2065
TIMPI expression and adverse
prognosis. 1369
prognostic markers
K-ras mutations, 41 1
thrombomodulin, 763
retinoblastoma gene family expression,
I 239
second, genetic analysis, I 103
serum cytokine levels. 553
small cell
gemeitabine pharmacokinetics and
metabolism. 359
squamous
I 31 I-labeled EGF radiolocalization, 13
vascular endothelial growth factor
mRNA expression. 141 1
Lung tumorscathepsins. 561
malignant
inhaled nIL-2, phase I trial, I 1 15
polyamine analogue-induced cell death,
441
Lycopene
plasma levels, cervical intraepithelial
neoplasia and cancer, 181
Lymphatic drug exposure
after intraperitoneal administration
vasopressin and, 3 1 1
Lymph nodesmetastases
Glut I overexpression and, colorectabcarcinogenesis. 1 151
I, breast cancer, 1887node-negative breast cancer
hsp27. 1199
Ki-67 vs S-phase fraction, 585
p53 expression, prognostic value,
2007
node-positive breast cancer
adjuvant tamoxifen. predictors of
outcome, 1191
treatment failure, Her2/neu
overexpression. I 509
Lymphocytes: see also B cells; I cellsactivation by anti-GD2-IL2 fusion
protein. 1951
peripheral blood
CD3 � expression. cervical cancer,1825
pml/RAR-a immune recognition. acute
promyelocytie leukemia, 593
quiescent
apoptosis, fiudarabine and, I 731
tumor-associated
signal transduction defects, ovarian
carcinoma. 161tumor cell killing. 785
Lymphoid leukemiagallium nitrate resistance, transferrmn and
Ga-PIH and, 1009
Lymphokine-activated killingsensitivity
modulation by oncogenes and protein
kinase A subunits, MCF-IOA cells,
207
Lymphomaliver metastasis
adhesion and costimulatory molecule
expression, 8 1 1
Lymphoma, B-cellrecurrent
9#{176}Y-labeled anti-CD2O mAb therapy.
457
Lysistumor cell
I-cell-mediated, I 001
M
Macrophage colony-stimulating factorrecombinant
continuous-infusion, metastatic
melanoma, 295
serum levels, lung cancer, 553
MAGEexpression, gastric carcinoma, 1619
Magnetic resonance spectroscopythree-dimensional localized ‘9F
hepatic 5-fluorouracil catabolism
quantitation. 339
Major histocompatibility complexclass I
and LMP and TAP genes. renal cell
carcinoma, 1427
Malignancy
colon
alkyltransferase. quantitative
immunohistoehemistry. 577
glioma
hypericin-enhanced radiosensitivity.
843
recurrent, high-dose 13-cis-retinoic
acid treatment, 1931
recurrent, high-dose tamoxifen
treatment, 619
lung tissue
cathepsins. 561
melanoma
CD44 variant isoforms, 447dacarbazine-induced DNA damage.
peripheral white blood cells. 303
metastatie melanoma
IL-6 levels, 1405ovarian epithelial cells
p2 1 expression and p53 mutation.
I 571
pulmonary
inhaled nlL-2, phase I trial. I 1 15
refractory
subcutaneous IL-3, phase I trial, 347
Mammary epithelial cells
lymphokine-activated killing sensitivity
modulation by oncogenes and protein
kinase A subunits, 207
Mass spectroscopyinductively coupled plasma
quantitation of platinum-DNA
adduets. peripheral blood leukocytes.
I829
Matrix metalloproteinasesinhibitor batimastat
growth inhibition. solid breast tumors.
1207
MCF-7 cellsapoptosis modulation by HER2
overexpression, 1215
TGF-�3� secretion
stimulation by INF-a, 827
MCF-1OA cellslymphokine-activated killing sensitivity
modulation by oncogenes and protein
kinase A subunits. 207
M-CSF: see Macrophage colony-stimulating factor
MDAM: see ‘y-Methylene-lO-deazaaminopterin
MDA-MG-468 cellspaclitaxel-induced death. 847
MDR: see Multidrug resistanceMedulloblastoma
chromosome 1‘lp loss of heterozygosity.
1559
Megestrol acetateplasma estrogen suppression.
postmenopausal breast cancer, I 515
Melanomaadvanced-stage
IL-6 growth-stimulatory factor, 1417chromosome 6 rearrangement, 641
HLA-A2 loss, 641
immunization
BEC2 anti-idiotypic vaccine, 679immunotherapy
ICR-V�3 repertoire after, 767
interleukin 10 antiangiogenic effects.
1969interleukin 10 production. 1383
malignant
CD44 variant isoforms, 447dacarbazine-induced DNA damage,
peripheral white blood cells. 303
metastatie
continuous-infusion recombinant M-
CSF, phase I study. 295IFN--y trial, 29
signaling deficiency, T cells, 1263
metastatic malignant
IL-6 levels. 1405refractory
carmustine and streptozocin, I I 29
T-eell epitopes, detection. 87treatment
HSV-IK DNA and ganciclovir. 47
melanosomal protein cell surface
target. 1837
Melanosomal proteincell surface target, 1837
Mel-CAMimmunoreactivity, mesenchymal
neoplasms, 569
Melphalanhigh-dose, multiple myeloma. 947
resistance
cytokeratin expression and, 97
Mesenchymal neoplasms
Mel-CAM immunoreactivity. 569Messenger RNA
CD44 isoforms. thyroid and breastcarcinoma. I 251
cyclin Dl and estrogen receptor
levels, breast cancer, 923
MDRIexpression, endometrium, I 981
vascular endothelial growth factor
expression. lung cancer. 141 1
Metabolismgemcitabine, small cell lung cancer, 359
irinotecan, 1943
Metaplasiabronchial epithelium
EGFr expression, 1787Metastasis
breast cancer
2066 Subject Index
omega-3 fatty acid suppressive
effects, 1751
p53 accumulation and, 2007
coboreetal cancer
dual antibody therapy with interferon,
1811
interbeukin 2 effects on natural killer
cells, 493
liver
c-src and c-yes, coloreetal carcinoma,
1397
lymph node
Glutl overexpression and, colorectalcareinogenesis, 1 151
I� breast cancer, 1887
lymphoma
adhesion and costimulatory molecule
expression, liver, 8 1 1malignant melanoma
IL-6 levels, 1405melanoma
continuous-infusion recombinant M-
CSF, phase I study, 295IFN--y trial, 29
signaling deficiency, I cells, 1263
suppression by IL-b, 1969
neck
occult, laryngeal carcinoma, 1801nonseminomatous germ cell tumors
serum tumor marker half-life, 1565occult neck
laryngeal carcinoma, I 801
prostatie carcinoma
variants, orthotopic implantation in
nude mice, 1627pulmonary
local tumor irradiation combined with
IL-2 therapy and, murine renal
carcinoma, I 543
Methotrexate
pharmacology
red blood cell, acute lymphocytic
leukemia in children, 331
MethylationER and PR genes, breast tumors, 805
Methylatorsresistance
MGMT and, brain tumor cell lines,735
Methyl DNA adductsperipheral white blood cells, malignant
melanoma treated with dacarbazineand hydroxyurea, 303
�y-Methylene-10-deazaaminopterinantitumor effects, preclinicab evaluation,
707
06-Methylguanine-DNAmethyltransferase
and brain tumor cell line methylator
resistance, 735
retrovirab gene transfer, human
hematopoietic progenitors. 1353
Mevabonateinhibitor lovastatin, phase I study, 483
MGMT: see 06-Methybguanine-DNAmethyltransferase
MIB-1and occult neck metastases, laryngeal
carcinoma, 1801
tumor cell proliferation rate, breast
carcinoma, 147
Micronutrientsplasma levels, cervical intraepithelial
neoplasia and cancer, 181
Microsatellite alterations
leukemia and myelodysplastic
syndrome, 1583
llp loci, head and neck squamous
carcinoma, 903
Microsatellite instability
sporadic endometrial tumors
DNA mismatch repair genes. 1907
Microvessel countprognostic model, non-small cell lung
carcinoma, 1067
Mitochondria
le anticarcinoma activity, 1335Mitomycin C
resistance
cytokeratin expression and, 97
Mitoxantroneresistance
cytokeratin expression and, 97
Molecular screeningp53 mutations, mubtifocab transitional
cell carcinoma of bladder, 1795
Monoclonal antibodyanti-CD2O
�#{176}Y-labeled, recurrent B-cell
lymphoma therapy. 457
antitenasein 81C6
intrathecal ‘31I-labeled, phase I trial
therapy, 963
BIINF-Bl(Fv) fusion protein, cytotoxic
antitumor activity. 1523
BEC2 anti-idiotypicimmunization, melanoma, 679
5C3IrkA protein detection,
neuroblastoma, 1361
MIB- 1and occult neck metastases, laryngeal
carcinoma, 1801
tumor cell proliferation rate, breast
carcinoma, 147
�#{176}Y-CYI-356hormone-refractory prostate cancer
treatment, 1289
Mononuclear cellsperipheral blood
dihydropyrimidine dehydrogenase
activity, 507
M�-[4-(Morpholinosulfonyl)benzyl-N�-
methyl-2,6-diaminobenz-[c,dJ-indole
glucuronate: see AG331Mr 67,000
expression, thyroid cancer, 1777mRNA: see Messenger RNAMRP: see Multidrug resistance proteinMRS: see Magnetic resonance
spectroscopy
MUC18: see Mel-CAMMultidrug resistance
inhibitor GG9I 8
Pgp inhibition, flow cytometric assay,
7
MDR gene
transfer into peripheral blood
progenitor cells, 873
MDRJ gene
expression, breast carcinoma, 1231
expression, endometrium, I 981
retroviral transfer, bisantrene
resistance, 973
upregulation prevention by
cyclosporin A and PSC 833, 713
MRP-mediated
modulation by acrolein and
chloroacetaldehyde. 1321
PAK-lO4P reversal, 369murine hepatoma model, 695
vulnerability to aromatic fatty acids, 865
Multidrug resistance proteingene expression, breast carcinoma, 1231
glutathione depletion and. 1961
multidrug resistance
modulation by acrolein and
chloroacetaldehyde. 1321
PAK-lO4P reversal, 369
Multiforme, glioblastomarecurrence
low-grade. biological and molecular
analysis. I 87
Multiple myelomahigh-dose melphalan. 947
MutationsAR, prostate cancer, 277
DNA mismatch repair gene, sporadic
endometrial tumors, 1907
hypoxanthine-guanine phosphoribosyl
transferase
peripheral white blood cells,
malignant melanoma treated with
dacarbazine and hydroxyurea, 303
K-ras
lung carcinoma, 41 1
non-small cell lung carcinoma, 1083
p53bladder cancer, 1055
endogenous. CTL target. 877expression, soft tissue sarcoma, I 391
molecular screening. multifocal
transitional cell carcinoma of bladder,
1795
p2 1 expression and, malignant
ovarian epithelial cells, 1571
recurring head and neck cancer, I 577
point
p53, colorectal carcinoma, 1049
Myelodysplastic syndrome
erythropoiesis stimulation by stem cell
factor, 1031
microsatelbite alterations, I 583
Myelomaall-trans retinoic acid and antireceptor
antibodies and, 253
Myeloma, multiple
high-dose melphalan, 947
N
Natural killer cells
CD3 � expression, cervical cancer, 1825
expansion by daily subcutaneous low-
dose IL-2, 669
interleukin 2 effects, metastatic cancer.
493
tumor-associated
signal transduction defects. ovarian
carcinoma, 161
Neck
Clinical Cancer Research 2067
metastases
occult, laryngeal carcinoma, I 801
Neoplasia, cervical intraepithelialmicronutrient plasma levels, 181
Neoplasms: see TumorsNeu/erbB-2
receptors
tumor cells expressing. I cell-
mediated cytolysis. 1001
Neuroblastoma
dissemination
DCC loss of expression. 1097
somatostatin receptor type 2 expression,
1757
IrkA protein detection by mAb 5C3,I 361
Neurotoxicity5-fluorouracil. dihydropyrimidine
dehydrogenase deficiency, 477
Newcastle disease virusinfected autologous tumor cell vaccine
active specific immunotherapy.
colorectal carcinoma, 21
Nitrosoureabifunctional chemotherapy with
anthracycline. bladder cancer, I 315
resistance
retroviral MGMT gene transfer,
human hematopoietic progenitors,
1353
Non-small cell lung carcinoma
advanced
paclitaxel. phase II study. 941
anti-erbB-2 effects, orthotopic human,
I 851
bel-2 protein expression. 915
chromosome 3p loss of heterozygosity.
1 185
K-ras mutations, 1083
p53 protein expression
prognostic significance. 155
retinoblastoma and. 1 169
and survival time, 915
prognosis
biological parameters. model, 1067
retinoblastoma protein expression, 1 169
TIMPI expression and adverse
prognosis. 1369
NSC 615291: see Bizelesin
Nuclear antigenproliferating cell
and occult neck metastases, laryngeal
carcinoma, 1801
truncated p2 1 adenovirus. growth
suppression. 1221
Nucleotide excision repairfludarahine-mediated inhibition
and apoptosis. quiescent lymphocytes.
I 731
0
Oligonucleotides
antisense
anti-EGF-related growth factor, colon
carcinoma, 601
c-rnvc blockade, thyroid
carcinogenesis. I 19
OLX-209: see also AR209lung cancer activity, 75
Omega-3 fatty acids
suppressive effects. breast cancer. I 751
Oncogenes: see also Genes; Proto-
oncogeneslymphokine-activated killing sensitivity
and. MCF-IOA cells, 207
Oncoprotein: see also Proteinbcl-2
expression. non-small cell lung
cancer, 915
expression, prostatic cancer, 389
expression. resectable pancreatic
adenocarcinoma, 2015
expression. T� breast cancer, 1887
-induced apoptosis. MCF-7 cells,
1215
prognostic model, non-small cell lung
carcinoma, 1067
prognostic significance. early stage
head and neck cancer after
radiotherapy. 261
p21
expression. and p53 mutation, 1571
expression, breast carcinoma, I 591
truncated adenovirus, growth
suppression, 1221
p53alterations, non-small cell lung
carcinoma, I I 69
cell death, 435
clustered immunostaining, prostate
cancer, 399
DNA damage response. tamoxifen
and. 1439
endogenous mutant, CTL target. 877
expression. breast carcinoma, 1591
expression, non-small cell lung
cancer. 155. 915
expression. resectable pancreatic
adenocareinoma, 2015
MIB-b tumor cell proliferation rate,breast carcinoma. 147
mutant expression. soft tissue
sarcoma, 1391
prognostic model, non-small cell lung
carcinoma. 1067
prognostic value, breast cancer. 2007
suramin induction, 269
Oncotoxinsanti-erbB-2
lung cancer, 75
orthotopic human lung cancer. I 851
Oral squamous carcinomaantitumor effects of cisplatin combined
with ALRIIO57, human xenografts.
511
Organotypic modeltopical gene therapy, head and neck
squamous cell carcinoma, 1659
Ornithine decarboxylase
and breast cancer prognosis, 1901
Ovarian carcinomacell motility inhibition by paclitaxel
(Taxol), 1725cyclic AMP-binding proteins. 201
immunotherapy
active, gene modification of tumor
cells. 59
p21 expression and p53 mutation, 1571
refractory
carboplatin combined with
cyclosporin A. phase II trial, 1693
refractory advanced
docetaxel, phase II study, 837
signal transduction defects. tumor-
associated lymphocytes. 161
telomerase activity. 2023tumor blood vessel markers
eosinophil peroxidase. I 867
variant and wild-type estrogen receptors.
2029
Ovarian epithelial cellsmalignant
p2 1 expression and p53 mutation.
I 571
pI6”�’
P
expression. breast cancer. 1993pJ9SRF
expression, breast cancer, I 993
p21 proteinexpression
and p53 mutation. malignant ovarian
epithelial cells. 1571
prognostic value, breast carcinoma,
1591
truncated adenovirus, growth
suppression. 1221
p53 proteinalterations, non-small cell lung
carcinoma, I 169
anti-p53 antibodies
serum, predating cancer. I 767
cell death, 435
clustered immunostaining. prostatecancer, 399
DNA damage response
tamoxifen and, 1439
expression
resectable pancreatic adenocarcinoma,
2015
gene
human papilloma virus and, head and
neck cancer, 755
mutant expression. soft tissue
sarcoma, 1391
mutations. bladder cancer. I 055. 1795
mutations, CIL target. 877
mutations. malignant ovarian
epithelial cells, 1571
mutations, molecular screening. 1795
mutations, recurring head and neck
cancer. 1577
point mutations. colorectal carcinoma,
1049
MIB-1 tumor cell proliferation rate,breast carcinoma, 147
prognostic model. non-small cell lung
carcinoma, 1067
prognostic value
breast cancer. 1591
breast cancer, validation, 2007
non-small cell lung cancer. 155, 915
suramin induction, 269
wild-type
adenoviral-mediated gene expression.
radiation sensitization, I 665
cytotoxicity potentiation, colon
cancer, I 649
dominance, colon carcinoma cells,
1639
2068 Subject Index
p107 protein
gene expression, lung cancer, 1239
Paclitaxel (see also Taxol)activity, cervical cancer, 1285
advanced non-small cell lung cancer,
phase II study, 941
-induced cell death, MDA-MG-468
cells, 847
resistance
PAK-104P reversal, 369
PAK-104PMRP-mediated multidrug resistance
reversal, 369
PALA: see N-Phosphonacetyl-L-
aspartatePancreatic adenocarcinoma
resectable
bcb-2 and p53 expression, 2015
Pancreatic carcinomahyaluronan receptor expression, 1607
Paracrine growth factorsinterleukin 6, breast carcinoma, 215
PDGF: see Platelet-derived growthfactor
Pediatric Oncology Group study
red blood cell methotrexatepharmacology, acute lymphocytic
leukemia, 311
Pediatrics: see ChildrenPenclomedine
metabolism, murine and human, 953
tissue and tumor distribution. rats, 541
Peptidesgrowth factors
cisplatin-induced cell death
modulation, ovarian cancer, 1307
Periepithelial stromaPDGF 13 receptor, breast carcinoma, 773
Peripheral bloodleukocytes
platinum-DNA adducts, ICP-MS
quantitation, 1829
lymphocytes
CD3 � expression, cervical cancer,1825
mononuclear cells
dihydropyrimidine dehydrogenase
activity, 507
progenitor cellsimmunomagnetic purging, breast
cancer, 81
MDR transfer into, 873
white blood cells
dacarbazine-induced DNA damage.
malignant melanoma, 303Peritoneal drug exposure
after intraperitoneab administration
vasopressin and, 3 1 1
P-glycoproteininhibition
GG918, flow cytometric assay, 7serum bioassay, 403
Pharmacokineticscarboplatin with paclitaxel, 549
carzelesin, 1717
gemeitabine, small cell lung cancer, 359
high-dose melphalan, multiple myeloma,
947
intraperitoneal drugs
vasopressin and, 3 1 1
tegafur combined with uracil, 1461
Phenylacetatemubtidrug resistance vulnerability, 865
Phenylbutyrate
apoptosis induction, prostate cancer, 379
multidrug resistance vulnerability, 865
Phorbol ester tumor promotergrowth inhibition, glioblastoma, 1017,
1638
N-Phosphonacetyl-L-aspartatecombined with fluorouracil and
dipyridamole, advanced cancer, 1 107
PIXY321effects on human tumor colony-forming
units, 1713
PKC: see Protein kinase CPlacental site trophoblastic tumor
molecular analysis and clinical
experience, 897
Plasmacyclosporin A chemosensitization, post-
liver transplant, 531
drug exposure
intraperitoneal, vasopressin and, 3 1 1
estrogen
suppression by megestrol acetate,
postmenopausal breast cancer, 1515
micronutrient levels, cervical
intraepithelial neoplasia and cancer,
181
topotecan study, 1489
Platelet-derived growth factor
13receptors, breast carcinoma, 773Platinum
combined with cyclosporin A, refractory
ovarian and fallopian tube cancer,
1693
DNA adducts
advanced germ cell cancer, 1063ICP-MS quantitation. peripheral blood
beukocytes, 1829
head and neck cancer chemotherapy,
GST staining and, 1859refractory advanced ovarian carcinoma
docetaxel, phase II study, 837
pml/RAR-a hybrid proteinimmune recognition, acute
promyeloeytic leukemia, 593
Poly(ADP-ribose) polymerasegene expression
and genomic instability, breast cancer,
1 163
Polyamine analogues-induced cell death, lung tumor cells,
441
Polymerase chain reactionreverse transcription-
MDRJ expression, endometrium,
1981
somatostatin receptor type 2
expression, neuroblastoma, 1757
Positron emission tomography
FDG and FES, breast cancer, 933Progenitor cells
hematopoietic
breast cancer treatment failure, Her2/
nez� overexpression. 1509
retroviral MGMT gene transfer, 1353
peripheral blood
immunomagnetie purging, breast
cancer, 81
MDR transfer into. 873
Progesterone
receptors
gene methylation. breast tumors, 805
Proliferating cell nuclear antigen
and occult neck metastases, laryngeal
carcinoma. 1801
truncated p2 1 adenovirus
growth suppression, 1221
Proliferative breast diseasevascularity. 1873
Prostate-specific antigen-producing prostatic carcinoma
xenograft LuCaP 23. characterization.
1039
Prostate-specific membrane antigenfolate hydrolase, prostatic carcinoma
cells, 1445
Prostatic carcinomaandrogen and glucocorticoid receptors,
889
apoptosis
phenylbutyrate induction. 379
AR gene mutations, 277
bcl-2 protein expression. 389
chromosomal aneusomies. prognostic
value, 137
clustered p53 immunostaining. 399
hormone-refractory
�#{176}Y-CYT-356 treatment, 1289
metastatic variants, orthotopic
implantation in nude mice, 1627
progression
trisomy 7 marker, 1553
prostate-specific membrane antigen
folate hydrolase. 1445
TGF-�3l receptor expression. 1255
TGF�3R-II levels, 635xenografts
LuCaP 23. characterization. 1039
Prostatic hyperplasiaandrogen and glucocorticoid receptors.
889
Proteases
prognostic markers. 613
Protein: see also Oncoprotein
anti-GD2-IL2
effector cell activation, I 95 1
bcl-XL
-induced apoptosis. MCF-7 cells.
1215
CD44
mRNA isoforms, thyroid and breast
carcinoma, 1251
cyclic AMP-binding. ovarian cancer,
201
Glut 1
overexpression, colorectal
carcinogenesis, 1 15 1
glycoprotein 75
cell surface target. melanoma, 1837
GM-CSF/IL-3
effects on human tumor colony-
forming units, 1713
keratin 18
expression. breast cancer, 1879
K-sam
immunohistochemical detection,
stomach cancer, I 373
low molecular weight
MHC class I and, renal cellcarcinoma. 1427
- alkyltransferase, malignant colon, 577
Quercetin
phase I clinical trial, 659
R
Radiationcytotoxicity
potentiation by wild-type p53, colon
cancer, 1649
Clinical Cancer Research 2069
melanosomal
cell surface target, 1837
multidrug resistance
gene expression. breast carcinoma,1231
glutathione depletion and, 1961
multidrug resistance, PAK-104P
reversal, 369
P-glycoproteininhibition, serum bioassay, 403
inhibition by GG9I8, flow cytometric
assay, 7
pml/RAR-a
immune recognition. acutepromyelocytie leukemia, 593
retinoblastoma
alterations, non-small cell lung
carcinoma, 1169
signal-transducing
defects, tumor-associated
lymphocytes, ovarian carcinoma, 161
INF-Bl(Fv)cytotoxie and antitumor activity, Le”antigen-expressing cells, 1523
IrkAdetection by mAb 5C3,
neuroblastoma, I 361
Protein kinase A
subunits
lymphokine-activated killing
sensitivity and, MCF-1OA cells, 207
Protein kinase Cinhibitor CGP 41251
growth inhibition, glioblastoma, 1017,1638
signal transduction pathway
drug-induced apoptosis modulation,
1915
Protein tyrosine kinaseppfj�JC�SrC
activation, colorectal carcinoma liver
metastases, 1397
pp62�e�
activation, coborectal carcinoma liver
metastases, 1397
Proto-oncogenesc-myc
overexpression, eoloreetal carcinoma,
1049
PSC 833prevention of MDR1 upregulation, 713
Purgingimmunomagnetie
peripheral blood progenitor cells,
breast cancer, 81
Pyrimidine
urinary levels, 1937
local
combined with lL-2, murine renal
carcinoma, I 543
sensitization by adenovirus wild-type
PS3, coloreetal cancer, 1665Radiosensitivity
hypericin-enhaneed. malignant glioma
cells, 843
Radiosensitization
5-fluorocytosine. colorectal carcinoma.
53
5-iododeoxyuridine
leucovorin modulation, phase I study,1299
Radiotherapyearly stage head and neck cancer
bcl-2 protein. 261
head and neck cancer
p53 mutations, 1577
Receptorsandrogen
gene mutations, prostate cancer, 277
prostatie hyperplasia and carcinoma,
889
anti-IL-6, antibodiescombined with retinoids, myeloma,
253
anti-If, antibodies
combined with retinoids, myeloma,
253
epidermal growth factor
expression, metaplastic bronchial
epithelium, 1787
gene amplification, esophageal
squamous cell carcinoma. 909
erbB-3
tumor cells expressing, I cell-
mediated cytolysis, 1001
erbB-4tumor cells expressing. I cell-mediated cytolysis, 1001
estrogen
FES-PET and, breast cancer, 933
gene methylation, breast tumors, 805
mRNA bevels, breast cancer, 923
status, angiogenesis determination
and, 1191
variant and wild-type, ovarian
carcinoma. 2029
folatedietary folate and, neoplastic murine
tissue, 1135
glucocorticoid
prostatic hyperplasia and carcinoma,
889
hyaluronan
expression. pancreatic cancer cells,
1607
insulin-like growth factor I
regulation by ICI 182780, 2037
interleukin 1
antagonist induction after IL- I
therapy, 501
laminin, Mr 67,000
expression, thyroid cancer, 1777NeulerbB-2
tumor cells expressing, I-cell-mediated cytolysis, 1001
platelet-derived growth factor �3,
breast carcinoma, 773
progesterone
gene methylation. breast tumors, 805
9-cis-retinoic acid
combined with cisplatin. human oral
squamous carcinoma xenografts. 5 1 1
phase I trial, 471phase I trial, solid tumors, 287
13-cis-retinoie acid
antiproliferative effects. renal cellcarcinoma, 1077
high-dose. recurrent malignant glioma
treatment, I 931all-trans-retinoie acid
apoptosis induction, head and neck
squamous cell carcinoma cell lines.
855
combined with antireceptor
antibodies, myeloma and. 253
retinoic acid, �
expression, renal cell carcinoma, 1077somatostatin, type 2
gene expression. neuroblastoma, 1757steroid
prostatie immunohistochemistry, 889
I-cell
13 variable region, melanoma afterimmunotherapy, 767
transforming growth factor �
type II, prostate cancer, 635transforming growth factor �3 I
loss of expression. prostate cancer,
I 255IrkA
protein detection by mAb 5C3,
neuroblastoma, 1361tumor necrosis factor
recombinant human lgG chimera,combined with IL-2. 1341
vascular endothelial growth factor
(KDR)
intestinal-type gastric cancer, I 679
Red blood cellsglucose transporter
overexpression, colorectal
carcinogenesis, 1151
methotrexate pharmacology. acuteIymphocytie leukemia in children.331
Renal carcinomalocal tumor irradiation combined with
IL-2 therapy, murine, 1543
Renal cell carcinomaIL- 13 antitumor effects, 1743MHC class I, LMP, and TAP genes,
1427
I 3-cis-retinoic acid antiproliferativeeffects. 1077
retinoic acid receptor �3 expression.
1077
Renal failurehigh-dose mebphaban autotransplants.
947
Replication errorshematological neoplasia. 1583
Resistance: see Drug resistanceRetinoblastoma
gene family expression, lung cancer,I 239
intraocular
chemotherapy combined with
eyelosporin, 1499
2070 Subject Index
protein alterations, non-small cell lungcarcinoma, I I 69
Retinoic acidreceptor 13
expression, renal cell carcinoma, 10779-cis-Retinoic acid
combined with cisplatinantitumor effects, human oralsquamous carcinoma xenografts, S I 1
phase I trial, 471phase I trial. solid tumors, 287
13-cis-Retinoic acid
antiproliferative effects, renal cell
carcinoma, 1077
high-dose
recurrent malignant glioma treatment,1931
all-irans-Retinoic acidapoptosis induction, head and neck
squamous cell carcinoma cell lines,
855
combined with antireceptor antibodiesmyeloma and, 253
Retinolplasma levels, cervical intraepithelial
neoplasia and cancer, I 81Retroviral gene transfer
MDRinto peripheral blood progenitor cells,873
MGMT, human hematopoieticprogenitors, 1353
Reverse transcription-polymerase chainreaction
MDRI expression, endometrium, 1981somatostatin receptor type 2 expression.
neuroblastoma, 1757Rhabdomyosarcoma, colon
therapyirinotecan combined with 5-
fluorouracil or etoposide. xenograftmodels, 107
RHAMM
expression. pancreatic carcinoma, 1607
Ricin A chain-containing immunotoxin treatment
serum fibronectin levels, 1705
RNA
breast carcinoma content, 419TIMPJ expression
and adverse prognosis, non-small celllung cancer, I 369
S
Sarcoma, soft tissuemutant p53 expression, 1391
Serumanti-p53 antibodies, predating cancer,
1767
autologous, combined with stem cellfactorerythropoiesis stimulation,
myebodysplastic syndrome, 1031
cytokine levels, lung cancer, 553fibronectin levels, immunotoxin therapy,
1705
P-glycoprotein inhibition, bioassay, 403
tumor marker
half-life, germ cell tumors, 1565
vascular endothelial growth factorlevels, 821
Severe combined immunodeficiencyB-cell precursor leukemia
B43-PAP plus cytosine arabinosidetreatment, mice, 1533
multidrug resistance, murine hepatoma
model, 695
Signaling moleculesI-cell activity, metastatic melanoma,
1263
Signal-transducing proteinsdefects
tumor-associated lymphocytes.
ovarian carcinoma, 161
Small cell carcinoma, lunggemcitabine pharmacokinetics and
metabolism, 359second lung cancer, genetic analysis,
I 103
Soft tissue sarcomamutant p53 expression, I 391
Solid tumors9-cis retinoic acid, phase I trial, 287
Solid tumors, breast
batimastat growth inhibition, mice, 1207omega-3 fauy acid suppressive effects.
1751
Somatostatinreceptor type 2
gene expression, neuroblastoma, 1757
S-phase fractionprognostic value, axiblary node-negative
breast cancer, 585Squamous cell carcinoma, cervical
advanced or recurrent
paclitaxel activity, 1285
Squamous cell carcinoma, esophagealcyclin A overexpression, 1781
cyclin Dl gene amplification, INM-
Gene, 1155EGFR gene amplification. 909
Squamous cell carcinoma, head andneck
antitumor effects of cisplatin combinedwith ALRI1O57, human xenografts,
511
apoptosis by ATRA and 4HPR, 855
cytotoxic therapytumor cell proliferation, 1453
early stageradiotherapy, bcl-2 protein andprognostic significance after, 261
growth stimulation by interleukin 4, 127
human papilboma virus and p53, 755microsatellite alterations at llp loci, 903
recurring
p53 mutations, 1577topical gene therapy, organotypic model,
1659Squamous cell carcinoma, laryngeal
cyclin Dl gene amplification, 175tebomerase activity, 1895
Squamous cell carcinoma, lung‘31I-labeled EGF radiolocalization, 13
prognostic markers
thrombomodulin, 763
Squamous cell carcinoma, oralantitumor effects of cisplatin combined
with ALRI1O57, human xenografts,
511
ST-4 cellsthioredoxin, 427
Stem cell factor
erythropoiesis stimulation,
myelodysplastie syndrome, 1031
Steroidsreceptors, prostatic
immunohistochemistry, 889
Stomach cancer: see Gastric carcinomaStreptozocin
combined with carmustine, refractorymelanoma, I I 29
resistance
MGMI and, brain tumor cell lines,735
Stromaandrogen and glucocorticoid receptors,
prostatic hyperplasia and carcinoma,
889
periepithelial
PDGF 13 receptor, breast carcinoma,773
Sulindaccombined with 5-FU and levamisole,
colon carcinoma, 37
Superficial bladder cancerprogression
p53 mutations and, 1055
Suramin
p53 protein induction, 269
T
Tamoxifenadjuvant therapy
node-positive breast cancer. predictors
ofouteome, 1191endometnal carcinoma and, 223high-dose
recurrent malignant glioma treatment,
619-induced apoptosis
modulation by HER2 overexpression,MCF-7 cells, 1215
and p53 DNA damage response, 1439
Taxolantiangiogenic activity. 1843
earboplatin pharmacokinetics with, 549
cell motility inhibition, ovarian
carcinoma, 1725
I cellsCD8�
GM-CSF release, melanoma I-cellepitope detection and. 87
cytotoxie
mutant p53-specific, lung cancer
cells, 877
epitopes
melanoma, detection, 87leukemia, adult
-derived factor, cisplatin resistance,
427
-mediated tumor cell lysis. 1001
peripheralCD3 � expression, cervical cancer,1825
receptor-13
repertoire, melanoma after
immunotherapy, 767recognition of pml/RAR-a, acute
promyelocytic leukemia, 593
Clinical Cancer Research 2071
signaling deficiency, metastatic
melanoma, I 263
tumor-associated
signal transduction defects, ovarian
carcinoma, 161
Te: see 3-Ethyl-3’-methyl-thiatelluracarbocyanine iodide
Tegafur
combined with uracib, phase I and
pharmacokinetic study. 1461
Tellurium-containing cyanine
anticareinoma activity. mitochondria.
I 335
Telomeraseactivity. gynecological tumors, 2023
acute myelogenous leukemia activity.
799
bladder cancer activity. 929
laryngeal squamous cell carcinoma
activity, 1895
Temozolomideresistance
MGMT and, brain tumor cell lines,735
Tenascinantitenascin 81C6 mAb
intrathecal ‘31I-labeled, phase I trial
therapy, 963
l2-O-Tetradecanoylphorbol-13-acetategrowth inhibition. glioblastoma, 1017.
I638
TGF-132: see Transforming growthfactor 132
TGF: See Transforming growth factorThioredoxin
cisplatin resistance, 427
Three-dimensional ‘9F magneticresonance spectroscopy
hepatic 5-fluorouracil catabolism
quantitation, 339
Thrombomodulinprognostic value, lung cancer, 763
Thymidylate synthaseinhibition
fluoropyrimidine efficacy and, colon
26-B tumors, 1327
inhibitors
AG331, phase I trial. 1685
folate analogues, 227
Thyroid carcinomaCD44 mRNA isoforms. 1251
c-mvc overexpression. 1 19
Mr 67.000 expression. 1777
Tissue‘4C-penclomedine distribution, rats, 541
Tissue inhibitor of metalloproteinaseRNA expression
and adverse prognosis, non-small cell
lung cancer, 1369
I lymphocytes: see 1 cellsTNF-a: see Tumor necrosis factor a
TNM-Gene
cyclin Dl gene amplification, squamous
cell carcinoma of esophagus, 1 155
a-Tocopherolplasma levels, cervical intraepithelial
neoplasia and cancer, I 81
‘r-Tocopherolplasma levels, cervical intraepithelial
neoplasia and cancer. I 81
Topotecanphase I trials, 1489
leukemia, 1921
total
AUC curve, limited sampling model,43
Toxicity: see also Cytotoxicity;
Hematotoxicity; Neurotoxicity
daily subcutaneous low-dose IL-2, 669
high-dose melphalan. multiple myeloma,
947
Toxins: see Immunotoxins; OncotoxinsTransferrin
anti-If receptor antibodies
combined with retinoids, myeloma
and, 253
and resistance to gallium nitrate,
lymphoid leukemie cells, 1009
Transforming growth factor 13receptor type II, prostate cancer, 635
Transforming growth factor 131
receptors
loss of expression. prostate cancer,
1255
Transforming growth factor 132secretion
stimulation by TNF-a. MCF-7 cells,
827
Transitional cell carcinomarecurrence
detection. clonality and, 1795
Transitional cell carcinoma, bladder
multifocal
molecular screening with p53
mutations, I 795
progression
p53 mutations and, 1055
Transplantation, livercyclosporin A chemosensitization, post-
liver transplant patient plasma. 531
Transplantsautotransplants
high-dose melphaban. renal failure.
947
Transporters associated with antigenprocessing
gene expression
MHC class I and, renal cellcarcinoma, 1427
Trisomy 7
prognostic significance. prostate cancer,
1553
Trisomy 12
chromosome 13ql4 deletions and, B-cell
chronic lymphocytic leukemia. 1673
TrkA proteindetection by mAb 5C3, neuroblastoma,
1361
Trophoblastic tumors
placental site
molecular analysis and clinical
experience. 897
Tumor antigen genesexpression, gastric carcinoma. 1619
Tumor-associated lymphocytes
signal transduction defects, ovarian
carcinoma, 161
Tumor blood vesselscounts, intestinal-type gastric cancer,
1679
eosinophil peroxidase. ovarian and
endometrial cancers, 1867
Tumor cell proliferationcytotoxic therapy, head and neck
tumors, 1453
prognostic significance, breast
carcinoma. 147
Tumor cellschemosensitivity
enhancement by gene therapy. 1089
death
apoptotie, and chemosensitivity, 623
HSV-IK DNA and gancicbovir. 47
lymphocytes. 785
gene modification
active immunotherapy. breast and
ovarian cancer, 59
growth suppression by truncated p21
adenovirus, 1221
lysis
I-cell-mediated, 1001
mubtidrug-resistant
vulnerability to aromatic fatty acids,
865
Tumor colony-forming unitsPIXY32I effects, I 713
Tumor markerseosinophil peroxidase. ovarian and
endometrial cancers, 1867
serum
half-life, germ cell tumors, 1565
Tumor necrosis factorreceptors
recombinant human IgG chimera.
combined with IL-2. 1341
Tumor necrosis factor astimulation of IGF-132 secretion, MCF-7
cells, 827
INF-Bl(Fv) fusion protein. cytotoxicand antitumor activity. 1523
Tumor promotersphorbol ester
growth inhibition. glioblastoma, 1017.1638
Tumors‘4C-penclomedine distribution. rats, 541
folate receptor expression
dietary fobate and, murine, 1 135
growth suppression by IL-b,
melanoma, 1969growth suppression by truncated p21
adenovirus, 1221
somatostatin receptor type 2 expression.
I 757
TNF-Bl(Fv) fusion protein antitumoractivity. 1523
Tumors, bladderdoxorubiein pharmacodynamies. 1275
Tumors, brainmethylator resistance
MGMI and, 735resection cavities with subarachnoid
communication
intrathecal 31 I-labeled 8 1C6 mAbtherapy, phase I trial, 963
Tumors, breastER and PR gene methylation, 805
Tumors, colonfluoropyrimidine efficacy and
thymidylate synthase inhibition, I 327
Tumors, coborectal
2072 Subject Index
apoptosis, 1999Tumors, endometrial
sporadic
DNA mismatch repair genes, 1907Tumors, germ cell
metastatic nonseminomatousserum tumor marker half-life, 1565
Tumors, gynecologicaltelomerase activity, 2023
Tumors, head and neckcytotoxic therapy
tumor cell proliferation, 1453Tumors, hematobogical
replication errors, 1583Tumors, leptomeningeal
intrathecal ‘31I-labeled 8lC6 mAb
therapy, phase I trial, 963Tumors, liver
regional chemotherapy
chemosensitivity-directed, prospective
decision-aiding trial, 1469
Tumors, lungcathepsins, 561
malignant
inhaled nIL-2, phase I trial, 1115polyamine analogue-induced cell death,
441
Tumors, mesenchymabMel-CAM immunoreactivity, 569
Tumors, solidbreast
batimastat growth inhibition, mice,
1207
omega-3 fatty acid suppressive
effects, 17519-cis retinoic acid, phase I trial, 287
Tumors, trophoblasticplacental site
molecular analysis and clinicalexperience, 897
Tumor suppressor genes: see also GenesDCC
loss of expression, disseminated
neuroblastoma, 1097
expression, breast cancer, 1993�J9ARF
expression, breast cancer, 1993
p53endogenous mutant CIL target, lung
cancer cells, 877
human papilloma virus and, head andneck cancer, 755mutations, bladder cancer, 1055
mutations, p21 expression and, 1571
mutations, recurring head and neck
cancer, 1577
point mutations, colorectal carcinoma,1049
Tyrosine kinaseinhibition by quercetin, phase I clinical
trial, 659
U
U-7779: see BizelesinU-80244: see CarzelesinUCN-01: see 7-HydroxystaurosporineUFT
phase I and pharmacokinetic study,
1461Uracil
combined with tegafur, phase I and
pharmacokinetic study, 1461
Urineirinotecan metabolites, 1943
pyrimidine levels, 1937
Urokinase plasminogen activatorprognostic significance, breast cancer,
613
V
VaccinesBEC2 anti-idiotypic
immunization, melanoma, 679
Newcastle disease virus-infected
autobogous tumor cell
active specific immunotherapy,
colorectal carcinoma, 21Vascular endothelial growth factor
intestinal-type gastric cancer, 1679
mRNA expression, lung cancer, 141 1
receptor (KDR)intestinal-type gastric cancer, 1679
serum levels, 821
Vascubarityproliferative breast disease and
carcinoma in situ, 1873
Vascular leak syndromeserum fibronectin levels and,
immunotherapy, 1705
Vasopressinand intraperitoneal drug
pharmacokinetics, 31 1
Vessel countsintestinal-type gastric cancer, 1679
VimentinMIB-l tumor cell proliferation rate,
breast carcinoma, 147
Viruses
human papilloma
and p53, head and neck cancer, 755
Virus-free gene transfer
HSV-IKcombined with gancielovir,
melanoma, 47
w
White blood cellsperipheral
dacarbazine-induced DNA damage,
malignant melanoma, 303
Whole bloodPgp inhibition, flow cytometric assay, 7
Wild-type estrogen receptorovarian carcinoma, 2029
Wild-type p53cytotoxicity potentiation, colon cancer,
1649
dominance, colon carcinoma cells, 1639
gene expression
adenoviral-mediated, radiation
sensitization, 1665
x
Xenografts
colon adenocareinoma orrhabdomyosareoma
irinotecan combined with 5-
fluorouracib or etoposide, I 07
colon carcinoma
5’-AdThd modulation of IdUrdmetabolism, 981
hepatocellular carcinoma
multidrug resistance, murine model,
695
MRP-mediated multidrug resistance
PAK-104P reversal, 369
oral squamous carcinomaantitumor effects of cisplatin
combined with ALRIIOS7, 511
prostatic carcinoma
LuCaP 23, characterization, 1039
Y
�#{176}Y-CYT-356hormone-refractory prostate cancer
treatment, 1289
Clinical Cancer Research
Submit papers directly to one of the six Senior Editors, each of whom
is responsible for a particular area of research. Senior Editors will
Instructions for AuthorsScope
Clinical Cancer Research, a journal of the American Association for
Cancer Research, publishes original articles describing clinical research onthe cellular and molecular characterization, prevention, diagnosis, and ther-
apy of human cancer. Its focus is on innovative clinical research and
translational research which bridges the laboratory and the clinic. Clinical
Cancer Research is especially interested in clinical trials evaluating new
treatments for cancer, research on molecular abnormalities that predict
incidence, response to therapy, and outcome; and laboratory studies of new
drugs and biological agents that will lead to clinical trials in patients.Specific areas of interest include clinical and translational research in:
molecular pharmacology and chemotherapy; drug sensitivity and resist-
ance; tumor immunology and immunotherapy; radiobiobogy and radiation
oncology; solid tumor oncology; hematological malignancies; surgical on-
cology; pediatric oncology; molecular oncology and cancer genes; pathol-
ogy, markers, and prognostic indicators; growth factors, cytokines, and
signal transduction; bone marrow transplantation; gene therapy; cancer
endocrinology; cell adhesion, invasion, and metastasis; prevention of pri-
mary and recurrent cancer; differentiation and cell death; clinical genetics;
and detection of minimal disease.
Editorial Policy
When a manuscript is received for consideration, the Editors assume
that no similar paper has been or will be submitted for publication
elsewhere. Further, it is understood that all authors listed on a manu-
script have agreed to its submission. The signature of the corresponding
author on the letter of submission signifies that these conditions have
been fulfilled.
Journal policy requires that authors, reviewers, Associate Editors, and
Senior Editors reveal in a letter to the Editor-in-Chief any relationships that
they have that could be construed as causing a conflict of interest with
regard to a manuscript under review. The letter should include a statement
of any financial relationships with commercial companies involved with aproduct under study.
Upon acceptance, authors must transfer copyright to the American
Association for Cancer Research, Inc., the copyright owner of the
journal, prior to publication. Once an article is accepted for publication
in Clinical Cancer Research, the information therein is embargoed from
reporting by the media until the mail date of the issue in which the
article appears.
The Editors endorse the principles embodied in the Declaration of
Helsinki and expect that all investigations involving humans will have beenperformed in accordance with these principles. To obtain a copy of the
Helsinki Declaration, please contact the World Medical Association, 28,
Ave. des Alpes, F-012l0, Femey-Voltaire, France. For animal experimen-
tation reported in the journal, it is expected that investigators will have
observed the Interdisciplinary Principles and Guidelines for the Use ofAnimals in Research, Testing, and Education issued by the New York
Academy of Sciences’ Ad Hoc Committee on Animal Research, a copy ofwhich is available for $5.00 from the Marketing Department, New York
Academy of Sciences, 2 East 63rd Street, New York, NY 10021-7289. All
human and animal studies must have been approved by the investigator’s
Institutional Review Board.
conduct the review process with the expert assistance of the journal’s
Associate Editors, will correspond with authors about their manuscripts,
and will make editorial decisions regarding publication. Papers within
the subject areas covered by the Editor-in-Chief, as well as manuscripts
that do not pertain to any of the research areas listed, should be
submitted to Dr. Mendelsohn. Research areas, mailing addresses, and
telephone and fax numbers for the Editor-in-Chief and Senior Editors
can be found at the end of these Instructions.
Submit four original sets (not photocopies) of figures along with fourcopies of the manuscript. If a manuscript is closely related to papers that are
in press or have been submitted elsewhere, please provide copies of those
papers with your submission. For both original and revised submissions,we cannot guarantee that manuscripts and illustrations will be re-
turned to the author.The letter of submission can suggest the Associate Editors who might
serve as reviewers of the manuscript. In addition, we invite authors to
provide the names, addresses, and telephone/fax numbers of other potential
reviewers who are not current or recent collaborators or advisors in the areaunder investigation.
Advances in Brief will be reserved for concise, defmitive reports of
novel observations and discoveries that have unusual importance. A request
for consideration for Advances in Brief should be included in the letter of
submission. A Minireview is a briefanalysis (typically 3-4 printed pages) of
a focused, timely research topic, aimed at a multidisciplinary audience.Minireviews and Controversies in Clinical Cancer Research that are sub-
mined or solicited will undergo editorial review. The Editors welcome
Letters to the Editor, which will be published if they are determined to be
appropriate.
FormatManuscripts must be written succinctly in clear, grammatical English.
Define abbreviations in an inclusive footnote to the text. Double-space
on 8 1/2 x I 1-inch paper. Dot-matrix printing is not acceptable. The
format is as follows:
1 . Title page, including title, authors and their institutions, research
support, and address plus telephone/fax numbers of the correspond-
ing author;
2. A running title of fewer than 50 characters;
3. Three to five key words that do not appear in the title;
4. Abstract, of not more than 250 words, stating briefly the objectives,
methods, results, and conclusions of the study;
5. Text arranged in this order: Introduction, Methods, Results, Discus-
sion, Acknowledgments, References;
6. Footnotes, on a page separate from the text. Designate footnotes
consecutively with superscript Arabic numerals;
7. Tables, on pages separate from the text, with descriptive titles and
legends that make the data understandable without reference to the
text;8. Figure legends, on pages separate from the text, with descriptive
titles and explanations to make the data understandable without
reference to the text. Define all symbols and include staining forhalftones where applicable;
9. Figures.
Review Process
The review process, expedited by fax transmission and overnight mailservice, is conducted as rapidly as possible. Each submitted manuscript
is reviewed by at least two experts in the field of investigation. If the
authors are invited to submit a revised manuscript for an expeditedfurther review, the revised version must be submitted within three
months.
Manuscript Submission
References
Include only those articles that have been published or are in press.
Unpublished data or personal communications must be cited as foot-
notes to the text. Personal communications should be substantiated by a
letter of permission. Number references in the order of their first
mention in the text. Cite only the number assigned to the reference.
References must be double-spaced.
SAMPLE REFERENCES:
1. Shaffer, D. W., Smith, L. S., Burns, H. A., Clark, G. M., Eckardt, J. R.,
Fields, S. M., Weiss, G. R., Rinaldi, D. A., Bowen, K. J., Kuhn, J. G., and
Von Hoff, D. D. A randomized phase I trial of chronic oral etoposide with
ii Instructions for Authors
or without granulocyte-macrophage colony-stimulating factor in patientswith advanced malignancies. Cancer Res., 53: 5929-5933, 1993.
2. Dimaggio, J. J., Scheinberg, D. A., and Houghton, A. N. Monoclonal
antibody therapy of cancer. In: H. M. Pinedo, B. A. Chabner, and D. L.Longo (eds.), Cancer Chemotherapy and Biological Response ModifiersAnnual, Vol. 1 1, pp. 177-203. Amsterdam: Elsevier Science Publishers
B.V., 1990.
Figures
Provide four original sets of figures (whether line-cut draw-ings or halftones). Each sorted set should be in a separate labeledenvelope, for distribution to reviewers. A typed label placed on thereverse side of each figure should contain the first author’s name, figurenumber, and an arrow indicating top of figure. Letters and numbers onfigures should not be smaller than 6-point or larger than 12-point type.
All figures will be published at a width ofapproximately 3 inches (8 cm)unless the author requests a greater width. Use tissue overlays toindicate important areas of the photographs that must be reproducedwith greater fidelity.
Authors are encouraged to submit color figures. The expense of
reproducing color photographs must be offset partially by the author. In
1996, the cost of color reproduction charged to authors will be $975 per
color figure. Submit color figures on flexible backing.
Proofs
Page proofs must be returned to the office of the American Association for
Cancer Research within 24 hours of receipt. Return proofs by overnightmail. Proofs not received by the deadline will be published without the
authors’ corrections. Accepted manuscripts are regarded as final copy and
should not be altered substantially in proof. Extensive alterations couldcause publication delays, and authors will be charged for excessive alter-ations in proof.
Typesetting Manuscripts from Computer Disks
Clinical Cancer Research welcomes disks to expedite production ofaccepted manuscripts. If your article is accepted for publication, you
will receive instructions regarding disk submission. It is the author’s
responsibility to ensure that the material on the disk matches the final
accepted version of the manuscript.
Research Areas of the Editor-in-Chief and Senior Editors
John Mendelsohn, M.D.Department of Educational Publishing Services-227The University of lexas M. D. Anderson Cancer Center1515 Holcombe BoulevardHouston, TX 77030Telephone: 713-792-6014Fax: 713-792-6016E-mail: [email protected]
Cell proliferation and death-preclinical, and clinical trials: radiation
therapy, surgery, and subspecialty investigation
Waun Ki Hong, M.D.
Department of Thoracic/Head & Neck Medical OncologyThe University of Texas M. D. Anderson Cancer CenterBox 801515 Holcombe Boulevard
Houston, TX 77030
Telephone: 713-792-6363
Fax: 713-796-8655
E-mail: [email protected]’.tmc.eduClinical trials targeted at specific malignancies, chemoprevention
Lance A. Liotta, M.D., Ph.D.
Laboratory of Pathology
National Cancer Institute
Building 10, Room 2A33
National Institutes of Health
10 Center Drive, MSC 1500
Bethesda, MD 20892-1500
Telephone: 301-496-3185Fax: 301-402-0043
E-mail: [email protected]
Pathology, metastasis
David Sidransky, M.D.
Otolaryngology/Head & Neck Cancer Research
Johns Hopkins University
818 Ross Research Building
720 Rutland Avenue
Baltimore, MD 21205-2196
Telephone: 410-550-5153
Fax: 410-614-1411
E-mail: [email protected]
Molecular pathogenesis, molecular correlates
Paul Sondel, M.D., Ph.D.Departments of Pediatrics, Human Oncology, & Genetics
University of Wisconsin Clinical Science Center
K4/448
600 Highland Avenue
Madison, WI 53792Telephone: 608-263-9069
Fax: 608-263-4226E-mail: [email protected]
Immunotherapy and cytokines-preclinical, and clinical trials
David R. Spriggs, M.D.
Developmental Chemotherapy Service
Memorial Sloan-Kettering Cancer Center1275 York Avenue
New York, NY 10021
Telephone: 212-639-2203Fax: 212-717-3272E-mail: [email protected]
Preclinical pharmacology, pharmacological clinical trials
Jeffrey M. Trent, Ph.D.
Laboratory of Cancer Genetics
National Center for Human Genome Research
National Institutes of Health
Building 49, Room 4A22
49 Convent Drive, MSC 4470Bethesda, MD 20892-4470
Telephone: 301-402-2023
Fax: 301-402-2040E.mail: [email protected]
Genetics, cytogenetics
For more information, contact:
John Mendelsohn, M.D., Editor-in-Chief, Clinical Cancer Research,
Department of Educational Publishing Services-227, The University of
Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard,Houston, IX 77030, Telephone 713-792-6014, Fax 713-792-6016
or:
Publications Department, American Association for Cancer Re-
search, Public Ledger Building, Suite 816, 150 South IndependenceMall West, Philadelphia, PA 19106-3483, Telephone 215-440-9300,
Fax 215-440-9355.
AACR SPECIAL CONFERENCE IN CANCER RESEARCH
Co-Sponsored by the Joint Section on Tumors of the American Association of
Neurological Surgeons and Congress of Neurological Surgeons
Cancer of the Central Nervous System
June 7-11,1997Loews Coronado Bay Resort
San Diego, CA
CONFERENCE CO-CHAIRPERSONS
Webster K. Cavenee I La Jolla, CA Peter McL. Black I Boston, MA
PROGRAM COMMITTEE
William F. Chandler I Ann Arbor, Ml Mark D. Noble I Salt Lake City, UTJoseph Piepmeier I New Haven, CT Bernd R. Seizinger I Boston, MA
Jean V. J. Wang I La Jolla, CA
CONFERENCE PROGRAM
Keynote AddressCharles B. Wilson I San Francisco, CA
Triumphs and Challenges of PresentDiagnosis and Management
Catherine Dumas-Duport I Paris, FrancePeter McL. Black I Boston, MAJay S. Loeffler I Boston, MAVictor A. Levin I Houston, TX
Neurobiology and DevelopmentalBiology
Fred H. Gage I La Jolla, CA
Mark D. Noble I Salt Lake City, UT
Genetic Predispositions to CNS TumorsJean V. J. Wang I La Jolla, CALawrence A. Donehower I Houston, TXEric C. Holland I Bethesda, MD
Molecular GeneticsDavid N. Louis I Boston, MAHuei-Jen Su Huang I La Jolla, CAOtmar D. Wiestler I Bonn, Germany
New Targets for TherapyMark L. Rosenblum I Detroit, MlDavid Hockenberry I Seattle, WAJerry W. Shay I Dallas, TX
Receptor Mediated Growth ControlCharles D. Stiles I Boston, MA
Webster K. Cavenee I La Jolla, CALewis T. Williams I San Francisco, CA
Novel TherapiesXandra 0. Breakefield I Boston, MAJackson B. Gibbs I West Point, PAJudah Folkman I Boston, MAFrank McCormick I San Francisco, CA
ADDITIONAL SPEAKERS TO BE ANNOUNCED
Application Deadline: March 14, 1997
Information and Application Forms:American Association for Cancer ResearchPublic Ledger Building, Suite 816150 South Independence Mall WestPhiladelphia, PA 19106-348321 5-440-9300 21 5-440-931 3 (FAX)E-mail: [email protected]: http://www.aacr.org
Hit our Home Page
on the
World Wide Web!
http://www.aacr.org
Our web siteftatures ...
. AACR scientifio meeting schedule
. Table of Contents of AACR journals
. Instructions for Authors
. Information about AACR Research
Fellowships and Travel Awards
Plus . . .The latest AACR newsletter, and much more!
�! �
IkCER �
AMERICAN ASSOCIATION FOR CANCER RESEARCH
GUIDELINES FOR APPLICATION FOR ACTIVE AND
CORRESPONDING MEMBERSHIP
Notification of Candidate
MarchJuly
November
2� �
�
BENEFITS OF MEMBERSHIP
The American Association for Cancer Research (AACR), a scientific
society of over 1 1 ,500 laboratory and clinical cancer researchers, was
founded in 1907 to facilitate communication and dissemination of knowl-edge among scientists and others dedicated to the cancer problem; to
foster research in cancer and related biomedical sciences; to encourage the
presentation and discussion of new and important observations in the
field; to foster public education, science education, and training; and to
advance the understanding of cancer etiology, prevention. diagnosis, and
treatment throughout the world.Members of the AACR enjoy the following benefits:
I . the privilege of sponsoring a proffered paper (abstract) for consider-
ation for presentation at the AACR annual meeting;
2. an advance copy of the Program and Proceedings of the American
Associationfor Cancer Research that contains over 4,000 abstracts of
proffered papers presented at the annual meeting;
3. reduced registration rates at annual meetings;
4. priority notice of small, focussed meetings in the AACR’s exciting
series of Special Conferences in Cancer Research;
5. substantially reduced registration rates for Special Conferences;
6. opportunities for participation in AACR meetings in North America
and abroad with other scientific societies around the world;
7. receipt of AACR Newsletters and other important announcements;
8. early notification of and reduced rates for participation in the AACR
Employment Register:9. an up-to-date Membership Directory of over 1 1,500 member re-
searchers in the cancer field;
10. the professional benefits of the AACR’s public education activities
concerning funding for cancer research and press coverage of the
latest research findings:1 1 . the opportunity to participate in three Summer Workshops that foster
knowledge in the cancer field for young investigators;12. the facilitation of informal scientific exchange with leading research-
ers in the cancer field; and
13. many more ongoing benefits.
QUALIFICATIONS FOR MEMBERSHIP
Active membership in the AACR is open to investigators who live inthe Americas. Individuals who have conducted two years of researchresulting in peer-reviewed publications relevant to cancer, or who have
made substantial contributions to cancer research in an administrative oreducational capacity, are eligible. If a candidate has conducted research in
an area of biomedical science related to cancer, he or she will qualify formembership. Evidence of patents relevant to cancer research may be
submitted as qualifications for membership in lieu of peer-reviewed
publications.
Corresponding membership is open to persons who are not residents
of the Americas. The qualifications for corresponding membership are thesame as those indicated above for active membership. Visiting scientists
from outside the Americas who intend to return to their countries of originby the anticipated time of election should apply for corresponding mem-bership. All other visiting scientists should apply for active membership
and transfer to corresponding status upon leaving the Americas.Graduate and medical students, postdoctoral fellows, and physicians in
training who do not yet meet the above qualifications for active orcorresponding membership should apply for associate membership.
Forms for associate membership are available from the AACR Office.
PROCEDURES FOR APPLICATION
There are three deadlines for the receipt of a membership application:January 1, May 1, and September 1 of each year. The Membership
Committee will review all complete applications for active membershipthat have been received by these deadlines and will submit recommenda-
tions on each candidate to the Board of Directors which formally elects allmembers. The same procedure is followed by the Special Memberships
Committee which receives applications for corresponding membership.
Candidates will be notified according to the following schedule:
Receipt of Application
in AACR Office _______________January 1
May I
September 1
A complete application consists of the following material:
1 . 6 copies of the form on the opposite side of this page, with all requestedinformation provided.
2. 5 copies of the candidate’s most current curriculum vitae and bibliog-
raphy.3. 5 copies of a letter of recommendation from a nominator who is an
active, corresponding, emeritus, or honorary member of the AACR (at
least one copy must be a signed, original letter). This letter shoulddescribe the candidate’s achievements in laboratory research, clinical
investigations, or epidemiological research, and it should affirm that
this research adheres to accepted ethical scientific standards. -OR- The
nominator may supply the responses requested at the bottom of the
application form in the section entitled “STATEMENT OF SUP-
PORT” (at least one copy of the form must be the signed original).
4. 5 copies of a letter of recommendation as described in Item 3 above
from a seconder who is an active, corresponding, emeritus, or honorary
member of the AACR (at least one copy must be a signed, originalletter). -OR- The seconder may supply the responses requested at thebottom of the application form in the section entitled “STATEMENT OF
SUPPORT “ (at least one copy of the form must be the signed original).
5. 5 reprints of each of two publications on which the candidate appears as
author. As noted above, evidence of patents developed by the candidate
may be submitted in lieu of one or both of the publications. If submittingpatents, supply patent number and year awarded.
All material should be collated into five complete sets with the originalapplication form as a covering document and sent to the address given
below. Questions regarding procedures for membership application mayalso be directed to the following address:
American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19 106-3483
Phone: 215/440-9300
FAX: 215/440-9313
E-mail: [email protected]
RESPONSIBILITIES OF MEMBERSHIP
Candidates should be aware of the following responsibilities of mem-
bership in the AACR. Active members must pay annual dues. In 1997
annual dues for active members are $175, $100 of which is designated forAACR journal subscriptions. Newly elected members of the AACR who
have already purchased subscriptions to Cancer Research, Clinical Can-
cer Research, Cell Growth & Differentiation, or Cancer Epidemiology,
Biomarkers & Prevention at the higher, nonmember rates will receivereimbursement of the unused portion of those subscriptions once their first
year’s membership dues are paid in full.
Corresponding members are required to pay dues ($90 in 1997) andmay, if they wish, subscribe to Cancer Research, Clinical Cancer Re-
search, Cell Growth & Differentiation, or Cancer Epidemiology, Biomar-
kers & Prevention at reduced member rates.
Applicants elected in March will be responsible for payment of that
year’s dues; applicants elected in July and November will pay dues for the
following year. Applicants elected in March and July will be eligible to
sponsor an abstract for the next annual meeting. Every effort will be made
to afford the same opportunity to applicants elected in November.
Margaret Foti, Ph.D.
Executive Director
AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.Public Ledger Building ‘ Suite 816 150 5. Independence Mall West ‘ Philadelphia, PA 19106-3483
APPLICATION FOR ACTIVE OR CORRESPONDING MEMBERSHIP
NAME OF CANDIDATE:_________________________________________ DATE OF BIRTH:_________
LAST FIRST MI.
PRESENT POSITION/TITLE:
INSTITUTIONAL AFFILIATION:_________________________________________________________
INSTITUTIONAL ADDRESS:
(City) (State/Province) (Country) (Postal Code)
TELEPHONE NUMBER:____________________________ FAX NUMBER:_________________________
E-MAIL NUMBER (CARRIER):
PRIMARY FIELD OF RESEARCH (Please check only one):
�Biochemistry and Biophysics �Biostatistics Carcinogenesis
_____Cellular Biology and Genetics _____Clinical Investigations Endocrinology
�Epidemiology Immunology Molecular Biology and Genetics
Preclinical Pharmacology and _____Virology _____Other:__________________________________
Experimental Therapeutics (Please specify)
ACADEMIC DEGREES (Including where and when granted)
EXPERIENCE SINCE HIGHEST DEGREE WAS GRANTED (Please list most recent first)
PUBLICATIONS (Reprints of two peer-reviewed articles on which the candidate appears as an author must accompany this application. For
these two articles list the authors, title, journal, volume, inclusive pages, and year. Do not submit abstracts. If submitting patents, supply patent
number and year awarded.)
CANDIDATE IS APPLYING FOR (Check one): E ACTIVE � CORRESPONDING MEMBERSHIP
CANDIDATE CANDIDATE
NOMINATED BY*:___________________________ SECONDED BY*:____________________________
(Please print) (Please print)
STATEMENT OF SUPPORTInstead of submitting letters of recommendation, either the nominator or the seconder or both may complete the following section:
I acknowledge by signing this statement of support that this candidate adheres to accepted ethical scientific standards and has or will make a
long-term contribution to cancer research.
Signature of Nominator* Date Signature of Seconder* Date
See Guidelines for Application on the reverse side of this form for further instructions.
*Both nominator and seconder must be active, corresponding, emeritus, or honorary members of the AACR.
(This form may be reproduced.) 1997
Margaret Foti, Ph.D.Executive Director
AMERICAN ASSOCIATION FOR CANCER RESEARCH
� GUIDELINES FOR APPLICATION FOR ASSOCIATE MEMBERSHIP]
QUALIFICATIONS FOR MEMBERSHIP
Associate membership is open to graduate students, medical students,
postdoctoral fellows, and physicians in training who are following a
course of study or who are working in a research program relevant to
cancer. Scientists in training who already have a substantial record of
publications may wish to apply for active or corresponding membership
which confers full benefits of membership.
BENEFITS OF MEMBERSHIP
The American Association for Cancer Research (AACR), a scientific
society consisting of laboratory and clinical cancer researchers, was
founded in 1907 to facilitate communication and dissemination of knowl-
edge among scientists and others dedicated to the cancer problem; to
foster research in cancer and related biomedical sciences; to encourage
presentation and discussion of new and important observations in the
field; to foster public education, science education, and training; and to
advance the understanding of cancer etiology, prevention, diagnosis, and
treatment throughout the world. Associate members of the AACR enjoy
the following benefits:
I . the privilege of sponsoring a proffered paper (abstract) for consider-
ation for presentation at the AACR annual meeting provided that (a)the associate member is the presenter of the paper and (b) an active,
corresponding, emeritus, or honorary member in good standing of the
AACR also signs the abstract of the paper in support of the work. (In
this instance, the member who cosigns the abstract does not lose his
or her own sponsorship privilege.):2. an advance copy of the scientific Program and (if one has been
purchased by the associate member) the Proceedings ofthe American
Association for Cancer Research that contains over 4,000 abstracts ofproffered papers presented at the annual meeting:
3. the privilege of registering for the annual meeting at the low associate
member rate;4. preferred access to the AACR Employment Register;
5. optional subscriptions to the Association’s high-quality journals Can-
cer Research, Clinical Cancer Research, Cell Growth & Differenti-
ation, and Cancer Epidemiology, Biomarkers & Prevention at re-
duced member rates:
6. priority notification of events in the AACR’s series of special con-ferences on timely subjects in the field:
7. substantially reduced registration rates at special conferences;
8. the receipt of AACR newsletters, meeting announcements, and an
up-to-date Membership Directory:9. the opportunity to participate in three Summer Workshops that foster
knowledge in the cancer field for young investigators; and
10. the facilitation of informal scientific exchange with leading research-
ers in the cancer field.
PROCEDURES FOR APPLICATION
Persons wishing to apply for associate membership must use the
official application form on the reverse side of these instructions. Each
candidate for associate membership must be nominated by an active,
corresponding, emeritus, or honorary member in good standing of the
AACR. Three completed copies of the form should be submitted: at leastone of these copies must carry the original signatures of both the candidate
and the nominator. In addition, the candidate should submit one copy of
his or her curriculum vitae. The application form may be submitted to the
Association Office at any time.
After review of applications for associate membership, the ExecutiveDirector will notify candidates of their election or deferral within onemonth of the receipt of the application form. A check for one year’s duespayment must accompany the application. Dues for 1996 are $35 forassociate members residing in the Americas and $45 for residents of othercountries. For 1997 these rates are $45 and $55, respectively. This fee willbe refunded to any candidate deemed to be ineligible for associate mem-
bership. Checks should be in U.S. currency, made payable to AACR, Inc.,
and drawn on a U.S. bank. Send the three copies of the application form
and the appropriate dues payment to:
American Association for Cancer ResearchPublic Ledger Building, Suite 816
150 5. Independence Mall West
Philadelphia, PA 19106-3483Phone: 215/440-9300
FAX: 215/440-9313
E-mail: [email protected]
RESPONSIBILITIES OF MEMBERSHIP
Associate members must pay annual dues in an amount to be deter-mined by the AACR Board of Directors. Dues for 1996 have been set at$35 per year for residents of the Americas and $45 for residents of othercountries. For 1997 these rates are $45 and $55, respectively. If an
application is submitted by August 3 1 , the accompanying dues payment
will be credited to the current year. Candidates submitting applications
between September 1 and December 3 1 may indicate whether they wishtheir dues payments credited to the current or forthcoming year. Candi-
dates should be aware, however, that associate members may sponsor an
abstract for the annual meeting only if their dues for the current year are
paid. For example, an associate member submiuing an abstract in No-
vember 1996 for the forthcoming annual meeting must have paid dues for1996. Any newly elected associate members of the AACR who havealready purchased subscriptions to Cancer Research, Clinical Cancer
Research, Cell Growth & Differentiation, or Cancer Epidemiology, Bio-
markers & Prevention at the higher, nonmember rate will receive a refundfor the unused portion of that subscription upon receipt of their paymentfor a member’s subscription.
Each Fall the AACR will send to current associate members an invoicefor dues for the forthcoming year. Payment of this invoice must be
accompanied by a statement signed by the associate member’s current
registrar, dean, or department head, verifying the member’s current aca-
demic status. The Association’s By-Laws state that dues are payable for
each year in advance by January 1 of the year to which they should be
applied. An individual may be an associate member for a maximum offive years. Each year in which an individual pays dues will count as one
full year of associate membership. Thus, an associate member who pays
dues for I 996 may retain associate membership until December 3 1 , 2000.The Board of Directors may terminate the membership of an associatemember whose dues are in arrears for two years.
AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.
Public Ledger Building ‘ Suite 816 . 150 5. Independence Mall West � Philadelphia, PA 19106-3483
APPLICATION FOR ASSOCIATE MEMBERSHIP I
NAME OF CANDIDATE:_______________________________________ DATE OF BIRTH:_________
LAST FIRST MI.
INSTITUTIONAL AFFILIATION:____________________________________________________________
INSTITUTIONAL ADDRESS:
(City) (State/Province) (Country) (Postal Code)
TELEPHONE NUMBER:____________________________ FAX NUMBER:_________________________
PRESENT ACADEMIC STATUS/TITLE (Please check only one): E-MAIL NUMBER (CARRIER):
_____Graduate Student Medical Student
�Physician in Training Postdoctoral Fellow
PRIMARY FIELD OF RESEARCH (Please check only one):
Biochemistry and Biophysics Biostatistics Carcinogenesis
_____Cellular Biology and Genetics _____Clinical Investigations Endocrinology
�Epidemio1ogy Immunology _____Molecular Biology and Genetics
Preclinical Pharmacology and Virology Other:__________________________________
Experimental Therapeutics (Please specify)
ACADEMIC DEGREES (Please indicate degree(s) acquired to date along with the name of the academic institution and date of receipt. Provide
information on degree currently being sought and the anticipated date of completion of this degree program.)
RELEVANT RESEARCH EXPERIENCE NOT RELATED TO COURSE WORK (Please list most recent first.)
PUBLICATIONS (List the authors, title, journal, volume, inclusive pages, and year of any article in a peer-reviewed journal on which the
candidate appears as an author. Do not list abstracts. Continue on a separate sheet, if necessary.)
CANDIDATE NOMINATED BY*:___________________________________________________________
(Please print)
SIGNATURES
I hereby apply for associate membership in the American Association for Cancer Research. I have read the instructions on the reverse side of
this form, and I understand the privileges and responsibilities of this class of membership. I certify that the statements on this application are
true.
Signature of Candidate:___________________________________________________________________ Date:___________________
I recommend this candidate for associate membership in the American Association for Cancer Research. To the best of my knowledge, the
candidate is qualified for this class of membership, and the statements on this application are true.
Signature of Nominator*:_________________________________________________________________ Date:___________________
Submit three copies of this form. At least one copy must contain the original signatures of the candidate and the nominator. In addition, submit
one copy of your curriculum vitae. Enclose a check in U.S. funds, made payable to AACR, Inc., and drawn on a U.S. bank for one year’s dues.
For 1996, dues are $35 for associate members residing in the Americas and $45 for residents of other countries. For 1997, these rates will be
$45 and $55, respectively.
Check one of the following boxes only if this form is being submitted between September 1 and December 31:
The enclosed dues payment should be applied to the fl current Eli forthcoming calendar year.
(NOTE: If dues are applied to the forthcoming year, membership will take effect on January 1, but the candidate will not be eligible to sponsor
an abstract for presentation at the annual meeting in March on April of that year.) See Guidelines for Application on the reverse side of this
form for further instructions.
*Nominator must be active, corresponding, emeritus, or honorary member of the AACR.
(This form may be reproduced.) 1997
Guidelines for Submitting Disksto
American Association for Cancer Research Publications
The word processing packages that we prefer are as follows:
MacWrite WordPerfect (DOS, Windows,Microsoft Word (DOS, Windows, and Macintosh)
and Macintosh) XyWrite (DOS and Windows)
Also acceptable:
Ability Mass 1 1 SoloWriterAmiPro MS Windows Write SprintAM STEX MS Works StxAppleworks MS Works WP Mac SunWriteArborTEX Multimate SymphonyArborText Multimate Advantage TEXClarisWorks WP Nibia T�X78CPT 8000 Nisus (to ASCII file) Text EXecutiveCTOS Notewriter TexturesDiablo Obun Total WordDisplayWrite OfficeWriter TroffDuet PC Write iTEXEinstein PFS First Choice VolkswriterEnable Professional Write VuWriterEXP Q&A Write Wang OSFinal Word Quark XPress Wang WPSFullWrite RagTime MS Works Wang WriterGemWord Plus (to ASCII file) Window WorksIBM Writing Assistant Rich Text Format Windows WriteInterleaf RSG (to ASCII file) WiziWordLATEX Signature WordstarLatex SLITEX Wordstar 2000Leading Edge SmartWhere WriteNowLotus Manuscript SmartWrite II XeroxLotus Write
Software packages that we are unable to translate:
FrameMaker Ready, Set, GoPageMaker Scientific Writer
Disks produced on IBM or IBM-compatible computers are preferred, but those produced on some Apple orWang computers can also be converted. Because of the file structures and internal coding, we cannot acceptdisks created on desktop publishing systems or those created on proprietary typesethng systems. We alsocannot guarantee that all special characters can be translated. Tabular and mathematical material, such asequations, will not be captured from the disk but will be rekeyed.
To expedite work and for your own security, we do require that you submit a hard copy printout of the diskfile. The tables and equations will be keyed from this hard copy. We also need to know the name of the fileto be converted, the type of hardware (e.g., IBM PC) on which the files were created, the operating system(e.g., DOS 3.3), and the version of the software (e.g., WordPerfect 5.1) used to create the file.
PLEASE FILL OUT ALL INFORMATION ON REVERSE SIDE AND SUBMIT THIS FORM WITH YOUR DISK.DISKS WILL NOT BE PROCESSED WITHOUT THIS INFORMATION.
DISK SUBMISSION FORM
AACR journals are now using personal computers to copyedit manuscripts accepted for publication. Whensubmitting a revised manuscript, authors are encouraged to submit an electronic disk of the paper along withthe required four hard copy printouts. Disks will ultimately be returned to the authors.
I See reverse for the word processing packages that can be accepted.
File preparation
Please be sure that the file you send is the most recent version of the manuscript and that it matches the mostrecently submitted printed copy. The file should contain all the parts of the manuscript in one file. Mathe-matical and tabular material, however, will be processed in the traditional manner and may be excluded fromthe disk file.
Note: AACR does not assume responsibility for errors in conversion of customized software, newly releasedsoftware, or special characters.
Please label the outside of the disk with the journal name, the first author’s name, a partial title of themanuscript, and the name of the computer file used to access the manuscript on disk. To process your diskefficiently, we need the following information. Please be sure to provide ALL the information.
Name used to access paper on disk: _____________________
Name of computer used (e.g., IBM/PS2):Operating system and version (e.g., DOS 3.3):Word processing program and version (e.g., WordPerfect 5.0):.
[See reverse for acceptable programs.]
Manuscript number: _________________________________First author: ________________________________________
Corresponding author (if different from first author):
Telephone/FAX numbers: ____________________________
This form (both sides) may be reproduced.
Clinical and translational investigations continue to have a dramatic
impact on the treatment of cancer, making the need for up-to-date
information increasingly important. Every month, basic and clinical
cancer researchers turn to Clinical Cancer Research for the latest
reports of significant new studies. Act now to ensure you receive
research findings that are too important to miss.
SUBSCRIBE TODAY Call 1-800-875-2997 or 201-627-2427 or mall back the coupon below.
Please charge my
Account Name
Account No.
hxpiration Date
city State Zip
countr�
ugnature
L�IYes! I’d like to subscribe!Clinical Cancer ResearchVol. 3, 1997, 12 issues, ISSN 1078-0432
Institutional (Available only as a combined subscription with Cancer Research)
�:i $685� $1 30 should be added for delivery outside the U.S.
Individual� $1 05 non-member� $40 should be added for delivery outside the U.S.
MCR members: Contact the AACR for rates, (21 5) 440-9300.
Canada: Add 7% GST. MD: Add state sales tax.Individual subscriber: I certify that this subscription issolely for my personal use and will not be used in a library.
Signature
Name
Address
Method of Payment� Enclosed check or money order in U.S. dollars drawn
on U.S. bank. Payable to American Association forCancer Research.
� Institutional purchase order # is enclosed.
� MasterCard � VISA� American Express
�:i Please send me Instructions for Authors.
Mail coupon to: Clinical Cancer Research, P.O. Box 3000, Denville, NJ 07834-9359.
Those paying by credit card can fax to: (215) 440-9354.
AMERICAN ASSOCIATION FOR CANCER RESEARCH
1997 RESEARCH FELLOWSHIPS
For Young Scientists at the Postdoctoral or Clinical Fellow Level
. 1997 Research Fellowship in Clinical/Translational Research: This Fellowship,
sponsored by Amgen, Inc., will provide a one-year grant of $30,000 to a young
scientist in the U.S. or Canada engaged in meritorious clinical or translational
cancer research.
. 1997 Research Fellowship in Clinical Research: This Fellowship,
sponsored by Bristol-Myers Squibb Oncology, will provide a one-year grant
of $30,000 to a young scientist in the U.S. or Canada engaged in
meritorious clinical cancer research.
. 1997 Research Fellowship in Prevention Research: This Fellowship,sponsored by the Cancer Research Foundation of America, will provide a
one-year grant of $30,000 to a young scientist in the U.S. or Canada
engaged in meritorious cancer prevention research.
. 1997 Research Fellowships in Basic Research: Three Fellowships, sponsored by
The Sidney Kimmel Foundation for Cancer Research, Hoechst Marion Roussel, and
the AACR, will each provide a one-year grant of $30,000 to a young scientist in
the U.S. or Canada engaged in meritorious basic cancer research.
. The winners of the Research Fellowships will be announced at the AACR Annual
Meeting in San Diego, CA, in April 1997.
Eligibility
Candidates must have completed the M.D., Ph.D., or other doctoral degree. Candidates must
currently be a postdoctoral or clinical research fellow and must have been a fellow for at least
two years but not more than five years prior to the year of the award. Academic faculty holding
the rank of assistant professor or higher, graduate or medical students, government employees,
and employees of private industry are not eligible. A candidate need not be a member of the
AACR at the time of application, but he or she must be nominated by an AACR Member.
Associate Members may not be nominators.
Selection Process
Applications will receive careful scientific evaluation by a prestigious, multidisciplinary
Committee consisting of AACR Members who are experts in basic, clinical, and translational
cancer research. Applications must be submitted in complete form by February 14, 1997.
For Further Information/Application FormsAMERICAN ASSOCIATION FOR CANCER RESEARCH
Public Ledger Building, Suite 816150 South Independence Mall West
Philadelphia, PA 19106-3483Telephone: (215) 440-9300
FAX: (215) 440-9313e-mail: aacr@ aacr.org
AMERICAN ASSOCIATION FOR CANCER RESEARCH88th Annual Meeting
Frederick P. Li, Program Committee Chairperson
Clara Derber Bloomfield, Program Committee Co-Chairperson
Stephen H. Friend, Program Committee Co-Chairperson
San Diego Convention Center, San Diego, California
April 12-16, 1997
Titles of Major Session(Names of confirmed session organizers are in parentheses)
PLENARY SESSION
Genetic Predisposition to Cancer (Louise C. Strong)
SYMPOSIA
Genes, Cell Proliferation, and Antineoplastic Drugs (George
F. Vande Woude)
Diagnostic, Prognostic, and Therapeutic Aspects of Tumor
Suppressor Genes (David Sidransky)
Cell Cycle Regulation (Peggy J. Farnham)
Breast Cancer Genes (Barbara L. Weber)
Metastasis, Adhesion, and Angiogenesis: Mechanisms and
Therapeutic Strategies (Marilyn M. Cornwell and Elise
C. Kohn)
Novel Clinical Trials Based on Genetics and Molecular
Therapeutics (Stephen H. Friend)
Apoptosis and Cancer Chemotherapy (Michael B. Kastan)
Identification and Management of Genetic-High-Risk
Individuals (Albert de la Chapelle)
Demystifying the Role of Cytokines in Tumor
Immunobiology: Status and Future Utility (Michael A.
Caligiuri)
Telomerase and Clinical Applications (Titia de Lange)
Acute Myelocytic Leukemia (Clara Derber Bloomfield)
Prostate Cancer (Donald S. Coffey)
Colon Cancer (Margaret A. Tempero)
Signaling Pathways for Novel Therapeutics (Anthony J.
Pawson)
Animal Models for Functional Analysis of Tumor
Suppressor Genes (Terry A. Van Dyke)
New Techniques for Molecular Diagnostics (Eric S. Lander)
Mechanisms of Cellular Senescence (J. Carl Barrett)
Damage Response Pathways (Philip C. Hanawalt)
Gene Interactions with the Environment/Carcinogenesis
(Allan Balmain)
Epidemiology and Pathogenesis of Secondary Cancers
(Frederick P. Li)
CONTROVERSY SESSIONS
What Are the Appropriate Therapeutic Uses of
Hematopoietic Growth Factors? (Peter J. Quesenberry)
Estrogen Replacement Therapy: Beneficial or Harmful?
(Larry Norton)
What is the Value of Mammography in Young and
Genetically Susceptible Women?
Is the Time Right for Cancer Chemoprevention? (Edward
Bresnick)
Gene Patents: Help or Hindrance to Conquering Cancer?
What is the Role of Prophylactic Surgery in Breast and
Ovarian Cancer? (Samuel A. Wells, Jr.)
What Are the Appropriate Guidelines for the Use of
Archived Human Tissue?
How Robust Are AntisenselThird Strand Techniques for
Gene Disruption?
“MEET-THE-EXPERP’ SUNRISE SESSIONS
Angiogenesis
Gene Therapy (Jack A. Roth)
Strategies for Drug Development (Daniel D. Von Hoff)
Advances in Our Molecular Understanding of
Lymphoproliferative Disease (A. Thomas Look)
FHIT Gene (Kay Huebner)
Cancer Vaccines (David P. Carbone)
Lung Cancer
Costimulatory Molecules in Tumor Immunity
New Approaches to Overcoming Multidrug Resistance
(Alan F. List)
Advances in Oncologic Imaging (Michael J. Welch)
Retinoids and Cancer Prevention (Waun Ki Hong)
Mechanisms of Regulation of p53 Function (Guillermina
Lozano)
Cell Cycle Control of Genetic Stability (Geoffrey Wahi)
Farnesyl Transferase Inhibitors (Allen I. Oliff)
B ioinformatics/Genomics
DNA Methylation in Cancer (Stephen B. Baylin)
Chemoprevention in Transgenic Animals (James M. Phang)
Advances in Stem Cell Transplantation
Psychosocial Issues in Cancer
Advances in the Management of AIDS-related Malignancies
(Ellen G. Feigal)
Recent Developments in Our Understanding of Minimal
Residual Disease (John G. Gribben)
Ovarian Cancer Update (Robert C. Bast, Jr.)
The Biological Basis of the New International Classification
of Lymphoma (Elaine S. Jaffe)
Recent Developments in Radiotherapy
Colon Cancer Genes
Extracellular Connections
Barrett’s Esophageal Cancer and Tumor Progression Models
(Brian J. Reid)
H. Pylon
Transcriptional Models and Drug Discovery (William G.
Kaelin)
METHODS WORKSHOPS AND EDUCATIONAL SESSIONS
To be announced
Abstract Deadline: November 12, 1996
Further Information: AACR Office . � Ledger Building . Suite
816 . 150 S. Independence Mall West . Philadelphia, PA 19106-
3483 . TELEPHONE: (215) 440-9300 . FAX: (215) 440-9313.
Email: [email protected] . For up-to-date information visit the AACR
Website at http:llwww.aacr.org
AACR SPECIAL CONFERENCE IN CANCER RESEARCH
Basic and Clinical Aspects ofBreast Cancer
March 7-12, 1997The Keystone Resort, Keystone , Colorado
CONFERENCE CHAIRPERSONS
J. Carl Barrett I Research Triangle Park, NCKaren S.H. Antman I New York, NY
Mary-Claire King I Seattle, WA
SCIENTIFIC PROGRAM
Keynote AddressesMary-Claire King I Seattle, WAKaren S.H. Antman I New York, NY
Basic Biology of the BreastJos#{233}Russo I Philadelphia, PA
Marc E. Uppman I Washington, D.C.C. Kent Osborne I San Antonio, TX
Molecular and Cellular Aspects of BreastCancerJerry W. Shay I Dallas, TXMina J. Bissell I Berkeley, CAMartha R. Stampfer I Berkeley, CA
Genetic Predisposition to Breast CancerDavid E. Goldgar I Lyon, FranceP. Andrew Futreal I Durham, NC
Mechanisms of Hormone ActionV. Craig Jordan I Chicago, ILMyles A. Brown I Boston, MAKenneth S. Korach I Research Triangle Park, NC
BRCA1 and BRCA2 Function/BiochemistryRoy A. Jensen I Nashville, TNWen-Hwa Lee I San Antonio, TXDavid M. Uvingston I Boston, MAFrank J. Calzone I Thousand Oaks, CA
Experimental Models of Breast CancerTak W. Mak I Toronto, Ontano, Canada
Michael N. Gould I Madison, WI
Epidemiology of Breast CancerWalter C. Willett I Boston, MAMaureen Henderson I Seattle, WAMalcolm C. Pike I Los Angeles, CA
Mary S. Wolff I New York, NY
Clinical Aspects of Breast CancerJudy E. Garber I Boston, MAJeffrey T. Holt I Nashville, TNM. John Kennedy I Baltimore, MD
Applicants are encouraged to submit abstractsfor poster presentation.
Application deadline: January 3, 1997
Information and Application Forms
American Association for Cancer ResearchPublic Ledger Building, Suite 816150 South Independence Mall WestPhiladelphia, PA 19106-348321 5-440-9300 21 5-440-931 3 (FAX)aacr@ aacr.org (E-mail)http:llwww.aacr.org